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ABSTRACT 
The goal of this research was to gain greater understanding about the management of heart 
failure patients. A particular focus was to evaluate exercise tolerance and behavior. The major 
findings of the first study included: (1) evidence that few heart failure patients receive adequate 
information regarding physical activity; (2) performance on a six-minute walk test were ~42% 
lower, and SF-36 scores were also lower in heart failure patients compared to controls; (3) 
stability in hemodynamic measures and distance walked on the 6-minute walk test were 
adequate, and (4) home exercise resulted in 19% improvement in maximum walking distance 
and 30% improvement in physical function score on the SF-36. The second study showed the 
feasibility to implement a care-managed program for heart failure patients in a family practice 
setting. However, a significant barrier was recruitment. Despite this failure, patients improved 
~24% on the maximum walking distance and 29%, 46%, and 13% on the physical function, 
vitality, and mental health scores on the SF-36. The third study examined the motivation and 
readiness of heart failure patients to engage in planned physical activity. The findings revealed 
22 patients in precontemplation, 33 in contemplation, 41 in preparation, 23 in action, and 29 in 
maintenance. In regards to the Transtheoretical model constructs (self-efficacy, pros and cons of 
decisional balance, and experiential processes) the data revealed that self-efficacy scores were 
lowest in the precontemplation and increased in linear fashion to maintenance. Decisional 
balance changed from greater perceived cons and lower perceived pros in precontemplation and 
contemplation to lower perceived cons and higher perceived pros in action and maintenance. 
Experiential processes were used predominantly in precontemplation and contemplation, 
whereas behavioral processes were more prominently used in action and maintenance. The most 
important predictors of physical activity stages of change were the behavioral processes (r2= .78) 
 viii
followed by perceived self-efficacy (r2= .66). Finally, this study indicated that patients in pre-
action stages of readiness to exercise have significant lower exercise tolerance then those in 
action and maintenance. These data suggest greater clinical emphasis should be placed on 
strategies to move patients toward the preparation and action stages of readiness. 
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CHAPTER 1. INTRODUCTION 
1.1 Introduction 
Heart failure is defined as the pathophysiological state in which an abnormality of cardiac 
function is responsible for failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolizing tissues, or to do so only from an elevated filling pressure1. 
Heart failure is not a homogenous disease. Rather, it is the final common pathway of several 
disorders that impair the heart’s pumping ability.  
An estimated 5.0 million Americans have heart failure, a chronic condition associated with 
frequent hospitalizations, widespread functional impairment, and a high mortality rate. Each 
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart 
failure as a primary or contributory cause2. During the last 10 years, the annual number of 
hospitalizations has increased from approximately 550,000 to nearly 900,000 for heart failure as 
a primary and from 1.7 to 2.6 million for heart failure as a secondary diagnosis.3 
In addition to the substantial morbidity and mortality associated with this condition, there is a 
significant financial impact on our society. In fact, heart failure is now the single most costly 
cardiovascular illness in the United States, with total treatment costs estimated at $24.3 billion.1 
The cost to society is expected to increase due to an aging population and prolonged survival 
rates of individuals with cardiovascular disease, therefore imposing a large burden on individuals 
and the healthcare system.  
Because heart failure is not a homogenous disease, management of the patient is extremely 
challenging with constant need for close monitoring and follow-up care. Primary goals of heart 
failure management include a reduction in the frequency of heart failure exacerbations, 
extending life, and improving quality of life. Additional goals include maximizing independence, 
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improving exercise capacity, enhancing emotional well-being, and reducing resource use and 
cost of care5-7. 
As a result of the increasing incidence of heart failure and the complex nature of the 
syndrome, the management of patients has become increasingly multidisciplinary in nature. 
Moreover, the composition of the team and relative importance of its members must constantly 
change depending on the status of the patient. Recent studies have shown the significant value of 
the use of a multidisciplinary approach in the management of the heart failure patient5-7. These 
programs emphasize the importance of close monitoring and patient education. Despite positive 
outcomes from these programs, including fewer readmissions and hospital days, decreased costs, 
and improved functional status and quality of life, patient participation and adherence remain 
suboptimal5-7. In fact, a major criticism of many large-scale therapeutic trials in heart failure is 
that the characteristics of the heart failure population at large are quite different from those being 
studied. This suggests there are a tremendous number of patients with heart failure who are 
currently not being reached. 
A major component of the management of the heart failure patient is planned physical 
activity. Such programs have shown great promise as studies have revealed dramatic 
improvements in functional ability and quality of life and a reduction in healthcare costs and 
mortality in patients engaged in exercise programs8.  Consequently, current recommendations on 
the management of heart failure patients strongly emphasize an active lifestyle, and if possible, 
participation in a moderate exercise training regimen9. However, despite the benefits of physical 
activity for patients with heart failure, research indicates that few individuals with heart failure 
actually engage in regular physical activity10. Numerous studies have revealed that traditional 
methods of promoting physical activity have been only marginally successful in patients with 
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heart failure, citing failure to adhere to recommendations as a predominant factor11,12. For 
example, our experience indicates that from a pool of approximately 350 heart failure patients, 
we were only able to recruit 20 patients for a 6 month intervention program. This was 
particularly disappointing given the fact we had an active recruiting program in place, which was 
coordinated by a dedicated nurse clinician. It has been suggested that these failures are in part 
due to the educational rather than behavior and motivational focus of many campaigns13. 
Furthermore, many exercise programs are designed for people who have decided to begin 
exercise, yet a large proportion of individuals are simply not interested or ready to engage in 
physical activity programs14.  Thus, in an effort to provide patients with the greatest 
opportunities to help manage the heart failure syndrome, it is critical to understand the 
underlying reasons that may prevent a patient from participation as well as patient readiness to 
engage in physical activity behaviors. Appreciation of “barriers” to treatment will ultimately 
contribute to the development of improved strategies for inclusion of all patients with this 
disease.   
The current document presents three research projects conducted at Louisiana State 
University designed to focus on the management of individuals diagnosed with heart failure. The 
focus of Chapter 2 was to evaluate physical function and perceived quality of life in patients with 
heart failure. Specifically, this project (1) examined written evidence regarding exercise 
recommendations to heart failure patients by their providers, (2) determined the construct 
validity of the 6-min walking test and a quality of life survey between patients with heart failure 
and age-matched controls; (3) examined the stability of the 6-min walking test, and (4) evaluated 
the effects of a care-managed exercise program. A unique contribution of this project was the 
fact it took place in a family practice clinic. Arguably it is this setting where the greatest numbers 
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of heart failure patients are managed, yet very little research concerning the management of these 
patients in this setting has been conducted. The first project led to the development of a grant 
proposal, which was ultimately funded through the Centers for Disease Control and Prevention. 
Consequently, the focus of Chapter 3 was to examine the influence of individualized, intensive 
education on measures of exercise tolerance and quality of life in patients with heart failure in a 
family practice setting. An important aspect of this study was the development and 
implementation of a tailored education handbook, as outlined by published guidelines for the 
evaluation and care of patients with heart failure by the Agency for Health Care Policy and 
Research (AHCPR)15. These guidelines include recommended topics for patient and family 
education and counseling, such as diet, medications, physical activity, compliance, and 
recognition of worsening symptoms. The study was powered on recruiting approximately 60 
patients from a pool of about 350 patients. A dedicated nurse clinician was coordinating 
recruiting efforts among approximately 6 physicians who were aware and for the most 
supportive of the study efforts. Despite this coordinated effort, the study failed to reach the 
targeted sample size. This failure is certainly not unprecedented in clinical trials and suggests 
two important problems. First, it suggests that data from many interventional trials with a focus 
on behavior modification may be biased to certain individuals. Second, it indicates there are a 
tremendous number of patients with heart failure who are currently not adequately reached and 
even managed. Recognizing this, it is not realistic to expect patients to make changes that they 
are not prepared to make that resulted in the development of the final project. In so, the focus of 
Chapter 4 was to assess the motivation and readiness of patients with heart failure to make 
necessary behavioral changes to aid in the management of their condition. No such studies are 
currently available for this patient population, despite strong suggestions that clinicians examine 
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theoretically based and practically important behavioral strategies that might be useful for 
encouraging and supporting a healthy behavior (such as exercise initiation) among individuals 
with chronic heart failure. Consequently, the final project aimed to (1) examine the associations 
of the constructs of the Transtheoretical model of behavior change and stage of change for 
planned regular physical activity; (2) determine the most important predictors of physical activity 
stages of change utilizing the constructs of the Transtheoretical model; and (3) examine the 
association of the stage of change construct for physical activity with maximum walking distance 
achieved on a 6 minute walk test among individuals with chronic heart failure. 
A summary of the unique findings and the potential relevance of each project are presented 
in Chapter 5. In addition, Chapter 5 outlines some future recommendations regarding subsequent 
research in this and other disease populations.  
Finally, the appendices include an extensive literature review on the heart failure syndrome, 
the educational workbook used in the second project, and the informed consent for project 3. 
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CHAPTER 2. EVALUATION OF PHYSICAL FUNCTION AND PERCEIVED 
QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE IN A FAMILY 
PRACTICE SETTING 
 
2.1 Introduction 
An estimated 4.9 million Americans have heart failure, a chronic condition associated with 
frequent hospitalizations, widespread functional impairment, and a high mortality rate1. Each 
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart 
failure as a primary or contributory cause1. The syndrome is the underlying reason for 12 to 15 
million office visits and 6.5 million hospital days each year2. Furthermore, during the last 10 
years, the annual number of hospitalizations has increased from approximately 550,000 to nearly 
900,000 for HF as a primary diagnosis and from 1.7 to 2.6 million for HF as a secondary 
diagnosis3.  In addition to the substantial morbidity and mortality associated with this condition, 
there is a significant financial impact on our society. In fact, heart failure is now the single most 
costly cardiovascular illness in the United States, with total treatment costs estimated at $24.3 
billion1. 
Despite traditional pharmacologic treatment, the clinical phase of HF includes a marked 
decline in functional state, as defined by exercise tolerance and capacity with a subsequent 
decrease in quality of life.  Furthermore, hospitalization rates remain high, owing in large part to 
a multitude of psychosocial, behavioral, and financial factors that serve as barriers to effective 
compliance with prescribed treatment.  To deal with these issues, many centers have adopted a 
multidisciplinary approach to HF disease management4-7. Comprehensive care programs for HF 
patients have been shown to be beneficial, but have largely been conducted in tertiary care 
settings. The fact the majority of patients are managed by primary care physicians warrants 
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further investigation to determine whether benefits of a comprehensive HF program, observed in 
tertiary settings, can be replicated in the primary care environment.  
The purpose of this study was 3-fold: (1) to examine written evidence regarding exercise 
recommendations to heart failure patients by their providers, (2) to determine the construct 
validity of the 6-min walking test and a quality of life survey between patients with heart failure 
and age-matched controls; (3) to examine the stability of the 6-min walking test, and (4) to 
evaluate the effects of a care-managed exercise program on functional status and perceived 
quality of life in patients with heart failure in a family practice.  
2.2 Methods 
• Participants   
 All patients were recruited from the Family Medicine Residency Program/ Baton Rouge 
General Medical Center. Men and women over the age of 18 years with diagnoses of heart 
failure (regardless of etiology) were eligible for the study. The duration of heart failure in all 
patients was no less than 4 months and patients were optimally managed as deemed by the 
participant’s primary care physician. Those patients with acute unstable myocardial ischemia 
and/or angina, other non-cardiac diseases that would interfere with the completion of the study 
(uncontrolled hypertension, severe chronic obstructive pulmonary disease, or severe arthritis), 
and those recovering from a recent medical emergency resulting in hospitalization (e.g. acute 
myocardial infarction, coronary bypass graft surgery, radiation therapy, etc.) are excluded from 
participation. Participants without heart failure were selected and matched with the patients for 
age, gender, height, and weight. 
• Study Design 
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 This study included a retrospective analysis of medical records to evaluate the dissemination 
of physical activity information for the heart failure patient. This study also included a 
prospective comparison component to determine the construct validity of the two major 
dependent measures (i.e. the 6-minute walk distance and SF-36 scores). The short-term stability 
of the 6-min walking test was determined using a simple test-retest design. Finally, the study also 
included a prospective, randomized design aimed at measuring the potential benefit of a carefully 
managed exercise program for patients with chronic heart failure in a family practice setting.  
• Experimental Measurements 
All tests were conducted over the course of 1 visit at the Family Medicine Residency 
Program/ Baton Rouge General Medical Center under the supervision of qualified clinicians as 
well as support staff from the Department of Kinesiology at Louisiana State University. Prior to 
testing a medical evaluation was performed by a qualified physician.  The medical evaluation 
included a medical history, review of symptoms, and routine examination of the major organ 
systems.  
Prior to testing, each patient’s medical records were carefully examined for evidence 
regarding recommendations or guidance toward incorporating physical activity into the patient’s 
medical management. A simple scoring system was implemented based on the following 
evidence. If no evidence of physical activity information was noted over the last year, a score of 
“0” was given. In the case of simple advise to “exercise as tolerated”, a sore of “1” was given. A 
score of “2” was given to more specific information about physical activity, and a “3” was given 
for specific exercise prescriptions according to the AHA guidelines8. 
Following the medical examination exercise tolerance was assessed using a 6-minute 
walking test on a motor driven treadmill.  The grade of the treadmill was set at 0%.  Patients 
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controlled the treadmill speed by themselves and were allowed to change it at any time. The 
speed could be altered in increments of 0.1 km/hr, allowing precise measurement of walking 
distance.  During the testing, blood pressure and heart rate were continuously monitored.  Prior 
to testing the patients were instructed to walk as far as possible, avoiding chest pain or marked 
dyspnea. To standardize the protocol, subjects were not be coached during testing but all subjects 
were made aware of the time remaining to completion. The maximum walking distance during 
the 6-minute walk test was considered the dependent measure. 
After the exercise tolerance test, the patients' perceived quality of life, defined for the present 
study as the subjective appraisal of general physical and emotional well-being, was assessed with 
the Short Form 36 (SF-36) questionnaire. The SF-36 was designed to measure the generic health 
concepts relevant across age, disease, and treatment groups.  The SF-36 was constructed to 
represent 8 of the most important health concepts included in the medical outcomes study and 
other widely used health surveys. The SF-36 is comprised of 36 items that describe health related 
physical and psychosocial dysfunction in 8 areas to include physical function, social function, 
role-limitation-physical, role limitation-emotional, mental health, vitality, bodily pain, and 
general health. A single item evaluates the patient’s perception of change in health over the past 
year. Scores range from 0% to 100% with higher scores consistent with better health status. To 
examine the stability of the maximum walking distance achieved on the 6 minute walking test, 
and SF-36, both tests were repeated one week after the initial test. 
• Intervention 
Participants were randomly assigned to one of 2 groups: home-exercise training or control.  
Exercise training consisted of aerobic activities of progressive duration and intensity performed 
on a daily basis for 16 weeks.  All participants received extensive follow-up through weekly 
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telephone contact with members of the research team.  In addition, all participant’s were 
scheduled for monthly clinic visits aimed at patient education, compliance to medication, 
identification of recurrent symptoms, and evaluation of exercise logs and modification of 
exercise prescription (only in those participants randomized to the exercise training group). 
• Statistical Analysis 
 All statistical analyses were conducted using the latest version of the SPSS statistical 
package for windows. To examine the written evidence regarding exercise recommendations 
simple ranking statistics were applied. To determine the construct validity of the 6-min walking 
test and a quality of life survey between patients with heart failure and age-matched controls, 
independent sample t-tests were conducted. The stability of the 6-min walking test was examined 
using an ANOVA with repeated measures, and intraclass correlation coefficients. Finally, the 
effects of the exercise program on exercise tolerance and perceived quality of life were evaluated 
using a paired sample t-test. Alpha levels were set at 0.10. 
2.3 Results 
• Patient Characteristics 
 The patient demographics in this study were characteristic of the wide range of individuals 
who present to the clinic (see Table 2.1). Of the 16 patients enrolled 14 were African-American 
and 2 Caucasian. There were 12 women and 4 men with a mean age of 61±14 years. 
Approximately 55% of the participants had systolic dysfunction as defined by a left ventricular 
ejection fraction below 45%. Thirty percent of the participants had been diagnosed with diastolic 
dysfunction and the etiology of heart failure in the remaining patients was unclear. In regards to 
the patients’ pharmacotherapy, 12 patients were on ACE-inhibitors, all patients were on 
diuretics, 5 on beta-blockers, and 6 on digitalis glycosides. Comorbidities included hypertension 
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(80%), diabetes mellitus (53%) and depression (32%). The age-matched controls did not have 
any evidence of overt disease.  
Table 2.1. Participant Characteristics 
Race Gender  n 
B W M F 
Age 
(yr.) 
Weight 
(kg) 
Height 
(cm) 
BMI 
Heart Failure 16 14 2 4 12 61±14 84.6±13 169.0±10 29.8±5 
Age-Matched 13 0 13 3 10 65±11 77.8±13 169.3±11 27.3±5 
p      0.341 0.181 0.941 0.186 
 
• Survey Results 
 The survey results indicated very little written evidence that clinicians provided patients with 
information regarding physical activity. Of the 16 patients, only one had received some specific 
information regarding physical activity over the last year. In contrast, there were no notes 
indicating any physical activity guidance for the remaining 15 patients. No patients were 
provided specific guidelines for exercise as recommended by the American Heart Association. 
• Validity and Reproducibility of the 6-minute Walk Test 
A major end-point in this study concerned the maximum walking distance achieved on the 6-
min walk test. Given a lack of information on the acute responses during the 6-min walk test in 
this population, a group of heart failure patients were matched with an age-matched control 
group.  The age-matched control group (63+6 years) consisted of individuals who had no 
evidence of underlying disease as determined by previous clinical examination.  As expected the 
healthy participants walked significantly faster compared to the patient group at every minute of 
the walk test (see Figure 2.1). Furthermore, the maximum distance walked for the healthy 
participants (552.03+73.80m) was much greater in comparison to the distance achieved by the 
patients with heart failure (242.35 +86.35m) (p<0.05). Thus, these data clearly show that the 6-
minute walk test differentiates between healthy and heart failure populations. 
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Importantly test-retest data reveals adequate reproducibility for maximum walking distance 
and heart rate responses for the 6-minute walking test. Results revealed an ICC and CV  
of 0.97 and 8.9% for visit 1 and 2, respectively. Hemodynamic measurements prior to and during 
the walk test were not significantly different from visit 1 to visit 2. The ICC and CV for heart 
rate in the last minute of exercise was 0.99 and 2.0%, whereas the ICC for BP ranged from 0.694 
to 0.772 with CV of 6.3 to 13.0%, respectively. The reproducibility of the measures is further 
detailed in figures 2.2 through 2.5. 
 
 
 
 
 
 
 
 
Figure 2.1. Comparison of Health vs. Disease: 6-minute Walk Test. *p<0.05 Healthy Controls 
vs. Heart Failure 
 
• Validity of the SF-36 
 A second major end-point in this pilot-study was the perceived quality of life measured using 
the SF-36 Health Survey. The survey provides information about 8 specific concepts (i.e. 
physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH), vitality 
(VT), social functioning (SF), role-emotional (RE), and mental health (MH)) and 2 combined  
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Figure 2.2. Six minute Walk Distance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Heart Rate Responses before, during and after the 6-Minute Walk Test 
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Figure 2.4. Blood Pressure Responses to the 6-minute Walk Test      
 
scores (i.e. physical component score (PCS) and mental component score (MCS). Table 2.2 
clearly shows that the scores are significantly lower for the heart failure patients suggesting 
greater decrements in functioning and well being than the age-matched controls. 
Table 2.2. Comparison of Heart Failure and Age-matched Healthy Controls: SF-36 Scales 
*p<0.05 Controls vs. HF 
 PF RP BP GH VT SF RE MH PCS MCS 
HF 44.7 31.3 55.7 48.6 44.1 67.2 54.2 67.0 31.0 45.7 
Controls 85.0* 100.0* 81.0* 84.3* 73.1* 100.0* 100.0* 90.5* 51.4* 59.1* 
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Figure 2.5. Ratings of Perceived Exertion during the 6-Minute Walk Test 
 
 In addition, data in Table 2.3 compared the scores for our heart failure patients to the norms 
established by Ware9. The data appear to indicate that despite the small sample size the scores 
are very similar to the national norms for congestive heart failure patients. 
Table 2.3. Comparison of Baton Rouge General Pilot Data and National Norms for Patients 
with Heart Failure: SF-36 Scales 
 PF RP BP GH VT SF RE MH PCS MCS 
HF  44.7 31.3 55.7 48.6 44.1 67.2 54.2 67.0 31.0 45.7 
Norms  47.5 34.4 62.7 47.1 44.3 71.3 63.7 74.7 34.1 47.3 
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• Effect of 4 Month of Care-Managed Exercise Program 
The 6-minute Walk Test 
The results of the study indicated modest yet statistically significant improvements in the 
maximum walking distance following the 16-week period. Patients consistently selected higher 
walking speeds at each minute during the test. The pattern of speed changes during the walking 
tests from start to finish for heart failure patients who completed a 16-week care management 
program are depicted in Figure 2.6.  
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Figure 2.6. Effects of a Care-Managed Program for Heart Failure: 6-minute Walk Test 
As can be seen from these data, patients selected higher speeds in the first minute of the test 
and were able to maintain these speeds throughout the 6-min walk test following the intervention 
period. Consequently, the maximum walk distance improved by 19%, 241.43+88.06m to 
285.65+ 99.69m (p=0.06). 
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 The SF-36 Health Survey 
 The preliminary findings on the effects of the 16-week Care-Managed Heart Failure Program 
are shown in Table 2.4. The data indicate a significantly higher score on the physical functioning 
(PF) component of the SF-36 in those subjects who completed the exercise arm of the pilot-
study.  
Table 2.4. Preliminary Data on the Effect of a 4 Month Care-Managed Heart Failure 
Program: SF-36 Scales 
 PF RP BP GH VT SF RE MH PCS MCS 
Pre 45 29.167 53 49.33 50 64.58 27.78 62.67 35.83 43.2 
Post 58* 25 63.17 44.33 60 50 27.78 68.67 38.17 42.53
*p<0.05 Pre vs. Post 
 
Relationship of the 6-minute Walk Test and SF-36 Health Survey 
Figure 2.7a depicts the relationship of the 6-minute walk test and the physical functioning 
score on the SF-36 Health Survey. The graph shows that as the physical functioning scores on 
the SF-36 decline so does the maximum walking distance on the 6-minute walking test (r2=0.72; 
p<0.05). Furthermore, as shown in Figure 2.7b these preliminary data also reveal that as 
maximum walking distance improved (observed measures of physical function), scores on the 
physical functioning scale of the SF-36 health survey also improved (subjective measures of 
physical function), indicating a positive correlation between the change in maximum walking 
distance following the care-managed program and the physical functioning score on the SF-36 
(r=0.59; p=0.06). 
2.4 Discussion 
The major findings of this study are as follows: (1) despite the overwhelming evidence of the 
benefits of exercise for patients with heart failure, there appears to be a lack of evidence to 
suggest that these patients are receiving adequate information regarding physical activity, (2) 
both the maximum walking distance on a 6-min walking test and the SF-36, a quality of life 
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Figure 2.7a and b Relationship of the 6-minute Walk Test and SF-36 Health Survey 
 
survey, clearly differentiate between patients with heart failure and age-matched controls; (3) the 
one-week stability in the hemodynamic measures and the distance walked on the 6-minute 
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walking test on a treadmill were adequate, and (4) home exercise with frequent patient contact 
resulted in modest improvements in exercise tolerance and perceived quality of life. 
• Survey  
It is not clear why the patients are apparently not receiving adequate information regarding 
physical activity. However, several factors may play into this dilemma. For example, the lack of 
physical activity recommendations may be secondary to a lack of appreciation of the importance 
of physical activity by the primary care physician, a lack of knowledge about the current 
guidelines on exercise in heart failure, an inability to discuss the subject matter effectively, a lack 
of time to discuss the subject matter, fear of precipitating further health or physical problems, a 
lack of confidence by the physician that the information may be put to use, and/or a lack of 
knowledge about available resources for these patients. In all fairness to the clinicians, the data 
from this study only suggest a lack of adequate information about physical activity. The data 
were collected directly from the medical records of the patients rather than examining the 
clinicians in action (i.e. the actual patient contact time). In some cases the clinician may in fact 
have discussed the role of physical activity with the patient but failed to note this in the medical 
records. Regardless of the barrier future research should aim to provide the clinicians with 
adequate strategies and the patients with the right opportunities to gather all the necessary 
information that may aid in improved management of the disease.  
• Validity and Reproducibility of the 6-minute Walk Test 
 The present study clearly shows that the 6-minute walking test differentiates between a 
healthy and heart failure population. In fact, the reported maximum walking distance for the 
heart failure patients in this study was quite consistent with previous reports10. Guyatt et al. 
(1985) were one of the first to study the potential value of the 6-minute walk as an objective 
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measure of exercise capacity in patients with chronic heart failure10. They administered the 6-
minute walking test six times over 12 weeks in 18 patients with chronic heart failure and 25 with 
chronic lung disease. The subjects also underwent cycle ergometer testing, and their functional 
status was evaluated by means of conventional measures. The walking test proved highly 
acceptable to the patients, and stable, reproducible results were achieved after the first two 
walks10. The results correlated with the conventional measures of functional status and exercise 
capacity. The authors concluded that the 6-minute walk is a useful measure of functional 
exercise capacity and a suitable measure of outcome for clinical trials in patients with chronic 
heart failure10. The present study is somewhat unique in that the stability of the measures was 
found using a treadmill test rather than the traditional hallway test. Recognizing the importance 
of using the same approach when conducting repeat measures the present data clearly show the 
usability of a treadmill for the purpose of obtaining the maximum walking distance on the 6-
minute walking test. The present data do support research by Guyatt et al.10 , who recommends a 
practice walk be performed. If the difference between the first and second walk is greater than 
10% a third walk should be undertaken and used as the baseline measure. In this study the 
magnitude of the difference did not exceed 10% in any of the participants. 
Uniquely, this is the first study to examine the stability of the hemodynamic responses to the 
6-minute walking test. Interestingly, the hemodynamic measurements prior to and during the 
walk test were not significantly different from visit 1 to visit 2. Blood pressure responses during 
the 6-minute walking test were not significantly different from pre-test values. Moreover, test-
retest comparison for blood pressure in the last minute of the 6-minute walking test revealed 
Interclass Correlation Coefficients ranging from -0.63 for systolic blood pressure to 0.77 for 
mean arterial blood pressure, suggesting much lower stability of the blood pressure responses. In 
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contrast, heart rate increased significantly from rest by the first minute of the 6-minute walking 
test, and returned to pre-test levels in the second minute of recovery. The Interclass Correlation 
Coefficients and Coefficient of Variation for heart rate in the last minute of exercise was 0.99 
and 2.0%, respectively. The stability of the heart rate response in the last minute of exercise 
suggests the potential of this parameter as an outcome measure.  
 In contrast, reports of symptoms and ratings of perceived exertion were inconsistent from 
visit 1 to visit 2 indicating these measures may not be sensitive in this population. Although the 
mean values appear similar between tests, within subject variability was high. The reason for the 
variability may be the subjective nature of these measures. Furthermore, pre-test instructions 
emphasize the importance to achieve a perceived exertion rating of 12 to 14 toward the end of 
the test. The fact that not all patients achieved this goal possibly indicates lack of knowledge of 
proper use of the scales, and/or stress or uncertainty about the test. This is an important 
consideration when examining the effects of interventions.    
 Importantly, the average walking distance in this study was 242.35±86.35m. In light of 
recent work an average walking distance below 300 meters carries a rather ominous prognosis11. 
Roul et al. (1998) 11 prospectively evaluated the potential of the 6-minute walk test compared 
with peak VO2 in predicting outcome of patients with New York Heart Association (NYHA) 
class II or III heart failure. Death or hospitalization for heart failure was used as the judgment 
criterion. Patients who walked less then or equal to 300 m had a worse prognosis than those 
walking farther (p=0.013). Furthermore, the investigators found a significant correlation between 
distance covered and peak VO2 (r=0.65, p=0.011). Thus, it appears that a distance walked in 6 
minutes less then or equal to 300 m can predict outcome in patients with heart failure11. 
Moreover, in these cases there is a significant correlation between the 6-minute walk test and 
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peak VO2 demonstrating the potential of this simple procedure as a first-line screening test for 
this subset of patients. 
 The precise mechanism for the low exercise tolerance is not fully known but involves a series 
of pathophysiological abnormalities that accompany the disease12-14. In addition, the low 
maximum walking distance achieved by the patients confirms previous reports indicating the six-
minute walk test is a simple objective guide to disability in patients with chronic heart failure10. 
• Validity of the SF-36 
 According to McHorney et al.15 the widespread use of standardized health surveys is 
predicated on the largely untested assumption that scales constructed from those surveys will 
satisfy minimum psychometric requirements across diverse population groups. McHorney et al. 
15 used data from the Medical Outcomes Study (MOS) to evaluate data completeness and quality, 
test scaling assumptions, and estimate internal-consistency reliability for the eight scales 
constructed from the MOS SF-36 Health Survey. Analyses were conducted among 3,445 patients 
and were replicated across 24 subgroups differing in sociodemographic characteristics, 
diagnosis, and disease severity. For each scale, item-completion rates were high across all groups 
(88% to 95%), but tended to be somewhat lower among the elderly, those with less than a high 
school education, and those in poverty. On average, surveys were complete enough to compute 
scales scores for more than 96% of the sample. Across patient groups, all scales passed tests for 
item-internal consistency (97% passed) and item-discriminant validity (92% passed). Reliability 
coefficients ranged from a low of 0.65 to a high of 0.94 across scales (median = 0.85) and varied 
somewhat across patient subgroups. Floor effects were negligible except for the two role 
disability scales. Noteworthy ceiling effects were observed for both role disability scales and the 
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social functioning scale. The authors conclude that their findings support the use of the SF-36 
survey across the diverse populations studied15. 
 Normative data for individuals with various disease conditions, including heart failure, have 
been estimated from the general US population and M.O.S. patient population. We recognize 
that the relatively small sample size (n=216) for heart failure and the fact that the norms are not 
adjusted for sociodemographics and comorbid conditions. However, it is clear from the currently 
available data that patients with heart failure exhibit markedly worse physical, role, and social 
functioning; mental health; health perceptions; and/or bodily pain compared with individuals 
with no chronic conditions.  
 In the present study the SF-36 scores for each specific concept are significantly lower for the 
patients compared to age-matched controls. This indicates reduced perception of quality of life. 
Despite our small sample size, these results are very similar to the national norms established by 
Ware9. Furthermore, these data reveal a direct relationship between maximum walking distance 
and quality of life scores. These results confirm previous reports by Havranek et al.16, suggesting 
the meaningfulness of these measures for the evaluation of heart failure interventions.  
• Effect of 4 Month of Care-Managed Exercise Program 
 The pattern of speed changes during the walking tests from start to finish for the heart failure 
patients who completed a 4 month care management program are depicted in Figure 2. As can be 
seen from these data patients selected higher speeds in the first minute of the test and were able 
to maintain these speeds throughout the 6-min walk test following the intervention period. 
Consequently, the maximum walk distance improved by 19%, from 241.43+88.06m to 285.65+ 
99.69m, p=0.06. The observed improvements in maximum walking distance in our pilot study 
are less than previously reported following a 3-week exercise training program17. However, our 
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findings are similar to Rector et al. (1996) who showed increases in maximum walking distances 
(390+91 versus 422+86 m, p<0.05) in a study to determine whether supplemental oral L-arginine 
augment peripheral blood flow and improve functional status in patients with moderate to severe 
heart failure18. Recognizing the limitations of a pilot study, these data do support the idea that a 
carefully managed program for heart failure patients may contribute to improvements in 6-
minute walk test performance. 
 The preliminary findings on the effects of the 16-week Care-Managed Heart Failure Program 
on quality of life indicate a significantly higher score on the physical functioning (PF) 
component of the SF-36 in those subjects who completed the exercise arm of the pilot-study.  
2.5. Conclusion 
 In conclusion, this study indicates that despite the overwhelming evidence of the benefits of 
exercise for patients with heart failure, there appears to be a lack of evidence to suggest that 
these patients are receiving adequate information regarding physical activity. Second, both the 
maximum walking distance on a 6-min walking test and the SF-36, a quality of life survey, 
clearly differentiate between patients with heart failure and age-matched controls. Third, the one-
week stability in the hemodynamic measures and the distance walked on the 6-minute walking 
test on a treadmill were adequate. Finally, home exercise with frequent patient contact resulted in 
modest improvements in exercise tolerance and perceived quality of life. 
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CHAPTER 3. IMPROVED EXERCISE TOLERANCE AND QUALITY OF LIFE 
FOLLOWING A HEART FAILURE PROGRAM IN FAMILY PRACTICE 
 
3.1 Introduction 
Heart failure is defined as "the pathophysiological state in which an abnormality of cardiac 
function is responsible for failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolizing tissues and/or to be able to do so only from an elevated filling 
pressure" 1. The alteration in the normal physiological pumping capacity of the heart is 
principally due to three distinct etiologies: (1) intrinsic myocardial disease including coronary 
heart disease, cardiomyopathy, and infiltrative disease; (2) excess work load due to increased 
resistance to ejection (pressure load) secondary to hypertension and hypertrophic 
cardiomyopathy or increased stroke volume (volume load) secondary to aortic and/or valvular 
insufficiency; (3) iatrogenic myocardial damage from drugs or radiation therapy 2. 
The National Health and Nutrition Examination Survey reports an estimated 4.8 million 
Americans have heart failure. Each year approximately 400,000 new cases are diagnosed, and 
36,387 Americans died from heart failure in 1992 3. This represents a significant rise in the 
number of deaths from heart failure since 1968.  In addition to the cost of human life, heart 
failure poses an enormous financial burden on American society.  The management of heart 
failure generally exceeds $5 billion 4.  It is expected that this cost to society will only rise in the 
future, as it is estimated that by the year 2020, the number of persons over 65 years of age 
population will represent over 20% of the general populous. This will undoubtedly result in a 
significant increase in the number of people with chronic conditions including heart failure.  
The treatment of heart failure is aimed at correcting the underlying cause and/or controlling 
the heart failure state.  The management of the heart failure patient generally includes a 
combination of pharmacological compounds aimed to relieve clinical symptoms and prolong life 
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5.  Numerous pharmacological agents are available which help improve central hemodynamics 
by reducing cardiac afterload or enhancing myocardial contractility.  Additional pharmacological 
agents are used to reduce excessive fluid retention.  Following initiation of such therapy 
mortality is reduced, and many patients experience resolution of their symptoms at rest 5-7.  
However, most patients continue to experience activity-related symptoms, including shortness of 
breath, muscle fatigue, and weakness.  As a result, patients with heart failure often complain of 
chronic fatigue and are unable to perform many of their normal activities of daily living.  Thus, 
despite traditional pharmacological treatment, the clinical phase of heart failure includes a 
marked decline in functional status, as defined by exercise tolerance with a subsequent decrease 
in quality of life. 
Modifications of lifestyle can be helpful in controlling the symptoms of heart failure and 
maintaining clinical stability. For example, it has been suggested that basic habits of moderate 
sodium restriction, weight monitoring, exercise, and adherence to medication schedules may aid 
in avoiding fluid retention or alerting the patient to its presence 8. Multiple studies have shown 
that patients who are educated and knowledgeable about their disease process and understand 
how their medications work and the importance of compliance have fewer hospital readmissions 
and experience an increase in exercise tolerance and quality of life 9-11. For example, in a review 
of the literature from 1966 to 1993 12, counseling and health education increased life expectancy 
and quality of life, and reduced hospitalization of patients with heart disease.  
In an effort to address this major public health concern, the Agency for Healthcare Policy and 
Research (AHCPR) published guidelines for the evaluation and care of patients with HF 13. 
These guidelines include recommendations for patient and family education and counseling, diet, 
physical activity, nursing and social services intervention, support groups, and specific measures 
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to improve compliance. It is noteworthy that the vast majority of patients with heart failure are 
managed in the primary care setting, yet few studies have examined the efficacy of 
comprehensive care as outlined by the AHCPR in this setting. In fact, one of the key areas for 
future research suggested by the AHCPR is to determine the efficacy of their guidelines in 
different practice environments and with diverse populations (i.e. gender, race, socioeconomic 
status, level of education and etiology of heart failure). Consequently, the purpose of the second 
study was to determine whether a tailored heart failure educational program as outlined by the 
Agency of Health Care Policy and Research (AHCPR) could be effectively implemented in a 
primary care setting. Specifically, this study examined the effects of a 3-month care-managed 
program on exercise tolerance and measures of perceived quality of life in patients with heart 
failure in a family practice setting. 
3.2 Methods 
• Participants   
All patients were recruited from the Family Medicine Residency Program/ Baton Rouge 
General Medical Center.  Men and women over the age of 18 years with diagnoses of heart 
failure (regardless of etiology) were eligible for the study. In addition, participants had to have 
the ability to read and write English. The duration of heart failure in all patients was no less than 
4 months and patients were optimally managed as deemed by the participant’s primary care 
physician. Participants were not excluded on the basis of gender, race, and/or etiology of heart 
failure. However, those patients with acute unstable myocardial ischemia and/or angina, other 
non-cardiac diseases that would interfere with the completion of the study (uncontrolled 
hypertension, severe chronic obstructive pulmonary disease, or severe arthritis), and those 
recovering from a recent medical emergency resulting in hospitalization (e.g. acute myocardial 
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infarction, coronary bypass graft surgery, radiation therapy, etc.) were excluded from 
participation. 
• Recruitment Strategies 
  In an effort to maximize the ability to recruit from a pool of approximately 350 patients, a 
dedicated nurse clinician was hired. A major portion of the nurse clinician’s job responsibilities 
was to identify all potential candidates and contact both patients and physicians in terms of their 
potential participation. The first strategy involved identification of the candidates through 
medical and computer records. The second strategy involved telephone contact and subsequently 
a direct meeting when the patient was scheduled for an appointment. Finally, each physician (a 
total of 6) was constantly reminded about the program to help in remind them about the study.  
• Study Design and Experimental Measures 
This study was a prospective, randomized controlled trial aimed at examining the effects of a 
multifaceted, care-managed program as outlined by the AHCPR in patients with heart failure in a 
family practice setting 13. Changes in exercise tolerance and perceived quality of life were 
followed over a 3-month period and patients were randomly assigned to one of two groups: 
Usual Care and Care-managed. Exercise tolerance was measured as the maximum distance 
(MWD) achieved on a six-minute walk test. Perceived quality of life (QOL) was evaluated using 
the short-form 36 health survey (SF-36). Patients in both the usual care and care-managed groups 
received an initial education session including general information about heart failure, followed 
by weekly telephone calls to monitor compliance and clinical status.  
Additionally, patients randomized to the care-managed group received education guided by 
an extensive heart failure patient workbook. The workbook included recommendations about 
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physical activity, medications, nutrition, and other pertinent issues as outlined by the AHCPR 
guidelines 13. Figure 3.1 displays an example of chapter outlines from the patient workbook.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Heart Failure Disease Management Patient Workbook Sample 
 
Table 3.1 provides an overview of the specific topics that were addressed and monitored 
throughout the course of the study. These topics were specifically recommended by the AHCPR 
for patient and family education and counseling. Furthermore the decision to use these topics 
was based on the available literature which indicates the use of these strategies to be effective in 
heart failure patients in tertiary settings 14,15.  
• Baseline Visit One 
Upon arrival to the clinic all participants received a comprehensive explanation of the 
proposed study, its benefits, inherent risks and expected commitments with regard to time and 
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patient responsibilities.  Each individual was required to complete an informed consent 
document approved by the Baton Rouge General and Louisiana State University Institutional 
Review Board prior to any testing procedures. All patients underwent a medical evaluation  
performed by the Medical Director of the study, which included a medical history, review of 
symptoms, and routine examination of the major organ systems. 
Table 3.1. Topics for Patient, Family, and Caregiver Education and Counseling 
 
General Counseling 
Explanation of Heart Failure and the Reason for Symptoms 
• Cause or probable cause of heart failure 
• Expected symptoms 
• Symptoms of worsening heart failure 
• What to do if symptoms worsen 
• Self-monitoring with daily weights 
• Explanation of treatment/care plan 
• Clarification of patient's responsibilities 
• Importance of cessation of tobacco use 
• Role of family members or other caregivers in the treatment/care plan 
• Availability and value of qualified local support group 
• Importance of obtaining vaccinations against influenza and pneumococcal disease 
Prognosis 
• Life expectancy 
• Advance directives 
• Advice for family members in the event of sudden death 
Activity Recommendations 
• Recreation, leisure, and work activity 
• Exercise 
• Sex, sexual difficulties, and coping strategies 
Dietary Recommendations 
• Sodium restriction 
• Avoidance of excessive fluid intake 
• Fluid restriction (if required) 
• Alcohol restriction 
Medications 
• Effects of medications on quality of life and survival 
• Dosing 
• Likely side effects and what to do if they occur 
• Coping mechanisms for complicated medical regimens 
• Availability of lower cost medications or financial assistance 
Importance of Compliance with the Treatment/Care Plan 
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Exercise tolerance was assessed using a 6 minute walking test on a motor driven treadmill 16.  
Prior to testing the patients were instructed to walk at a self-selected speed, avoiding chest pain 
or marked dyspnea. The grade of the treadmill was set at 0%.  Patients controlled the treadmill 
speed and were allowed to change it at any time. The speed could be altered in increments of 0.1 
km/hr, allowing precise measurement of walking distance.  Heart rate and blood pressure were 
monitored during the test. To standardize the protocol, participants were not coached during 
testing but all participants were made aware of the time remaining to completion. 
Finally, patients' perceived quality of life, defined for the present study as the subjective 
appraisal of general physical and emotional well-being, was assessed with the Short-Form 36 
(SF-36) questionnaire 17. The SF-36 is comprised of 36 items that describe health related 
physical and psychosocial dysfunction in 8 areas to include physical function, social function, 
role-limitation-physical, role limitation-emotional, mental health, vitality, bodily pain, and 
general health. A single item evaluates the patient’s perception of change in health. Scores range 
from 0% to 100% with higher scores consistent with better health status.  
• Baseline Visit Two 
To ensure stability of the measure, the six minute walk test was repeated one week after the 
initial test.  Therefore, upon arrival to the clinic participants were prepared for assessment of 
exercise tolerance. After a 15 minutes rest period, resting heart rate and blood pressure were 
obtained from the dominant arm, using standard auscultation procedures and a Trimline mercury 
sphygmomanometer (Pymah Co., Somerville, NJ). Subsequently, exercise tolerance was again 
assessed using the 6 minute walking test on a motor driven treadmill as described in the previous 
section. 
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 Following these procedures, all patients received a general educational session with the nurse 
educator. The purpose of this session was to educate the patient about the serious implications of 
their diagnosis, an explanation of what patients can expect to experience during activities of 
daily living, typical symptoms of worsening heart failure, and who to contact if such symptoms 
develop. Furthermore the nurse educator discussed medication compliance, low salt-diet and 
encouraged regular physical activity. In addition, patients randomized to the care-managed group 
received an educational workbook that included information regarding physical activity, diet, 
medications, and other pertinent issues as recommended by the AHCPR 13.  
• Follow-up 
All patients received weekly telephone follow-up to monitor clinical status. Additionally, 
patients randomized to the care-managed group received intensive education regarding specific 
topics as outlined by the AHCPR and individualized program modification. Furthermore, these 
patients were scheduled for monthly group visits for additional education on selected topics.  
• Three Month Follow-up 
At the end of the 3 month period, all patients were scheduled to undergo the same series of 
assessments as described for the baseline visits (Physical examination, quality of life survey, and 
the 6-minute walking test).  In order to control for the possible confounding effects of 
pharmacotherapy, circadian rhythms, and other external sources of variability the tests were 
performed by the same team of investigators at approximately the same time of day. 
• Statistical Analysis 
 All statistical analyses were conducted using the latest version of the SPSS statistical 
package for windows. To examine the influence of the intervention on exercise tolerance and 
hemodynamic measures a 2 (intervention and usual care group) by 2 (Pre versus Post) ANOVA 
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was conducted. To examine the influence of the intervention on quality of life a 2 (intervention 
and usual care group) by 2 (Pre versus Post) ANOVA was conducted. The stability of the 6-min 
walking test was examined using an ANOVA with repeated measures, and intraclass correlation 
coefficients. Alpha levels were set at 0.10. 
3.3 Results 
• Patient Characteristics 
Of a possible 350 patients, only 18 patients with HF (NYHA class II or III) were taken 
through the program. From the 18 patients, ten were randomized to the care managed group 
(n=10; age=57+13) and eight to the usual care group (n=8; age=53+14). The main etiology of 
heart failure for the patients was ischemic heart disease followed by hypertensive heart disease. 
There were no differences between the groups prior to the intervention for age, height, weight, 
BMI, or any hemodynamic measures (see Table 3.2).  
Table 3.2. Participant Characteristics 
Participant Characteristics  
Intervention 
(n=10) 
Usual Care 
(n=8) 
Age (yrs) 57±14 53±13 
Height (cm) 167±7 167±10 
Weight (kg) 98.44±15.50 98.80±38.61 
BMI (kg/m2) 34.67±5.35 37.51±15.85 
HRrest (b/min) 66±14 80±15 
SBPrest (mmHg) 143±17 132±14 
DBPrest (mmHg) 80±10 82±11 
Co-Morbidity 5±3 3±2 
 
• Six-minute Walk Test 
 
The test-retest values for the 6 minute walk test prior to training are presented in Figure 3.2. 
As previously reported the reproducibility and stability of the test is adequate. For the purpose of 
comparing the pre and post training values the second test was used as the true baseline value. 
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Six-minute walking distances at baseline and three months are depicted in Table 3.3. Patients 
in the care-managed group walked significantly farther at 3-months as compared to baseline for 
each minute of the test; consequently, maximum walking distance improved by 24% (199.7+26 
to 247.1+92; p=0.014). Maximum walking distance did not significantly improve for patients in 
the usual care group. 
Table 3.3. Six Minute Walking Distance at Baseline and 3 months 
Six-Minute Walk Test  
(Walking Distance) 
Intervention(n=10) Usual Care (n=8) 
 
Baseline 3-Months Baseline 3-Months 
Min 1(m/min) 30.25±15.80 35.76±17.54* 15.71±5.04 19.93±3.94 
Min 2(m/min) 32.48±14.03 38.74±17.34* 16.86±5.47 21.27±5.15* 
Min 3(m/min) 34.87±14.51 42.31±15.51* 18.78±6.90 22.22±6.24 
Min 4(m/min) 36.66±14.75 42.91±15.29* 20.69±9.09 24.14±8.43 
Min 5(m/min) 36.66±14.75 42.32±15.86+ 20.69±9.09 24.72±9.09 
Min 6(m/min) 36.66±14.75 42.32±15.86+ 21.46±9.96 24.52±8.87 
MWD(m) 199.70±29.00 247.10±92.00* 114.19±45.43# 136.79±41.38 
 
Table 3.4 shows the hemodynamic measures immediately after the 6th minute on the walk 
test. No significant differences between the periods or the groups were noted.  
Table 3.4 Hemodynamic and Perceived Exertion in the Last Minute of the Walk Test 
Six-Minute Walk Test  
(Hemodynamics and Perceived Exertion @ 6 min) 
Intervention(n=10) Usual Care (n=8) 
 
Baseline 3-Months Baseline 3-Months 
Heart Rate  (Bts/min) 103±13 96±17 108±17 110±18 
Systolic Blood Pressure (mmHg) 144±23 165±12 167±15 159±12 
Diastolic Blood Pressure (mmHg) 81±16 77±8 100±8 88±12 
RPE 9.33±1.63 10.44±1.51 8.43±1.06 9.57±1.67 
 
• Quality of Life 
 The results of the effects of the 3-month Care-Managed Heart Failure Program on the 
perceived quality of life measured using the SF-36 Health Survey are shown in Table 3.5.  
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Table 3.5. Perceived Quality of Life before and after the intervention 
Perceived Quality of Life(SF-36) 
Intervention(n=10) Usual Care (n=8) 
 
Baseline 3-Months Baseline 3-
Months 
Physical Function 50±27 65±25+ 40±25 40±38 
Role Physical 39±42 50±45 44±42 70±36 
Bodily Pain 63±30 65±27 80±16 79±25 
General Health 48±23 55±19 21±10 24±12 
Vitality 42±23 62±24* 39±19 37±19 
Social Function 67±38 64±31 75±18 97±6 
Role Emotional 59±32 78±24 58±32 67±47 
Mental Health 66±21 75±26+ 59±31 64±30 
Physical Component Score 37±11 40±9 37±9 39±10 
Mental Component Score 46±12 50±10 45±13 51±12 
*p<0.05 vs. Baseline; +p<0.10 vs. intervention 
The data indicate that following the 3-month intervention, physical function (PF), vitality (VT), 
and mental health (MH) scores improved by 29% (50+27 to 64.5+25), 46% (42+23 to 61.5+24), 
and 13% (66.4+21 to 75.2+26), respectively (p<0.10), in patients randomized to the care-
managed group.  
3.4. Discussion 
The present study indicates it is feasible to implement a multifaceted, care-managed program 
for individuals with heart failure in a family practice setting. However, a significant barrier to its 
success was the inability to effectively recruit patients from the pool of candidates. Despite this 
failure, the present data indicate moderate improvements in exercise tolerance and perceived 
quality of life in heart failure patients following a care-managed program in a family practice 
setting. 
• Reproducibility of the 6-minute Walk Test 
 The present study clearly shows that the 6-minute walking test differentiates between a 
healthy and heart failure population. In fact, the reported maximum walking distance for the 
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heart failure patients in this study was quite consistent with previous reports10. Guyatt et al. 16 
were one of the first to study the potential value of the 6-minute walk as an objective measure of 
exercise capacity in patients with chronic heart failure. They administered the 6-minute walking 
test six times over 12 weeks in 18 patients with chronic heart failure and 25 with chronic lung 
disease. The subjects also underwent cycle ergometer testing, and their functional status was 
evaluated by means of conventional measures. The walking test proved highly acceptable to the 
patients, and stable, reproducible results were achieved after the first two walks16. The results 
correlated with the conventional measures of functional status and exercise capacity. The authors 
concluded that the 6-minute walk is a useful measure of functional exercise capacity and a 
suitable measure of outcome for clinical trials in patients with chronic heart failure16. The present 
study is somewhat unique in that the stability of the measures was found using a treadmill test 
rather than the traditional hallway test. Recognizing the importance of using the same approach 
when conducting repeat measures the present data clearly show the usability of a treadmill for 
the purpose of obtaining the maximum walking distance on the 6-minute walking test. The 
present data do support research by Guyatt et al. 16, who recommends at least a practice walks be 
performed. If the difference between the first and second walk is greater than 10% a third walk 
should be undertaken and used as the baseline measure. In this study the magnitude of the 
difference did not exceed 10% in any of the participants. 
• Effect of 3 Month Intervention 
 Exercise tolerance as defined by the maximum walking distance achieved on a six-minute 
walk test improved in the patients randomized to the care-managed group. The pattern of speed 
changes during the walking tests from start to finish indicated patients in the care-managed group 
selected higher speeds in the first minute of the test and were able to maintain these speeds 
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throughout the 6-min walk test following the3-month intervention period. Consequently, the 
maximum walk distance improved by 24%, from 199.7+26 to 247.1+92 (p=0.014). The observed 
improvements in maximum walking distance in this study are slightly better than our pilot study 
(19%, 241.43+88.06m to 285.65+ 99.69m (p=0.06).These findings are also similar to Rector et 
al. 18 who showed increases in maximum walking distances (390+91 versus 422+86 m, p<0.05) 
in a study to determine whether supplemental oral L-arginine augment peripheral blood flow and 
improve functional status in patients with moderate to severe heart failure. Recognizing the 
limitations of this study, these data support the idea that a carefully managed program for heart 
failure patients may contribute to improvements in 6-minute walk test performance. 
In addition, data from the present study indicate a significantly higher score on three 
components of the SF-36. These included physical function, vitality, and mental health scores, 
which improved by 29%, 46%, and 13%, respectively (p<0.10). These improvements were only 
evident in the patients randomized to the care-managed group. The improvements are somewhat 
modest in comparison to another study that reported significant improvements in energy (80%), 
physical mobility (74%), and emotional reactions (83%) in heart failure patients 3 months 
following cardiac transplantation 19. Obviously such changes are difficult to compare as the 
present study did not involve transplantation. The present changes are also less than those 
reported by Kavanagh et al. 20, although they reported their improvements after one year of 
training. 
• Recruitment Failures 
 The greatest failure of this study was the inability to effectively recruit, despite a dedicated 
nurse clinician, a committed medical director, and a large enough candidate pool. It is certainly 
not easy to pin-point the reasons for the lack of success but a few barriers are presented in an 
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effort to aid future attempts to overcome these more quickly. A major reason appeared to be a 
general lack of interest by many patients with heart failure. The reasons for the lack of interest 
are unknown but it is not uncommon to see this problem in populations with similar 
demographics. It has been suggested that some patients may be somewhat fearful, in greater 
denial, or mistrusting of a particular program that is not directly associated with their physician. 
Other issues could certainly include a lack of perceived benefits, transportation problems, a lack 
of education or other socioeconomic factors. Many of these factors have previously been 
identified and should become a greater part of the planning stages of these sorts of efforts 21-23. 
Another issue that may have affected the recruitment was the fact that the clinic was undergoing 
a major transition in leadership. It appeared the physicians were somewhat distracted by these 
issues which may have affected their attention to this study.  
 A second issue that requires a lot more thought and planning is the fact that it appeared many 
patients were just not ready to engage, regardless of a specific reason. Given this lack of 
readiness, it is not realistic to expect such patients to make changes that they are not prepared to 
make. Thus it would appear greater attention to assessing the motivation and readiness of 
patients with heart failure could be an important factor prior to forcing or implementing 
behavioral changes24. In fact clinicians have been encouraged to examine theoretically based and 
practically important behavioral strategies that might be useful for encouraging and supporting 
behavior changes (e.g. exercise initiation and/or maintenance) among individuals with chronic 
heart failure13, 25, 26. Application of behavioral theories, such as the Transtheoretical model 
(TTM) of behavior change may be useful in designing effective intervention programs for 
patients with heart failure26. These approaches could be used to guide strategies that go beyond 
traditional patient educational approaches27. For example, with the appropriate activities to meet 
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the patient’s stage of readiness for change, healthcare providers may facilitate a patient’s 
movement along the continuum of change to alter lifestyle behaviors, such as physical activity, 
that can result in improved outcomes 24,26,28. Therefore, the TTM offers an opportunity to 
improve compliance with published guidelines by individualizing the change process to meet the 
needs of each patient.  
• Educational Workbook 
 A major effort of this study was the development of an educational workbook that was 
specifically tailored to the patients’ level of education and disease. The workbook was designed 
to allow patients gain a greater understanding of their condition and teach them the importance 
of adhering to their program and recognizing early warning signs that may lead to congestive 
heart failure. Perhaps somewhat surprising few patients had any awareness of their condition and 
the steps needed to protect them from deteriorating. The workbook appeared to raise the patients’ 
awareness about their condition, which according to other researchers is a necessary component 
in the successful management of the patient 15. 
 Clearly more work is needed. On the basis of the data from this study it would be important 
to modify the workbook to include strategies that may help individuals become more motivated 
and prepared to engage in these important behavioral strategies such as exercise, weighing, and 
careful adherence to diet and medications.   
3.5 Conclusion 
The present study indicates it is feasible to implement a multifaceted, care-managed program 
for individuals with heart failure in a family practice setting. The present data indicate moderate 
improvements in exercise tolerance and perceived quality of life in heart failure patients 
following a care-managed program in a family practice setting. A greater appreciation of factors 
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that may prevent patients from participation in these intervention programs is necessary. One 
such factor may include pre-intervention assessments of the motivation and readiness of patients 
with heart failure to make behavior changes.  
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CHAPTER 4. EXAMINATION OF THE CONSTRUCTS OF THE 
TRANSTHEORETICAL MODEL IN PATIENTS WITH HEART FAILURE: A FOCUS 
ON PHYSICAL ACTIVITY READINESS 
 
4.1 Introduction  
Chronic heart failure remains a significant health problem in the United States, with frequent 
hospitalizations, widespread functional impairment, and a high mortality rate. Recent studies 
have shown the significant value of the use of a multidisciplinary approach in the management of 
the heart failure patient. These programs emphasize the importance of close monitoring and 
patient education1, 2. Despite positive outcomes from these programs, including fewer 
readmissions and hospital days, decreased costs, and improved functional status and quality of 
life, patient participation and adherence remain suboptimal1, 3.  
A major component of the management of the heart failure patient is planned physical 
activity. Such programs have shown great promise as studies have revealed dramatic 
improvements in functional ability and quality of life and a reduction in healthcare costs and 
mortality in patients engaged in exercise programs1, 4.  Consequently, current recommendations 
on the management of heart failure patients strongly emphasize an active lifestyle, and if 
possible, participation in a moderate exercise training regimen5, 6. However, despite the benefits 
of physical activity for patients with heart failure, research indicates that few individuals with 
heart failure actually engage in regular physical activity7. Numerous studies have revealed that 
traditional methods of promoting physical activity have been only marginally successful in heart 
failure patients, citing failure to adhere to recommendations as a predominant factor8, 9.  
Given the importance of physical activity, and the high levels of inactivity among individuals 
with chronic heart failure, clinicians have been encouraged to examine theoretically based and 
practically important behavioral strategies that might be useful for encouraging and supporting 
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exercise initiation and/or maintenance among individuals with chronic heart failure5, 10, 11. 
Literature suggests that it is not realistic to expect patients to make changes that they are not 
prepared to make and little attention has been given to assessing the motivation and readiness of 
patients with heart failure to make necessary behavioral changes7. Application of behavioral 
theories, such as the Transtheoretical model (TTM) of behavior change may be useful in 
designing effective intervention programs for patients with heart failure10. These approaches 
could be used to guide strategies that go beyond traditional patient educational approaches12. For 
example, with the appropriate activities to meet the patient’s stage of readiness for change, 
healthcare providers may facilitate a patient’s movement along the continuum of change to alter 
lifestyle behaviors, such as physical activity, that can result in improved outcomes 10, 13, 14. 
Therefore, the TTM offers an opportunity to improve compliance with published guidelines by 
individualizing the change process to meet the needs of each patient. To date, no studies have 
examined the full TTM among patients with heart failure. Therefore, the specific aims of this 
research were three-fold: 
1. To examine the associations of TTM behavior change constructs (behavioral and 
cognitive processes of change, decisional balance, and self-efficacy) by stage of change 
for planned regular physical activity among individuals with chronic heart failure.  
2.  To determine the most important predictors of physical activity stages of change 
utilizing the constructs of the TTM among individuals with chronic heart failure 
3. To examine the association of the stage of change construct for daily physical activity 
and maximum walking distance achieved on a 6 minute walk test. 
In regards to specific aim one, the following hypotheses were tested: 
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Hypothesis I: Self-efficacy will increase in linear fashion from precontemplation to 
maintenance  
Hypothesis II:  Perceived pros will increase across the stages from precontemplation to 
maintenance; whereas, perceived cons will decrease across the stages. The 
crossover point in decisional balance scores will be observed in the preparation 
stage.  
Hypothesis III: Experiential and behavioral processes will increase across the stages of change.   
In regards to specific aim two: 
The predictive power of the TTM constructs to the stage of change is unknown in 
patients with heart failure; therefore, no specific hypothesis is stated. 
In regards to specific aim three, the following hypothesis was tested: 
Hypothesis IV:  Both maximum walking distance and daily physical activity scores will be 
higher in the action and maintenance stages as compared to the previous stages.  
• Background and Significance 
Heart failure is defined as the pathophysiological state in which an abnormality of cardiac 
function is responsible for failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolizing tissues, or to do so only from an elevated filling pressure15. 
Despite traditional pharmacological treatment, the clinical phase of heart failure includes a 
marked decline in functional status, defined by exercise tolerance and capacity with a subsequent 
decrease in quality of life. 
An estimated 4.9 million Americans have heart failure, a chronic condition associated with 
frequent hospitalizations, widespread functional impairment, and a high mortality rate. Each 
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart 
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failure as a primary or contributory cause16. Elderly individuals are particularly at risk for 
developing heart failure. In fact, heart failure is the most common hospital discharge diagnosis 
for patients over 65 years. The syndrome is the underlying reason for 12 to 15 million office 
visits and 6.5 million hospital days each year17. Furthermore, during the last 10 years, the annual 
number of hospitalizations has increased from approximately 550,000 to nearly 900,000 for heart 
failure as a primary diagnosis and from 1.7 to 2.6 million for heart failure as a secondary 
diagnosis18.  In addition to the substantial morbidity and mortality associated with this condition, 
there is a significant financial impact on our society. In fact, heart failure is now the single most 
costly cardiovascular illness in the United States, with total treatment costs estimated at $24.3 
billion16. The cost to society is expected to increase due to an aging population and prolonged 
survival rates of individuals with cardiovascular disease, therefore imposing a large burden on 
individuals and the healthcare system18. 
Research indicates that a multidisciplinary approach to heart failure management may be 
associated with important clinical benefits, including fewer readmissions and hospital days, 
decreased costs, improved functional status and quality of life1,3,19. An important component of 
such programs focuses on the promotion of behavior modification, including proper diet, 
adequate exercise and rest, and other lifestyle changes. Unfortunately, adherence to heart failure 
programs is generally low, and noncompliance remains a serious problem8. In fact, failure to 
adhere to recommendations continues to be a primary reason for hospital readmission for 
patients with decompensated heart failure8, 9. The reasons behind the noncompliance are poorly 
understood. Clearly, a better understanding of factors that may contribute to noncompliance may 
lead to better strategies for the clinician to engage the patients in their disease management.  
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The use of appropriate and adequate physical activity may be of particular importance in the 
management of the heart failure patient. Arguably, there is no single intervention with greater 
promise than physical activity in the management of the heart failure syndrome20. Not only does 
physical training improve measures of exercise tolerance and capacity, but exercise training also 
reverses a number of maladaptations in the vasculature, skeletal muscle, neuroendocrine systems, 
and metabolism in heart failure patients. Moreover, patients’ functional ability and quality of life 
improve dramatically. Lastly, a recent meta-analysis reveals a significant reduction in mortality 
in patients engaged in exercise programs4. Consequently, the current recommendations on the 
management of heart failure patients strongly emphasizes an active lifestyle, and if possible, 
participation in a moderate exercise training regimen5, 6. However, as previously stated, few 
individuals with heart failure actually engage in regular physical activity7. In fact, Sneed & Paul7 
reported only 38% of patients with heart failure (age=56+12) exercise regularly (at least 3 days 
per week for at least 20-minute intervals). 
Traditional strategies to alter behaviors such as physical activity patterns include educational 
classes, videos, and written materials. These materials are generally presented to all patients in 
the same manner. More recently, there is clear evidence that education will only work if the 
patient is willing to engage in the process14. For example, despite the use of an individualized 
intervention focused on preventing exacerbations of heart failure through symptom recognition, 
medication, dietary education, and modification of poor health behavior, a 33% readmission rate 
was noted within the first 6 months after hospital discharge8. The authors attributed the high 
readmission rates to lack of social support and individual motivation to learn and manage health 
behavior8.  
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The problems with motivating individuals to change health-related behaviors are similar in 
other populations. For example, Marcus et al.21 revealed that population-based interventions such 
as media-based campaigns, aimed at increasing the public’s interest in initiating physical activity 
have been ineffective in reaching large numbers of people. The authors speculate that the failures 
are in part due to the educational rather than behavior and motivational focus of many 
campaigns21. Furthermore, many exercise programs are designed for people who have decided to 
begin exercise, yet a large proportion of individuals are simply not interested or ready to engage 
in physical activity programs22.  A general rule of thumb is that at any given moment, only about 
20% of at-risk populations are ready to take meaningful action to change a health behavior and 
40% of those with a problem are in a stage of change marked by denial and resistance23. This 
reflects a mismatch between what is currently offered (action-oriented programs) and where 
individuals might be regarding their readiness to change (i.e., sedentary and not interested in 
exercise)24. Consequently, interventions should be tailored to the specific needs of the population 
of interest. The following section will describe a theoretical framework for understanding 
behavioral change. 
• The Transtheoretical Model of Health Behavior Change 
The TTM provides a theoretical framework for assessing and addressing readiness for 
changes in behavior. A strength of the model is its focus on the dynamic nature of health 
behavior change, or understanding behavior change as a process rather than a single event23. The 
use of the TTM originated in studies to treat addictive behaviors25, but has since been offered as 
a coherent framework to help understand readiness to begin physical activity24. Additionally, the 
TTM has been applied successfully to a wide variety of populations in the physical activity 
domain26, 27, 28. Although only one study has utilized the TTM to assess readiness for behavior 
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change in patients with heart failure7, currently there are no studies that have specifically 
addressed physical activity behaviors using the TTM in patients with heart failure. 
Understanding how the model works in patients with heart failure may yield insight into why 
some patients are ready to engage in physical activity programs and others are not. Furthermore, 
once the correct stage of an individual is identified more appropriate interventions can be 
implemented to move a person along the continuum of physical activity behavior change.  
The framework of the TTM consists of four core constructs (see Table 4.1): the stages of 
change, processes of change, decisional balance, and self-efficacy23. It has been recommended 
that interventions to increase physical activity participation be designed utilizing these 
constructs29. Each construct will be briefly discussed in the following sections. Particular 
attention will be given to the need to use these constructs in the heart failure population. 
Table 4.1. Transtheoretical Model: Core Constructs 
Construct Description 
 
Stages of Change 
 
Processes of Change 
 
Decisional Balance 
 
 
Self-efficacy 
 
The five sequential stages involved in any behavior change 
 
Strategies and techniques that support the change process 
 
The balance between perceived advantages and disadvantages of 
behavioral change 
 
Self-confidence in ability to perform and maintain new behavior in the 
face of temptation 
 
Stages of Change  
The central construct of the TTM is the stages of change. The stage construct was developed 
to reflect the temporal dimension of health-behavior change23. A change in behavior is viewed as 
a 5-stage process that may progress in a linear fashion, but most often progresses in a cyclical 
pattern, including relapse to previous stages, before the change becomes stable23. Five stages that 
have been proposed within the TTM include: 1) Precontemplation; individuals in this stage are 
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not intending to take action in the foreseeable future, usually measured as the next 6 months; 2) 
Contemplation; reflects the intent to change within the next 6 months; 3) Preparation; indicates 
the intent to change in the immediate future, usually measured within the next 30 days; 4) 
Action; during which specific, overt modification in lifestyle has occurred within the past 6 
months; and 5) Maintenance; maintenance of an overt behavior change for more than 6 months23.  
Studies that have used the stage of change construct generally report greater success in terms 
of adopting targeted behaviors. More specifically, research suggests physical activity 
interventions targeted to stage of change are more effective than interventions not tailored to 
stage of change21, 30. Currently, clinicians typically provide generic health advice to patients with 
heart failure. Although literature suggests that it is not realistic to expect patients to make 
changes that they are not prepared to make, little attention has been given to assessing the 
motivation and readiness of patients with heart failure to make necessary behavioral changes7. 
Therefore, knowledge of a person’s stage of readiness to begin regular physical activity could be 
used to assist clinicians in developing targeted, effective behavior change interventions and to 
guide strategies that go beyond traditional patient educational approaches12.  
Self-efficacy 
The self-efficacy construct originated with Bandura’s theory that successful change is based 
on the degree of confidence an individual has in his/her ability to be physically active under a 
number of specific circumstances31. Self-efficacy is positively associated with physical activity 
behavior21 and motivational readiness for physical activity adoption27, 32. Additionally, many 
studies have found that self-efficacy is the best predictor of physical activity behavior, 
suggesting that improved self-efficacy leads to higher levels of physical activity26. Although 
there have been no studies that have addressed this construct in heart failure patients, Hellman13 
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utilized the TTM to determine that perceived self-efficacy was an important predictor of stage of 
change and exercise adherence in a cardiac rehabilitation population.  
 The self-efficacy construct may be particularly important in the heart failure patient. Many 
patients are somewhat fearful in engaging in activities that may bring on symptoms associated 
with their condition. Thus information about their perceived self-efficacy for regular physical 
activity may be particularly important for the clinician.  
Decisional Balance 
The decisional balance construct is based on the theoretical model of decision-making 
developed by Janis and Mann33 and reflects an individual’s relative weighing of the pros and 
cons, or benefits and costs, of changing behavior. The underlying assumption is that a person 
will not decide to change behavior to begin an activity unless the pros of changing exceed the 
costs of changing the behavior. Differences in decisional balance tend to correspond to different 
stages of motivational readiness23. People in precontemplation stage perceive more barriers 
(cons) than benefits (pros) to change, while those in the action stage perceive more benefits than 
barriers34. Prochaska and colleagues34 studied twelve problem behaviors and noticed that for all 
twelve behaviors, the cons of changing are more important than the pros for people in the 
precontemplation stage. The opposite is true for people in the action stage in eleven out of twelve 
behaviors. Additionally, across all twelve behaviors, the pros of changing always increase from 
precontemplation to contemplation, whereas, the cons of changing always decrease from 
contemplation to action35. Furthermore, the cross-over point for pros and cons for exercise 
behavior was observed in the preparation stage34, and this finding has been replicated in recent 
studies27, 28. Once more, there are currently no data available regarding decisional balance for 
any behavior (including physical activity) in the heart failure patient.  
  
 
 
55
Processes of Change 
Processes of change include strategies and techniques used to support efforts to progress 
through the stages of change23. Ten distinct processes can be divided into 5 experiential 
processes that are internally focused on emotions, values, and cognitions; and 5 behavioral 
processes that are focused on behavioral changes23. Experiential processes include 
consciousness-raising, dramatic relief, environmental reevaluation, social liberation, and self-
reevaluation. Behavioral processes include counter-conditioning, helping relationships, 
reinforcement management, stimulus control, and self-liberation (Table 4.2).  
Table 4.2. Process of Change Descriptions for Physical Activity Behaviors 
Experiential Processes                                                        Description 
Consciousness raising                    Seek new information about exercise 
Dramatic relief                               Experience and express intense feelings about being inactive 
Environmental re-evaluation          Assess how being inactive affects physical and social environment 
Self re-evaluation                           Re-appraise values regarding inactivity 
Social-liberation                             Develop awareness and acceptance of active lifestyle 
Behavioral Processes                                                          Description 
Counter-conditioning                      Substitute alternative behaviors for sedentary activities 
Helping relationships                     Use support from others to be more active 
Reinforcement management          Changes contingencies; reward physical activity 
Self-liberation                                Choose and commit to being more active; believe that change  is 
possible 
Stimulus control                             Control situations and cues that support inactivity 
 
The TTM posits that the use of specific processes varies by stage of change23. In general, 
sedentary individuals, those in the earlier stages of motivational readiness (precontemplation, 
contemplation), tend to place greater emphasis on cognitive processes, while regularly active 
individuals, those in later stages of physical activity adoption tend to endorse more behavioral 
processes26, 35. Moreover, use of behavioral processes of change has been shown to significantly 
predict physical activity behavior36, and stage of motivational readiness for physical activity28. 
Kosma and colleagues28 utilized the TTM constructs to examine the most important physical 
activity stage of change predictors for mostly inactive adults with physical disabilities. Results 
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revealed that the most important predictors were the behavioral (r2 = .88) and cognitive processes 
(r2 = .50), followed by self-efficacy (r2 = .33), and decisional balance (r2 = .13). . These results 
are consistent with findings for other populations26. 
Furthermore, research has demonstrated that an integration of the stages and processes of 
change can provide a useful guide for interventions21, 32. Once an individual’s stage has been 
assessed, interventionists have a better idea of which processes to emphasize in order to facilitate 
progress to the next stage of change24.  
Table 4.3. Stages of Change in which Processes are most emphasized. 
Stages of Change 
                    Precontemplation     Contemplation     Preparation     Action     Maintenance 
Processes                        Consciousness Raising 
                                        Dramatic relief 
                                        Environmental 
                                             reevaluation 
                                                       Self-reevaluation 
                                                                                   Self-liberation 
                                                                                                          Contingency management 
                                                                                                          Helping relationships 
                                                                                                          Counter-conditioning 
                                                                                                          Stimulus control 
 
With the appropriate activities to meet the heart failure patient’s stage of readiness for change, 
healthcare providers may facilitate a patient’s movement along the continuum of change to alter 
lifestyle behaviors, such as physical activity, that can result in improved outcomes13. 
Summary of the Transtheoretical Model 
The TTM consists of 4 distinct constructs. Careful examination and appreciation of these 
constructs generally results in greater success in adoption of a targeted behavior, such as planned 
physical activity. In a meta-analysis of eighty studies using the TTM in the physical activity 
domain, no study was included that examined the TTM’s constructs among individuals with 
heart failure26. Interestingly the majority of the guidelines for management of the heart failure 
syndrome emphasize the need for using targeted behavioral strategies5, 6, 11. Therefore, 
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considering the lack of data regarding the full TTM in patients with heart failure, and given the 
success of the TTM for understanding physical activity behaviors in other populations, the TTM 
has been identified as a potentially useful model for understanding the exercise behavior of 
individuals with chronic heart failure10, 14. However, before the TTM is widely used for 
intervention studies, its utility and relevance must first be examined within this population 
segment.  
• Measure of Physical Activity 
As stated above, a patient’s perception of his or her stage of readiness might not always 
match the patient’s actual behavior14. Therefore, an actual assessment of physical activity should 
also be included in order to compare the results of such assessments with the individual’s stage 
of change27. The measurement of actual physical activity or exercise tolerance is difficult in 
patients with heart failure. Numerous tools are available, for assessment of actual exercise 
behavior such as activity logs or journals, accelerometers, symptom limited graded exercise tests, 
and submaximal tests such as the 6-minute walk37. Each of these assessments has limitations and 
flaws and may not be very representative of the patient’s actual physical activity behavior. One 
of the better predictors of a patient’s functional ability, exercise tolerance and physical activity 
behavior may be the maximum distance an individual can travel on a 6-min walk test37, 38. 
Moreover, the 6-min walk test provides prognostic information about the heart failure patient and 
appears to be sensitive to interventions such as exercise training. A recent review37 revealed that 
the 6-min walk test is recommended as a useful, simple, noninvasive alternative for assessing 
physical activity in patients with heart failure. There currently are no studies that have examined 
the TTM constructs for physical activity behavior to an actual measure of exercise tolerance in 
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patients with heart failure. Such data could potentially provide a better understanding of the links 
between the TTM constructs and the patient’s physical activity behavior.   
• Clinical Relevance 
There is clear evidence that implementation of a tailored heart failure educational program as 
outlined by the Agency of Health Care Policy and Research is effective in improving 
physiological and functional outcomes, as well as reduces hospitalization and associated health 
care costs39. Despite this evidence a significant number of patients with heart failure do not 
participate in such programs even when accessible. For example, our experience shows that from 
a pool of approximately 250 heart failure patients we were only able to recruit 20 patients. This 
is particularly disappointing given the fact we had an active recruiting program in place, which 
was coordinated by a dedicated nurse clinician. Moreover, a major criticism of many large-scale 
therapeutic trials in heart failure is that the characteristics of the heart failure population at large 
are quite different from those being studied. This suggests there is a tremendous number of 
patients with heart failure who are currently not being reached. Knowledge regarding factors that 
may provide a better understanding of reasons that may prevent a patient from participation will 
ultimately contribute to the development of improved strategies for inclusion.   
4.2 Methods 
• Participants   
 One hundred and forty-eight patients with a diagnosis of heart failure were recruited from the 
Baton Rouge, LA and Jackson, MS areas. Participants had to be at least 18 years of age, and be 
on stable and optimal pharmacotherapy for their heart failure condition as determined by their 
physician. In addition, participants had to have the ability to read and write English. Participants 
were not excluded on the basis of gender, race, and/or etiology of heart failure. Exclusion criteria 
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included individuals with acute medical conditions related or independent of the primary 
diagnosis (e.g. congestive heart failure requiring hospitalization, unstable angina, active 
infections etc.). Prior to participation, each individual was required to complete an informed 
consent approved by the area Institutional Review Board.  
• Study Design 
 The study was a cross-sectional design aimed at examining the application of the full TTM 
for physical activity in a group of individuals with chronic heart failure. Upon arrival to a 
scheduled Cardiology appointment, each participant was asked at check-in if they would mind 
completing information regarding physical activity behaviors and beliefs. If willing to 
participate, the individual was given a folder containing all questionnaires to be completed for 
the study, including stage of change, decisional balance, processes of change, self-efficacy, and 
Daily Activity in Heart Failure Questionnaire (DAIHFQ). Additionally, each participant 
underwent a six minute walk (6MW) test and a review of medical history and demographics. 
Data were collected in one visit. 
• Experimental Measurements 
Stage of Change 
Each participant’s stage of change for physical activity adoption was assessed by the Stages 
of Change for Physical Activity Questionnaire, using the algorithm recommended by Reed and 
colleagues40. Specifically, participants were asked to indicate their present levels of physical 
activity behavior. Regular physical activity or exercise was defined as “any planned physical 
activity of moderate intensity (e.g., brisk walking, cycling, jogging, swimming, aerobics, etc.) 
aimed at improving/ maintaining your health. The activity does not have to be painful to be 
effective but should be done at a level that increases your breathing rate and causes you to break 
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a sweat. For activity to be regular it must add up to a total of 30 or more minutes per day, 
and be done at least 5 days per week. For example, you could take a 30 minute walk or take 3 
ten minute walks each day.” Participants were asked to indicate whether they engage in planned 
regular physical activity, according to the above definition, by marking one out of five 
statements, each of which reflects one of the five stages: precontemplation: “I do NOT plan to 
start regular physical activity in the next 6 months ”; contemplation (C): “I am planning to start 
regular physical activity in the next six months”; preparation (P): Not regularly, but I engage in 
such activities occasionally and plan to start on a regular basis within the next month; action (A): 
“I have been physically active for LESS than six months”; and, maintenance (M): I have been 
physically active for MORE than six months”.  This staging measure is recommended as the 
most accurate estimate for adults45, and the construct validity and test-retest reliability of this 
methodology has received strong support in previous research41. 
Processes of Change 
The processes of change were assessed using a 30-item, five-point Likert scale designed 
specifically for exercise36. Fifteen items assessed the behavioral processes of change (i.e., 
counter-conditioning, contingency management, helping relationships, self-liberation, and 
stimulus control) and fifteen items assessed the cognitive processes of change (i.e., 
consciousness raising, dramatic relief, environmental reevaluation, self-reevaluation, and social 
liberation).  An example of a behavioral process is “Instead of relaxing by watching TV or 
eating, I take a walk or do physical activity”; whereas, an example of a cognitive process is “I 
read articles to learn more about physical activity”35.  
Self-efficacy 
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Self-efficacy was assessed using a six-item survey designed to measure confidence in one’s 
ability to persist with exercising in various situations32. A sample item is, “I am confident I can 
participate in regular physical activity when I am tired.” Participants responded to each item 
using a five-point Likert scale (1 = “not at all confident,” 2 = “somewhat confident,” 3 = 
“moderately confident,” 4 = “very confident”, and 5 = “completely confident”). Prior studies 
have shown an alpha coefficient of this scale is 0.82 and scores have been shown to significantly 
differentiate individuals at most stages of motivational readiness for physical activity   
adoption26, 32. 
Decisional Balance 
Decisional balance was measured using a 10-item inventory assessing five perceived benefits 
(pros) and five perceived barriers (cons) to physical activity participation42. Items were rated 
using a five-point Likert scale with 1 being “not at all important” and 5 being “extremely 
important”. This measure has been shown to have good internal consistency for both pros and 
cons of physical activity participation, at .82 and .72, respectively42. The actual decisional 
balance score was determined by subtracting the participant’s con score from the pro score (i.e. 
pros-cons). 
Six-Minute Walk Test 
Exercise intolerance is defined as the reduced ability to perform activities that involve 
dynamic movement of large skeletal muscles because of dyspnea or fatigue38. Exercise tolerance 
was measured as the maximum walking distance achieved on a 6-min-walk test38. The six-
minute walk test is recommended as a useful, simple, noninvasive alternative for assessing 
physical activity in patients with heart failure. The test was performed in a corridor and 
participants were instructed to walk as far as possible in 6 minutes, avoiding chest pain, marked 
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dyspnea, or other symptoms44. To standardize the protocol, the participants were not coached 
during the test, but made aware of time remaining to completion. The use of the six-minute walk 
test has received a lot of attention recently, due to its relative ease of administration. The test is 
also thought to reflect a realistic effort as performed in daily life, and appears highly acceptable 
to patients38. Furthermore, several studies have reported the prognostic significance of the 6-
minute walk test in patients with heart failure43, 44. 
Physical Activity Questionnaire 
Garet et al. (2004) recently published a detailed self-administered questionnaire of daily 
energy expenditure dealing with 7 dimensions of everyday life to better reflect habitual activities 
in patients with heart failure45. To validate this questionnaire the investigators45 measured actual 
VO2peaks and found it to be a valid and reliable reflection of physical activity status. The 
original questionnaire was in French; therefore, in the present study a translation of the French 
questionnaire was used. The translation was made with help of the original investigators of the 
questionnaire. The questionnaire considers seven main areas including sleeping and resting, 
basic everyday activities (e.g. eating and washing), housework activities, leisure time physical 
activities, physical activity in salaried or voluntary work, moving about, and miscellaneous 
activities.  Subsequently, activities could be classified in terms of intensity, i.e. activities below 3 
METs, between 3 and 5 METs, and above 5 METs, as well as duration (minutes performed)45.  
Three response models were applied depending on the item. For example, participants reported 
information pertaining to time spent on each activity, quantifying the number of times the 
activity is done per week or day, and reported whether help or interruption was needed 
systematically, sometimes, or never during an activity45. Detailed scoring instructions are 
provided elsewhere64. 
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• Statistical Analysis 
The Statistical Package for the Social Sciences (SPSS version 12.0, SPSS Inc., Chicago, IL) 
was used for all data analysis. Descriptive statistics were performed to provide demographic 
characteristics of the study participants. The first specific aim and respective hypotheses were 
examined using a one-way MANOVA with Univariate F-tests to describe the general trend of the 
associations among the constructs of the Transtheoretical model. Specifically, this includes the 
associations between the stages of change (independent variable) and the other constructs of the 
TTM (i.e., self-efficacy, decisional balance, and the cognitive and behavioral processes), which 
serve as the dependent variables.  
In terms of the second specific aim, a direct discriminant function analysis (DDF) was 
conducted from which a classification matrix was generated46 to identify the most influential 
predictors of exercise stage of change as well as overall prediction accuracy. Criterion for a 
significant relationship between predictors and discriminant functions is >.3346. Finally, the 
hypothesis associated with the final aim was tested using a univariate general linear model with 
the maximum walking distance as the dependent measure and the stage of change constructs as 
the independent measures. In addition, to examine the concurrent and construct validity between 
the physical activity questionnaire and the six-minute walk test, simple correlation coefficients 
and a multivariate general linear model with the categories of activity as the dependent measures 
and stages of change as the fixed factor were used. 
4.3 Results 
• Patient Characteristics 
Patient characteristics are presented in Table 4.5 through 4.9. A total of 148 patients were 
studied. Ninety eight participants were men, and fifty women. The mean age for the total group 
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was 52±13 (years), the average left ventricular ejection fraction (LVEF) for the group was 
31±11%. Etiology of heart failure included: ischemic heart disease (18.5%), non-ischemic 
cardiomyopathy (20.0%), hypertensive heart disease (16.9%), pregnancy induced heart failure 
(3.1%), viral induced heart failure (3.1%), heart failure related to cancer treatments (1.5%), 
idiopathic cardiomyopathies (32.3%), and congenital heart failure (4.6%). The duration of heart 
failure averaged just over 6 years, ranging from 2 months to 35 years. The majority of patients 
were classified as New York Heart Association (NYHA) Class II (61%) and III (38%). One 
patient was considered between a Class III and IV, and was included in the analyses. Forty-six 
percent of the patients were married, 26% were separated/divorced or widowed, and the 
remaining 28% of the participants were single or engaged. Sixty-five percent of the participants 
were Caucasian, 34% were African-American, and 1% Hispanic. In regards to the level of 
education 26% of participants did not have a high-school diploma, 57% did have at least a high 
school diploma or equivalent, 13% had an earned bachelor’s degree, and 4% had an earned post-
baccalaureate degree.  
 The majority of participants reported being in the preparation stage of change (n = 41, 
27.7%), followed by contemplation (n = 33, 22.3%), maintenance (n = 29, 19.6%), action (n = 
23, 15.5%), and precontemplation (n = 22, 14.9%). In regards to the stage of change 
classification, no significant differences were noted for age, LVEF and heart failure duration (see 
Table 4.5 and 4.6). Furthermore, as depicted in Tables 4.7 and 4.8, no differences in the stage 
classifications for race, employment status, income level, education level, heart failure diagnosis, 
number of co-morbidities and medications were observed. Therefore, these demographic 
variables were not treated as moderators in subsequent analyses. However, there was a tendency 
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for a greater percentage of women (75%) than men (60%) to be in the precontemplation and  
contemplation stages of readiness (p=0.06).  
 
Table 4.5 Descriptive Statistics (Age, Height, Weight, BMI) 
Stage of Change Age (yrs) Height (m) Weight (kg) BMI (kg/m2) 
 Mean SD Mean SD Mean SD Mean SD 
Precontemplation  55 13 1.72 0.10 98.49 33.56 34 11 
Contemplation  52 16 1.72 0.08 88.52 27.38 30 8 
Preparation  50 13 1.74 0.09 105.14 32.99 35 11 
Action  55 9 1.77 0.09 93.13 13.65 29 3 
Maintenance  50 15 1.76 0.08 91.96 16.64 31 7 
Total  52 13 1.75 0.10 95.28 26.43 31 10 
 
 
Table 4.6 Descriptive Statistics (Hemodynamics) 
 Stage of Change LVEF (%) HR (bts/min) SBP (mmHg) DBP (mmHg) 
 Mean SD Mean SD Mean SD Mean  SD 
Precontemplation  35.58 12.83 74 12.74 130 22.91 73 14.93 
Contemplation  29.80 12.55 75 19.37 115 26.99 71 18.99 
Preparation  29.16 10.26 78 13.99 117 18.50 68 10.17 
 Action  31.35 7.07 74 11.70 110 15.90 70 6.85 
Maintenance  29.84 11.79 76 11.42 121 8.51 69 6.69 
 Total  30.70 11.03 76 13.98 118 19.59 70 12.09 
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Table 4.7 Test for Differences between Stages of Change: One Way ANOVA  
  Sum of Squares df Mean Square F Sig. 
Age (yrs) 435.585 4 108.896 .597 .665 
Height (m) .039 4 .010 1.196 .318 
Weight (Kg) 3646.859 4 911.715 1.324 .267 
BMI 476.563 4 119.141 1.690 .160 
LVEF (%) 377.627 4 94.407 .769 .548 
RHR (b/min) 122.191 4 30.548 .146 .964 
SBP (mmHg) 1774.276 4 443.569 1.171 .335 
DBP (mmHg) 133.878 4 33.469 .215 .929 
 
Table 4.8 Test for Differences between Stages of Change: Kruskal Wallis Test 
 Gender Race NYHA Employ
Status 
Income 
level 
Educ. 
Level 
CHF 
Diagnosis 
Comorbidities (#) Med (#) 
X2 9.027 2.157 5.204 .297 1.475 1.237 9.320 3.433 1.273 
df 4 4 4 4 4 4 4 4 4 
Sig .060 .707 .267 .990 .831 .872 .054 .488 .866 
Grouping Variable: Stage of Change 
 
• Hypotheses I-III 
 
The MANOVA, used to examine the associations between the stages of change and the TTM 
constructs, revealed a statistically significant relationship (F(20, 461) = 26.4; p < .001, η2 = .47) 
between the stages of change (independent variable) and other constructs of the TTM (self-
efficacy, decisional balance, behavioral and experiential processes) that served as the dependent 
variables. The means, standard deviations, F-tests, variance explained (η2), and Tukey post hoc 
contrasts of the follow-up ANOVAs for self-efficacy, decisional balance, and the cognitive and 
behavioral processes of change across the five stages are shown in Table 4.9. Based on these 
results, the behavioral processes of change explained most of the variance (η2 = .83), followed by 
self-efficacy (η2 = .77), perceived pros (η2 = .62), perceived cons (η2 = .54), and experiential 
processes (η2 = .53). 
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Table 4.9 Descriptive Associations between the Constructs of the Transtheoretical Model 
across the Stages of Change 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1PC = precontemplation, C = contemplation, PR = preparation, A = Action, M = maintenance  
*p < .001 
 
As depicted in Table 4.9, the general trend of the scores for the dependent variables 
illustrates an increase from the lower to the higher stages in all variables except for perceived 
cons. Specifically, individuals in the precontemplation stage had the lowest scores for self-
efficacy, showed minimal use of the behavioral and experiential processes of change, and 
perceived relatively fewer pros and higher cons than any other stage. Whereas, the participants in 
the contemplation stage reported higher self-efficacy scores as compared to those in 
precontemplation, were clearly using some experiential strategies, yet continued to report 
relatively high perceived cons for exercise. In the preparation stage, individuals reported using 
the behavioral processes of change more so than in the previous stages, along with advances in 
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Variable           
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the use of the experiential processes of change, higher self-efficacy scores, the perception of 
more pros to exercise, along with significantly fewer perceived cons to exercise as compared to 
previous stages. Those individuals in the action stage reported higher self-efficacy scores and 
extensive use of behavioral processes, whereas, the scores for experiential processes were similar 
to those in the preparation stage. Decisional balance clearly favored the pros, with higher pros as 
compared to previous stages and the cons diminishing to a lower level than any previous stage. 
In the maintenance stage, participants continued to use the behavioral processes extensively, self-
efficacy scores and perceived pros also remained high, experiential processes remained similar to 
those in preparation and action stages, and perceived cons remained low and were similar to 
those in the action stage. 
In summary, based on the results of the general linear model multivariate procedure, the 
hypotheses were generally supported. First, self-efficacy scores were lowest in the 
Precontemplation stage and increased in linear fashion to maintenance (PC<C<PR<A, M). 
Secondly, decisional balance shifted from greater perceived cons and lower perceived pros in the 
precontemplation and contemplation stages to lower perceived cons and higher perceived pros in 
the action and maintenance stages (Cons: PC,C>PR>A,M;  Pros: PC<C<PR<A,M). Furthermore, 
although both experiential and behavioral processes increased from lower to the higher stages, it 
should be noted that scores for experiential processes were higher than behavioral processes in 
precontemplation, contemplation, and preparation stages; whereas, the opposite was true for the 
action and maintenance stages.  
• Predictors of the Stage of Change 
A direct discriminant function analysis (DDF) was conducted to identify the most important 
stage-of-change predictors based on the TTM constructs (perceived pros and cons, self-efficacy, 
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and behavioral and experiential processes of change), which served as the independent variables. 
The structure matrix for each discriminant function, along with canonical correlations, 
eigenvalues, and % variance are shown in Table 4.11. Of the four discriminant functions 
produced in the DDF analysis, the predictor variables were found to differentiate the stages of 
change with two significant functions, which accounted for 95.0% (Wilks’ λ = .080, X2(20) = 
358.76, p<.001) and 4.8% (Wilks’ λ = .705, X2(12) = 49.62, p<.001), respectively, of the 
between-group (stage of change) variability. The a priori criterion for an accepted canonical 
correlation was >.33 46. Thus, the third and fourth functions were neither statistically (p=.87 and 
p=.72) nor practically (r2= .11 and r2 =.07) significant, respectively. Therefore, the focus was on 
the first two discriminant function analyses and the other two were discounted.  
As depicted in Table 4.10, the structure coefficients (i.e., correlation between each predictor 
and the first discriminant function) revealed that the most important stage of change predictors 
were the behavioral processes (r2= .78) and perceived self-efficacy (r2= .66), followed by pros 
(r2= .44), cons (r2= -.38), and experiential processes (r2= .33). According to the functions at 
group centroids (mean discriminant scores for each stage of change) (see Table 4.11 and Figure 
4.1), these predictors contributed mostly in the discrimination between precontemplation and the 
other four stages, as well as in discriminating contemplation and preparation from action and 
maintenance. Furthermore, the second function revealed that the experiential process of change 
(r2= .80) and the pros of decisional balance (r2=.48) distinguished those in the precontemplation 
stage from contemplation and preparation, as well as those in the preparation stage from action 
and maintenance.  
The number & corresponding percentages of correctly classified cases within the five stages, 
on the basis of predictors, and after weighing for different group sizes are shown in Table 4.14.  
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Table 4.11 Discriminant Function Structure Matrix 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Largest absolute correlation between each variable and any  
  discriminant function. 
 
Table 4.12 Functions at Group Centroids 
Function  
Stage of Change 1 2 
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
-3.98 
-2.19 
- .42 
3.13 
3.62 
- .97 
 .17 
 .82 
- .52 
- .20 
Function 1
6420-2-4-6
Fu
nc
tio
n 
2
6
4
2
0
-2
-4
Group Centroids
Maintenance
Action
Preparation
Contemplation
Precontemplation
54
3
2
1
 
Figure 4.1 Canonical Discriminant Functions 
Function Predictor Variable 
1 2 3 4 
Behavioral Processes 
Self-efficacy 
Experiential Processes 
Cons 
Pros 
.781* 
.657* 
.334 
-.384 
.439 
.010 
-.143 
.800* 
- .002 
.476 
.245 
.234 
.417 
.861* 
.098 
-.444 
-.138 
-.255 
.290 
.740* 
Eigenvalue 
% Variance 
Cumulative % 
Canonical correlation 
P 
.78 
95.0 
95.0 
.94 
.000 
.39 
4.8 
99.8 
.53 
.000 
.01 
.20 
99.9 
.11 
.87 
.01 
.10 
100 
.07 
.72 
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Table 4.13 Correlation Matrix among the Predictor Variables for the Discriminant 
Function Analysis 
 
 
 
 
Results revealed that 34 individuals (82.9%) were correctly classified in preparation, 18 (81.8%) 
in precontemplation, and 25 (75.8%) in contemplation, followed by 18 (62.1%) in maintenance 
and 11 (47.8%) in the action stage. Overall, the probability of correct stage classification was 
71.6%. 
Table 4.14. Classification Results 
Predicted Group Membership   
  
  
SOC 1 2 3 4 5
Total 
  
Count 
  
  
  
  
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
18
2
1
0
0
4
25
4
0
0
0
6
34
0
0
0
0
2
11
11
0
0
0
12
18
22 
33 
41 
23 
29 
% 
  
  
  
  
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
81.8
6.1
2.4
.0
.0
18.2
75.8
9.8
.0
.0
.0
18.2
82.9
.0
.0
.0
.0
4.9
47.8
37.9
.0
.0
.0
52.2
62.1
100.0 
100.0 
100.0 
100.0 
100.0 
a  71.6% of original grouped cases correctly classified. 
 
• Hypothesis IV 
 A total of 111 subjects were available to examine if the 6 minute walk distance is capable of 
distinguishing the action and maintenance stages from the previous stages of readiness. No 
significant differences were noted between the groups according to age, height, weight, and 
LVEF.  As indicated in Table 4.15, the average walking distance for the entire group was 
349±118meters. The walking distance appears to increase dependent on the stage of change 
 Pros Cons Experiential 
Processes 
Behavioral 
Processes 
Self-
efficacy 
Pros 
Cons 
Experiential Processes 
Behavioral Processes 
Self Efficacy 
1.00 
 .15 
 .39 
 .09 
 .04 
  
1.00 
 .17 
- .16 
- .20 
  
  
1.00 
 .52 
 .17 
 
 
 
1.00 
 .38 
 
 
 
 
1.00 
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category. Indeed, as indicated in Table 4.16, the univariate general linear model analyses with 
the 6 minute walk distance as the dependent measure and stages of change as the fixed factor, 
revealed a significant main effect. Post hoc examination, using a Tukey test, indicates the 
following differences (see Figure 4.2): The 6-minute walk distance for individuals in 
precontemplation, contemplation and preparation stages appear to be similar, whereas the 6-
minute walk distance for the action and maintenance groups are significantly higher. Finally, 
there does not appear to be a significant difference between the action and maintenance groups. 
These findings suggest the 6-minute walk distance is capable of distinguishing the action and 
maintenance stages from the previous stages of readiness and is in support of the stated 
hypothesis.  
 
Table 4.15 Descriptive Statistics: Maximum Walking Distance (Meters) on the 6-minute 
Walk Test 
Stage of Change Mean Std. Deviation n
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
297
276
323
401
472
137
108
80
87
73
12
29
30
20
20
Total 349 118 111
 
• Validity of the 6-minute walking distance 
Stage of Change according to Estimated Exercise Capacity  
To further examine the influence of the stage of change categories on exercise 
tolerance/capacity, an estimated VO2peak was calculated from the 6-minute walking distance, 
using a regression equation 47. The equation: VO2peak = 0.03 * 6-minute walking distance + 
3.98 (r2 = 0.42 vs. actual VO2peak measures) was validated against actual VO2peak measures 
and is based on the fact that the 6-minute walking distance is the best predictor of VO2peak47. 
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Table 4.16 Tests of Between-Subjects Effects: Dependent Variable: 6-minute Walk 
Distance   
Source 
Type III 
Sum of 
Squares 
Df Mean Square F Sig. 
Partial 
Eta 
Squared 
Noncentral 
Parameter 
Observed 
Power 
Corrected 
Model 
567212 4 141803 16 0.0001 0.371 63 1.000 
Intercept 12450284 1 12450285 1374 0.0001 0.928 1374 1.000 
Stage of 
Change 
567212 4 141803 16 0.0001 0.371 63 1.000 
Error 960766 
10   
 6 
9064           
Total 15016475 
11  
 1 
            
Corrected 
Total 
1527978 
11 
 0 
            
Computed using alpha = .05; b  r2 = 0.371 (Adjusted r2 = 0.347) 
Figure 4.2 Six-Minute Walk Distance per Category 
 
Means and standard deviations for the estimated VO2peak are presented in Table 4.17 and 
depicted in figure 4.3. Consistent with the analysis for the 6-minute walk distance there was a 
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significant main effect for stage of change category (p=0.0004), and significant differences in the 
means for VO2peak between the Action and Maintenance categories vs. the remaining three 
categories. Importantly, the average estimated VO2peak for the Action and Maintenance groups 
is above the prognostically relevant 14 ml/kg/min threshold (as indicated by the dashed line on 
figure 4.3).   
Table 4.17 Estimated VO2peak (ml/kg/min) per category  
Stage of Change Mean Std. Deviation n
Precontemplation 12.90 4.11 12
Contemplation 12.24 3.22 29
Preparation 13.66 2.40 30
Action 16.01 2.60 20
Maintenance 18.15 2.199 20
Total 14.44 3.54 111
 
Stage of Change according to Daily Physical Activity 
To examine the criterion validity between the physical activity questionnaire and the six-
minute walk test, 78 data sets were available which allowed for simple correlation coefficients 
and a multivariate general linear model with the categories of activity as the dependent measures 
and stages of change as the fixed factor.  
 
 
 
 
 
 
 
 
 
              
 
 
 
 
 
 
Figure 4.3 Estimated VO2peak per Category 
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Figure 4.4 Estimated Minutes of Physical Activity above 5 METs vs. 6-minute Walk Distance 
 
Simple correlation coefficients revealed significant associations between the 6-minute walk 
test and self-reported amount of minutes spent at rest (r = -0.27, p = 0.02), performing activities 
between 3 and 5 METs (r = 0.52, p = 0.0009), and activities over 5 METs (r = 0.56, p = 0.0001). 
A significant association was also seen between total minutes of daily physical activity and the 
6-minute walk test (r = 0.32, p = 0.005). Interestingly, it appears from the scatterplot (see figure 
4.4), that the amount of activity may be dependent on the patients stage of change. 
On the basis of a multivariate general linear model with the categories of activity as the 
dependent measures and stages of change as the fixed factor, a significant main effect was found 
(p = 0.0005). Subsequent univariate tests revealed no differences between minutes at rest and 
stage of change category, but significant differences for the other measures as indicated in Table 
4.18 and 4.19. Figures 4.5a and b further highlight the observed differences between the stages 
of change categories. 
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Table 4.18 Minutes of Rest and Various Intensities of Physical Activity per Day 
Variable  Stage of Change Mean Std. Deviation n
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
613 
604 
531 
573 
551
108 
111 
137 
126 
192
14 
23 
24 
15 
15
Rest 
  
  
  
  
  Total 572 137 91
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
820 
995 
1030 
1133 
1041
224 
223 
339 
341 
393
14 
23 
24 
15 
15
Total Activity (min) 
  
  
  
  
  Total 1008 315 91
Minutes up to 3 METs  
  
  
  
Precontemplation 
Contemplation 
Preparation 
Action 
684 
879 
907 
927
230 
201 
277 
312
14 
23 
24 
15
Maintenance 824 299 15  
  Total 855 269 91
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
73 
107 
111 
186 
180
86 
61 
101 
86 
121
14 
23 
24 
15 
15
Minutes between 3 to 5 METs 
  
  
  
  
  Total 128 99 91
Precontemplation 
Contemplation 
Preparation 
Action 
Maintenance 
2 
8 
13 
20 
37
7 
13 
14 
14 
27
14 
23 
24 
15 
15
Minutes above 5 METs 
  
  
  
  
  Total 15 19 91
 
Table 4.19: Univariate Tests for Activity categories and Stage of Change 
Dependent 
Variable 
Sum of 
Squares 
df Mean 
Square
F Sig. Partial Eta 
Squared
Noncent. 
Parameter 
Observed 
Power
Rest 95549 4 23887 1.29 0.281 0.057 5.155 0.387
Total Activity 
(min) 
763952 4 190988 2.01 0.100 0.086 8.041 0.580
Minutes up to 3 
METs  
579684 4 144921 2.09 0.089 0.089 8.374 0.600
Minutes between 3 
to 5 METs  
150391 4 37598 4.47 0.003 0.172 17.872 0.928
Minutes above 5 
METs 
11267 4 2817 11.12 0.000 0.341 44.461 1.000
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Figure 4.5a Estimated Minutes of Physical Activity above 5 METs according to Stage of Change 
*p < 0.05 vs precontemplation, contemplation, preparation, and action; †p < 0.05 vs. 
precontemplation, contemplation, and maintenance; +p < 0.10 vs. precontemplation 
Figure 4.5b Estimated Minutes of Physical Activity between 3 and 5 METs according to Stage of 
Change. *p < 0.05 vs. precontemplation, contemplation, and preparation  
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• Summary Section 4 
 In summary, these data indicate that the 6-minute walking distance is capable of 
distinguishing individuals in the action and maintenance stages from the pre-action stages of 
readiness. Furthermore, the data clearly indicate differences in the means for estimated VO2peak 
between the action and maintenance categories vs. the remaining three categories. Uniquely, the 
average estimated VO2peak for the action and maintenance groups is above 14 ml/kg/min, and 
perhaps more importantly the estimated VO2peak is below this powerful prognostic indicator for 
the pre-action stages. These data reveal significant associations between self-reported physical 
activity and the 6-minute walk distance. Finally, the number of minutes at higher intensities of 
physical activity is greater in individuals in the action and maintenance stages compared to the 
pre-action stages of readiness. 
4.4 Discussion 
• Patients Characteristics 
Review of the available literature reveals very few studies, which have attempted to examine 
the readiness for behavioral changes in patients with heart failure7,14. Consequently, it is difficult 
to compare the patient characteristics in the present study to other studies. Perhaps the only study 
of comparison is by Sneed and Paul (2003). In this study a mail survey was sent to patients with 
heart failure7. Respondents were asked to select the stage of readiness for change in 6 lifestyle 
behaviors important in management of the heart failure syndrome. Unfortunately, Sneed and 
Paul (2003) did not examine the full TTM model among individuals with heart failure7. Despite 
that, it is interesting to note the patient population in that study was remarkably similar to the 
present study7. In general, their subjects were also relatively young (mean 55.6 years vs. 
52±13yrs). Fifty-nine percent of the participants were Caucasian and 40% were African-
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American as compared to 65% Caucasian, 34% African American, and 1% Hispanic in our 
study. Sixty-two percent were men and 38% women compared to sixty-six percent men and 34% 
women in the present study. Fifty-nine percent of the patients were married and most had a high 
school education; whereas, in the present study forty-six percent of the patients were married and 
57% did have at least a high school diploma or equivalent. The duration of heart failure was 
virtually the same as the present study (mean 6.5 years, range: 6 months to 35 years vs. 6 years, 
range: 2 months to 35 years in our study).   
Unfortunately the authors did not report the patients LVEF, etiology of heart failure, or 
NYHA class, although it appears from a Specific Activity Scale that the patients ranged from a 
Class I to IV, which appears to be a little more diverse than the patients in the present study.  
However, it is not known how the Specific Activity Scale compares to the more widely used 
NYHA classification.  
Considering the present study also examined the association of the stage of change construct 
for physical activity with actual measures of exercise tolerance (six minute walk test), and self-
reported daily physical activity, a second comparison study is offered by Garet et al.(2004)45. 
These investigators assessed the reproducibility, sensitivity, and concurrent validity of self-
reported daily energy expenditure in a population of stable patients with heart failure. Their 
population consisted of 105 Caucasian participants (mean age: 55.8±12.4 yr, range 31–80 years). 
Mean left ventricular ejection fraction was nearly exactly as reported in the present study (LVEF: 
33.2±6.1%). Interestingly the majority of the patients in the comparison study suffered from 
dilated cardiomyopathy (66 patients) and ischemic cardiomyopathy (39 patients), which is 
somewhat higher than the major etiology in the present study45.  
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In summary, although few comparison studies are available, the present population 
characteristics appear to be similar to published studies. Moreover, based on the available 
guidelines for the management of heart failure, it would appear that the participants in this study 
would be excellent candidates for heart failure intervention programs including exercise training. 
Classification according to the TTM for stage of change reveals the majority of participants 
in this study were in the preparation stage of change (n = 41, 27.7%), followed by contemplation 
(n = 33, 22.3%), maintenance (n = 29, 19.6%), action (n = 23, 15.5%), and precontemplation (n 
= 22, 14.9%). These findings are somewhat similar to a previous which examined the predictors 
of exercise adherence and the validity of the Stages model among older adults (N = 349) with a 
cardiac diagnosis (not heart failure) after discharge from a cardiac rehabilitation inpatient 
program13. In that study, 16% of the patients were in precontemplation, 16% in contemplation, 
22% in preparation, and 23% in both the action and maintenance stage13. In yet another study, 
the theorized associations of the TTM of behavior change constructs were examined along with 
exercise barriers, by stage of change for exercise behavior among individuals with physical 
disabilities 27. In that study the majority of participants reported being in the maintenance stage 
of change (53.7%), followed by precontemplation (18.9%), action (11.8%), contemplation 
(9.0%), and preparation (6.5%) 27. One possible explanation for the greater number of 
individuals classified in the maintenance stage in this comparison study 27 is the passive 
recruitment method used by the authors, which tends to over-represent those individuals with an 
interest in the subject matter. Other than differences in recruiting strategies, it is difficult to 
reconcile the differences among studies, given the vast differences in terms of populations, 
geographical location, and overall subject number. However, it is important to appreciate that in 
the current study 65% of patients were in the pre-action stages of readiness to engage in a 
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treatment strategy known to be critical in the management of their disease. In fact, the present 
data falls very much in line with the study by Sneed & Paul7 who reported only 38% of patients 
with heart failure exercised regularly. 
• Hypotheses I-III 
This study was unique in that it was the first study to examine the full TTM among 
individuals with chronic heart failure.  The first purpose of this study was to examine the 
associations of TTM behavior change constructs (behavioral and cognitive processes of change, 
decisional balance, and self-efficacy) and stage of change for planned regular physical activity 
among individuals with chronic heart failure.  It was hypothesized that 1) self-efficacy would 
increase in linear fashion from precontemplation to maintenance; 2) the crossover point in 
decisional balance scores would be observed in the preparation stage; and 3) experiential 
processes would be utilized in the earlier stages; whereas, behavioral processes would be utilized 
in the latter stages of change.  
Based on the results of the one-way MANOVA, the hypotheses were generally supported. 
First, self-efficacy increased across the stages of change in linear sequence, although differences 
were not significant between the action and maintenance groups. These results suggest that 
confidence to be active increases with advances in stage of change, as proposed by the TTM26.  
Similar findings have been reported among individuals with a cardiac diagnosis13, and those 
with27 and without26 disabilities. Thus, the conclusion from various studies and narrative reviews 
that self-efficacy differentiates between individuals at most stages appears supported13, 24, 48, 49.   
This is an important finding because the self-efficacy construct may be particularly relevant in 
the heart failure patient. Many patients are somewhat fearful in engaging in activities that may 
bring on symptoms associated with their condition. Thus, information about a patient’s perceived 
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self-efficacy for regular physical activity may be particularly important for the clinician to guide 
strategies for physical activity adoption.  
Secondly, decisional balance shifted from greater perceived cons and lower perceived pros in 
the precontemplation and contemplation stages to lower perceived cons and higher perceived 
pros in the action and maintenance stage, which is consistent with TTM theory34 and previous 
research49.  Once again, this research is unique in that prior to this study there was no data 
available regarding decisional balance for any behavior (including physical activity) in the heart 
failure population. The underlying assumption of TTM theory is that a person will not decide to 
change behavior unless the benefits (pros) of change exceed the costs (cons)23. Differences in 
decisional balance tend to correspond to different stages of motivational readiness23, 34. Results 
of this study support previous research which suggests that people in the precontemplation stage 
perceive more barriers (cons) than benefits (pros) to change, while those in the action stage 
perceive more benefits than barriers34. For example, patients in the early stages 
(precontemplation and contemplation) endorsed such items as “I am too tired to get regular 
physical activity because of my other daily responsibilities.” Additionally, these patients 
perceived physical activity would take too much time, cost too much, or they would worry about 
looking awkward. In contrast, patients in the advanced stages (action and maintenance) indicated 
that physical activity would help them have a more positive outlook, control their weight, sleep 
better, reduce tension or manage stress, and feel more confident about their health. These 
findings are in line with Prochaska and colleagues34 who studied twelve problem behaviors and 
noticed that for all twelve behaviors, the cons of changing were more important for people in the 
precontemplation stage than the pros. The authors34 concluded the opposite was true for people in 
the action stage in eleven out of twelve behaviors. These findings suggest that progress from 
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precontemplation to contemplation involves an increase in the perceived pros (perceived 
benefits) of physical activity; whereas, progressing from contemplation to action involves a 
decrease in the perceived cons (barriers). This implies the increase in the pros followed by a 
decrease in the cons should lead to a crossover in decisional balance across the stages of 
change34. Consequently, it was hypothesized that the cross-over point (or “balance point”) for 
pros and cons for physical activity behavior would be observed in the preparation stage, because 
this finding has been observed in recent studies27, 28. Interestingly, results of this study revealed 
the crossover occurred in the contemplation stage. It has been suggested that the stage in which 
the crossover occurs is a function of how much and when the pros increase and how much and 
when the cons decrease34. This implies that the strategies for moving patients from 
precontemplation to contemplation, or toward thinking about physical activity must focus on 
increasing perceived benefits; whereas, to move someone from contemplation to action, would 
require a decrease in perceived barriers. 
Another possible explanation could be the manner in which the preparation stage was defined 
in the present study. The studies in which the crossover occurred in preparation, defined the 
preparation stage with an intention to change behavior only. Based on recommendations from 
previous research27, 28, 50, we defined the preparation stage as currently participating in planned 
physical activity but less than the recommended guidelines AND an intention to engage in 
planned physical activity at the target level within the next month. Therefore, the present data 
reveal individuals in the preparation stage were engaging in some physical activity and 
consistent with theory34, these individuals exhibited more pros and fewer cons than those in 
previous stages. Consequently, consistent with the literature, the present data reveal the 
crossover prior to the preparation stage. 
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The clinical relevance of these findings suggests a systematic approach for changing the pros 
and cons to facilitate progress from precontemplation to action. For example, initially the 
intervention should first target increasing the perceived pros (benefits) of physical activity, 
which should lead to progression from precontemplation to contemplation. Once progression to 
the contemplation stage has occurred, the intervention should focus on decreasing the perceived 
cons (barriers) to physical activity, while continuing to increase perceived pros. This should lead 
to further progress from the contemplation to the action stage.  
Lastly, as hypothesized, the experiential processes were used predominantly in the 
precontemplation and contemplation stages, whereas behavioral processes were more 
prominently used in the action and maintenance stages of change23. Specifically, scores for the 
experiential processes of change increased in linear sequence from precontemplation to 
preparation, before leveling off between preparation, action, and maintenance. The behavioral 
processes increased linearly from precontemplation to action, and leveled off between action and 
maintenance. This is consistent with theoretical predictions23, previous studies27, and narrative 
reviews48 which indicate that behavioral processes peak during action and then level off during 
maintenance. The lack of significance between action and maintenance suggests that efforts to 
maintain physical activity habits do not require additional changes in behavioral and experiential 
strategies 53a,b. Additionally, these data support previous research which reveals sedentary 
individuals, those in the earlier stages of motivational readiness (precontemplation, 
contemplation), tend to place greater emphasis on experiential processes, while regularly active 
individuals, those in later stages of physical activity adoption tend to endorse more behavioral 
processes26, 35.  
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These results support previous studies which have demonstrated that an integration of the 
stages and processes of change can provide a useful guide for interventions21, 32. The clinical 
relevance of this work is that once an individual’s stage has been assessed, interventionists may 
have a better idea of which processes to emphasize in order to facilitate progress to the next stage 
of change24. Moreover, with the appropriate activities to meet the heart failure patient’s stage of 
readiness for change, healthcare providers may facilitate a patient’s movement along the 
continuum of change to alter lifestyle behaviors, such as physical activity, that can result in 
improved outcomes13. 
• Predictors of the Stage of Change 
The objective of specific aim two was to determine the most important predictors of physical 
activity stages of change utilizing the constructs of the TTM among individuals with chronic 
heart failure. This study is unique in that it is the first to have examined this in patients with 
chronic heart failure. These data may provide clinicians with a greater understanding how to 
‘move’ patients toward the action stages of behavior change. The results of this study are similar 
to other studies that have used the full TTM to investigate the most important psychosocial 
predictors of the exercise stages of change. For example, Cardinal et al. (2004) have used the full 
TTM to investigate the most important predictors of the exercise stages of change among mainly 
active adults with physical disabilities 27. In descending order of significance, the most important 
predictors were behavioral processes of change, self-efficacy, cognitive (experiential) processes 
of change, perceived pros, and perceived cons. In a similar study focusing on inactive adults with 
disabilities 28, the behavioral processes of change also contributed mostly to the physical activity 
stage of change distinction followed by the cognitive (experiential) processes of change, self-
efficacy, and decisional balance. Further confirmation of this finding was found amongst 
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university students where behavioral processes of change contributed to the stage-of-change 
classification in the first function; whereas, the experiential processes of change and perceived 
pros mostly contributed to the stage of change differences in the second function 50. Likewise, in 
the present study, behavioral processes (r2= .78) were the most significant predictors, followed 
by self efficacy (r2= .66), pros (r2= .44), cons (r2= -.38), and experiential processes (r2= .33). 
These predictors contributed to the first discriminant function and were important in the 
discrimination between precontemplation and the other four stages, as well as in distinguishing 
individuals in contemplation and preparation from those in action and maintenance stages. 
Furthermore, similar to previous results 50, the second function revealed that the experiential 
process of change (r2= .80) and the pros of decisional balance (r2=.48) distinguished those in the 
precontemplation stage from contemplation and preparation, as well as those in the preparation 
stage from action and maintenance.  
In contrast, in a study among older cardiac rehabilitation patients, slightly different results 
were reported 13. In that study the authors concluded that self-efficacy was the most important 
predictor, followed by perceived benefits of exercise (pros), perceived barriers to exercise (cons), 
and interpersonal support for exercise 13.  A possible reason for the differences in said study is 
that predictors of stage of change in exercise adherence were examined in patients who were 
recently discharged following a cardiac event. It could be argued these patients were more 
concerned with issues of self-efficacy due to their recent events. Interestingly, other patients in 
that study had, in fact, enrolled in cardiac rehabilitation. It could be argued that self-efficacy 
scores would be higher for that subset of patients’ as well.  
In summary, the behavioral processes of change appear to be the most important predictors 
of physical activity stages of change among patients with chronic heart failure. Such results have 
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been reported for individuals with27, 28 and without disabilities50, and university students3. These 
results suggest that the behavioral processes as predictors may be similar across diverse 
populations and conditions. In this study, self efficacy also contributed significantly for stage 
prediction, followed by pros, cons, and experiential processes, reinforcing the use of all TTM 
constructs for physical activity behavior change. It has been suggested that the experiential 
(cognitive) processes of change were more important to inactive individuals than active 
individuals, whereas, self-efficacy contributed more to active participants than inactive 
participants. Clearly, more work needs to go into further understanding these constructs. 
However, the clinical relevance of this work is that once an individual’s stage has been assessed, 
interventionists may have a better idea of which processes to emphasize in order to facilitate 
progress to the next stage of change. Moreover, with the appropriate activities to meet the heart 
failure patient’s stage of readiness for change, healthcare providers may facilitate a patient’s 
movement along the continuum of change to alter lifestyle behaviors, such as physical activity, 
that can result in improved outcomes. 
• Classification Accuracy 
Using the behavioral and experiential processes of change, self-efficacy, and the perceived 
pros and cons to classify participants into their respective stage of change for physical activity, 
the most reliably predicted stages were preparation (82.9%), precontemplation (81.8%),  
contemplation (75.8%), followed by maintenance (62.1%), and action (47.8%). Overall, the 
probability of correct stage classification was 71.6%. Relative to previous studies employing the 
full TTM among different population segments, and using similar multivariate statistical 
techniques, the overall prediction accuracy was similar to that reported by Cardinal and 
colleagues27 in adults with physical disabilities (69.6%) but was slightly higher than other studies 
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involving college students52, older adults53, and older adults with a cardiac diagnosis13, which 
range from 50% to 64%. The enhanced classification accuracy observed in the present study 
could be due to the fairly even distribution of individuals among the stages of change in this 
study as compared to previous studies, the various methods of recruiting, or simply the relevance 
of TTM for this population segment. 
• Hypothesis IV 
 A unique contribution of these data are the findings that the 6-minute walking distance is 
capable of distinguishing individuals in the action and maintenance stages from the early stages 
of readiness (precontemplation, contemplation). Moreover, using the 6-minute walking distance 
to estimate VO2peak reveals that a greater majority of those individuals above 14 ml/kg/min are 
in the action and maintenance categories. Perhaps more importantly these data suggest that the 
majority of patients with heart failure in the early stages of readiness are below the 14 ml/kg/min 
threshold, a powerful prognostic indicator of an increased likelihood of death or hospitalization 
within 3 months to a year. Finally, these data suggest that individuals in the action and 
maintenance stages perform a greater amount of physical activity, especially at higher intensities, 
compared to the those in the early stages of readiness (precontemplation, contemplation). 
 The 6-minute walk test has been used as an outcome measure in clinical trials since 1988 54. 
The test is a self-paced walk test, simple to administer, and because of the familiarity of the 
activity is a measure of overall mobility and physical function. Importantly, the test carries 
important prognostic information. The total group average for the maximum walking distance 
(349±118meters) in this study appears to be quite typical for patients with heart failure, with a 
NYHA Class II and III. For example, Opasich et al (2001) reported a maximum walking distance 
of 396±92meters in 315 chronic heart failure patients (age: 53±9 years, NYHA class: II (182), III 
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(133)) 55.  More importantly, based on the literature indicating that a maximum walking distance 
less than 300 meters is associated with an increased likelihood of early mortality47,56-58; the 
results of the present study suggest many of the patients are at elevated risk for complications. In 
fact, 36% of all the participants in this study scored below the 300 meter threshold. Interestingly, 
patients who scored below 300m on the 6-minute walk test were not different from the patients 
scoring above 300m, in terms of age, BMI, LVEF, resting blood pressure and heart rate. In 
addition, no differences were noted for race, employment status and income, etiology, and length 
of heart failure, comorbidities, or number of medications. One interesting observation in the 
present study is that a greater percentage of women scored below the 300 meter threshold.  
Given the evidence that the distance of < 300 m also identifies women at high risk of death 58, 
this requires further examination and focus from a clinical perspective. A further important 
observation is that the average age for the women in this study was significantly lower than the 
men, yet their average maximum walking distance (MWD) was much lower as well. 
Unfortunately, these findings can not be explained by the available information concerning the 
clinical status of the patients in this study, but this should certainly receive greater attention in 
future studies.  
 Generally, the validity of the 6-minute walk test has been investigated through the 
comparison against a “gold-standard” functional capacity test 59. Usually the “gold-standard” test 
for this comparison has been a maximal exercise test with or without gas analyses on a treadmill 
or cycle ergometer. To date 28 such studies are available, and are extensively reviewed 
elsewhere 59.  For the most the comparison studies reveal moderate to strong correlations 
between the 6-minute walk test and VO2peak obtained through exercise ergometry (treadmill or 
cycle) 56. The consistent findings that the 6-minute walk test is a good estimate of functional 
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capacity have led to several multivariate equations that allow estimation of the VO2peak. In the 
present study, the equation developed by Cahalin et al. (1996) was used to estimate the VO2peak 
of this cohort 47. The rationale for this selection was that the present study population was similar 
to those in the aforementioned study 47, and the fact that the simple equation: VO2peak = 0.03 
(MWD) + 3.98, was able to account for nearly 45% of the variance in that study. In this study the 
average VO2peak was 14.42±3.52 ml/kg/min. The average estimated VO2peak in this study are 
similar to many studies that have examined NYHA Class II and III heart failure patients.  This 
average is particularly relevant given the evidence in the literature that individuals below 14 
ml/kg/min have a much poorer prognosis in terms of survival compared to those above this 
threshold 60-62. In fact, even today the threshold is an important factor, considered clinically, 
when evaluating heart transplant candidates 63. In other words those individuals that drop below 
the threshold of 14 ml/kg/min are immediately moved up on the transplant lists, as their 
immediate risk for mortality increases exponentially. In the present study 50% of patients are 
below the threshold score. Again the data indicate a gender difference in that approximately 62% 
of the women and 47% of the men are below 14 ml/kg/min.  
 In recent publications by a group of French investigators, a detailed self-administered 
questionnaire, specifically for the heart failure patient, was used to examine daily energy 
expenditure 45,64. The questionnaire deals with 7 dimensions of everyday life to provide a picture 
of habitual activities. The questionnaire was compared against actual VO2peak measures and it 
was found it to be valid and reliable. In the present study a translation of the French 
questionnaire was used. The translation was made with help of the original investigators of the 
questionnaire and with some modifications was implemented in the study. Most of the 
modifications dealt with exchanging activities that were more appropriate choices for the present 
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study population. Recognizing that this approach may require further modifications and 
improvements, the data did allow further comparison to the functional scores. The findings 
revealed significant associations between the 6-minute walk test and the self-reported amount of 
minutes spent at rest (r = -0.27, p = 0.02), performing activities between 3 and 5 METs (r = 0.52, 
p = 0.0009), activities over 5 METs (r = 0.56, p = 0.0001). Moreover, a significant association 
was apparent between the total minutes of physical activity performed throughout the day, and 
the 6-minute walk test (r = 0.32, p = 0.005). This is the first study to report these associations 
using a submaximal performance test. In comparison to previous work 45 the reported 
associations are somewhat lower. The discrepancy may in part be a consequence of the 
questionnaire modifications, or the fact that the 6-minute walk test was used. Irrespective of 
those possibilities, the findings are intriguing and suggest the questionnaire is able to 
differentiate between patients who score high or low on the 6-minute walk test.  Interestingly, the 
patients in the present study had lower estimated VO2peak values, then their French counterparts. 
In addition, the patients in this study performed fewer activities above 5 METs and had slightly 
lower overall energy expenditures over the course of the day. It is difficult to reconcile these 
differences as the American patients were similar in terms of age, gender, LVEF, NYHA class, 
and etiology of disease. However, there are apparent differences in terms of weight and BMI, 
with the American cohort heavier (American Cohort: 95.28±26.43; French Cohort: 74.80±15.00) 
and with a greater average BMI (American Cohort: 31.68±8.53; French Cohort: 25.08±4.00). 
Unfortunately, failure to show an association between weight and BMI and the 6-minute walk 
test and estimated energy expenditures, in the present study, does not allow for a real 
appreciation of these apparent differences compared to previous studies 45,64. 
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 In summary, the present data compare favorably to a number of studies which have used the 
6-minute walk test to examine functional capacity in patients with heart failure. In addition to the 
risks associated with the heart failure diagnosis, a large number of patients appear to be at even 
greater risk for hospitalization and mortality, secondary to their low scores on the 6-minute walk 
test, and subsequent estimated VO2peak. In addition, these data reveal significant associations 
between measures of functional ability and a valid physical activity questionnaire for patients 
with heart failure. Finally, patients in this study appear to spend fewer minutes performing 
activities above 5 METs and overall physical activity throughout the day compared to a similar 
study 45,64.  
 In regards to Hypothesis IV, it was predicted that the maximum walking distance would be 
capable of distinguishing the action and maintenance stages from the precontemplation and 
contemplation stages of readiness. As indicated in Table II, the univariate General Linear Model 
analyses with the 6 minute walk distance as the dependent measure and stages of change as the 
fixed factor, a significant main effect was revealed. Figure 1 shows that indeed the action and 
maintenance stages were different from the precontemplation and contemplation stages of 
readiness. Closer observation of these data reveal that the majority of patients in the action and 
maintenance stages were in fact above the 300meter, and 14 ml/kg/min threshold, compared to 
the majority of patients in the early stages (i.e., precontemplation, contemplation) who were 
below these clinically important cut-offs. More specifically, 51% and 71% of patients in the 
precontemplation stages were below the 300meter, and 14 ml/kg/min threshold compared to only 
7.5% and early stages were in NYHA class III (precontemplation, contemplation, preparation) 
47% vs. action/maintenance: 25% (p < 0.05), were women (early stage: 40% vs. 
Action/Maintenance: 21%, p < 0.05), and had LVEFs below 30% (Pre-contemplation, 
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contemplation, preparation: 56% vs. Action/Maintenance: 45%). Finally, those in the pre-action 
stages reported fewer minutes of daily activity (Pre-action: 977±288min vs. Action/Maintenance: 
1087±365min, p < 0.10), and activities above 5 METs (Pre-action: 11±23min vs. 
Action/Maintenance: 29±23min, p < 0.05), then the patients in the Action and Maintenance 
stages. 
 These data suggest that those in the early stages are clinically more fragile, are less involved 
in daily physical activities and are women. The importance of this information obviously lies in 
the fact that specific strategies need to be developed to move patients in these pre-action stages 
toward the Action stage. This study is the first to identify individuals who may need more 
specific behavioral strategies as part of their disease management. Clearly future studies should 
continue to identify these patients and develop these strategies in clinical practice.    
• Clinical Relevance 
Careful examination and appreciation of the TTM constructs generally results in greater 
success in adoption of a targeted behavior, such as planned physical activity. In a meta-analysis 
of eighty studies using the TTM in the physical activity domain, no study was included that 
examined the TTM’s constructs among individuals with heart failure26. Interestingly the majority 
of the guidelines for management of the heart failure syndrome emphasize the need for using 
targeted behavioral strategies5, 6, 11. Therefore, considering the lack of data regarding the full 
TTM in patients with heart failure, and given the success of the TTM for understanding physical 
activity behaviors in other populations, the TTM has been identified as a potentially useful 
model for understanding the exercise behavior of individuals with chronic heart failure10, 14. 
However, before the TTM is widely used for intervention studies, its utility and relevance must 
first be examined within this population segment.  
  
 
 
94
This study is unique in that the full TTM was evaluated in a group of patients with chronic 
heart failure. It is anticipated that this information will greatly facilitate the further development 
of even more effective heart failure programs. For example, research has demonstrated that an 
integration of the stages and processes of change can provide a useful guide for interventions21, 
32. More specifically, knowledge of an individual’s self efficacy, decisional balance, and stage of 
readiness to begin regular physical activity could be used to assist clinicians in developing 
targeted, effective physical activity interventions and to guide strategies that go beyond 
traditional educational approaches for individuals with chronic heart failure. Furthermore, 
knowledge regarding factors that prevent a patient from participation may ultimately contribute 
to a better understanding of the reasons for noncompliance and to the development of improved 
strategies for physical activity promotion in patients with heart failure.   
Finally, this study suggests that the stage of change algorithm aids in the identification of 
patients with heart failure at increased risk for complications and early mortality. Consequently, 
‘moving’ patients toward the action stages may ultimately contribute to the well-being of the 
patient and perhaps have an impact on health-care costs associated with this disease. 
• Limitations 
 In considering the findings of this study, it is important to keep the following limitations in 
mind. First, as mentioned previously, this was a cross-sectional design and therefore 
developmental trends in stage of change cannot be observed. Future studies should include 
longitudinal designs in order to examine the stability of various physical activity predictors 
across time. Secondly, although the defined level of physical activity appears appropriate for 
patients in this study, the exercise prescription must be something that is feasible for the 
population and the best prescription for physical activity in patients with heart failure has yet to 
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be determined. Additional research may be warranted to determine the most appropriate activity 
levels for more diverse groups of patients.  
4.5 Conclusion 
 In conclusion, this is the first study to examine stage of change for physical activity in 
patients with heart failure on the basis of the full TTM. The data reveal that despite the fact that 
participants in the study would be excellent candidates for heart failure intervention programs 
including exercise training, only 35% of patients are actively engaged in planned physical 
activity as recommended by the AHA. Thus, 65% of patients were in the pre-action stages of 
readiness to engage in a treatment strategy known to be critical in the management of their 
disease.  
The stage of change algorithm revealed 22 patients in precontemplation, 33 in contemplation, 
41 in preparation, 23 in action, and 29 in maintenance. In regards to the TTM constructs (self-
efficacy, pros and cons of decisional balance, and experiential processes) the data revealed that 
self-efficacy scores were lowest in the precontemplation stage and increased in linear fashion to 
maintenance. Decisional balance changed from greater perceived cons and lower perceived pros 
in the precontemplation and contemplation stages to lower perceived cons and higher perceived 
pros in the action and maintenance stage. Experiential processes were used predominantly in the 
precontemplation and contemplation stages, whereas behavioral processes were more 
prominently used in the action and maintenance stages. These findings are similar to available 
literature among patients with a cardiac diagnosis (not heart failure), and those with and without 
disabilities. Therefore, these data support the external validation of TTM to a unique and 
understudied population segment.  
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In addition, this study aimed to determine the most important predictors of physical activity 
stages of change utilizing the constructs of the TTM. Findings revealed that the most important 
stage of change predictors were the behavioral processes (r2= .78) and perceived self-efficacy 
(r2= .66), followed by pros (r2= .44), cons (r2= -.38), and experiential processes (r2= .33).  
The clinical relevance of this work is that once an individual’s stage has been assessed, 
interventionists may have a better idea of which processes to emphasize in order to facilitate 
progress to the next stage of change. Moreover, with the appropriate activities to meet the heart 
failure patient’s stage of readiness for change, healthcare providers may facilitate a patient’s 
movement along the continuum of change to alter lifestyle behaviors, such as physical activity, 
that can result in improved outcomes. 
Finally, data from this study indicate that patients in pre-action stages of readiness to exercise 
have significant lower exercise tolerance/capacity then those in the action and maintenance 
stages. In fact, over 50% of patients in pre-action may be at even greater risk for complications 
and early mortality secondary to scoring <300 meters on the six-minute walk test and having an 
estVO2peak of <14 ml/kg/min. Moreover, patients in the pre-action stages have significant lower 
daily energy expenditures. These data suggest greater clinical emphasis should be placed on 
strategies to move patients toward the action and maintenance stages of readiness. 
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CHAPTER 5. SUMMARY 
5.1 Summary 
The overall goal of the research conducted was to gain a greater understanding regarding the 
management of patients with heart failure. A particular focus of the research projects was to 
evaluate exercise tolerance and to examine exercise behavior. The rationale for this focus is 
evidence that the clinical phase of heart failure includes a marked decline in functional state, as 
defined by exercise tolerance and capacity with a subsequent decrease in quality of life. 
Moreover, there is growing evidence that exercise training reverses many of the peripheral 
abnormalities present in the heart failure patient1. These improvements translate in an increased 
exercise tolerance, reduction in activity-related symptoms, and improved quality of life.  Perhaps 
most importantly, exercise training improves survival, reduces health care costs and re-
hospitalization in patients with chronic heart failure2.  Unfortunately, despite this evidence 
patient participation and adherence in these types of programs remain suboptimal. 
Chapter 2 indicated that despite the overwhelming evidence of the benefits of exercise for 
patients with heart failure, patients are not receiving adequate information regarding physical 
activity. Furthermore, Chapter 2 also showed that measures of exercise tolerance and quality of 
life were significantly lower for the patients with heart failure compared to age-matched controls. 
Finally, some preliminary data indicated that a very basic home exercise program with frequent 
patient contact resulted in modest improvements in exercise tolerance and perceived quality of 
life. 
Chapter 4, in part, evolved from failure to adequately recruit from the available heart failure 
pool for projects 1 and 2. In fact, it appeared that many patients just did not want to make 
behavior changes. Thus, Chapter 4 assessed the motivation and readiness of patients with heart 
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failure to make necessary behavioral changes to aid in the management of their condition. The 
findings revealed that only 35% of patients were actively engaged in planned physical activity as 
recommended by the American Heart Association. Thus, 65% of patients were in the pre-action 
stages of readiness to engage in a treatment strategy known to be critical in the management of 
their disease. More specifically, the stage of change algorithm revealed 22 patients in 
precontemplation, 33 in contemplation, 41 in preparation, 23 in action, and 29 in maintenance. 
Further analyses revealed that self-efficacy scores were lowest in the precontemplation stage and 
increased in linear fashion to maintenance. Decisional balance changed from greater perceived 
cons and lower perceived pros in the precontemplation and contemplation stages to lower 
perceived cons and higher perceived pros in the action and maintenance stage. Experiential 
processes were used predominantly in the precontemplation and contemplation stages, whereas 
behavioral processes were more prominently used in the action and maintenance stages. These 
findings are similar to available literature among patients with a cardiac diagnosis (not heart 
failure), and those with and without disabilities3-5. Therefore, these data support the external 
validation of the Transtheoretical model to a unique and understudied population segment.  
In addition, this study aimed to determine the most important predictors of physical activity 
stages of change utilizing the constructs of the Transtheoretical model. Findings revealed that the 
most important stage of change predictors were the behavioral processes and perceived self-
efficacy.  
Finally, data from this study indicated that patients in pre-action stages of readiness to 
exercise have significant lower exercise tolerance/capacity then those in the action and 
maintenance stages. In fact, over 50% of patients in pre-action may be at even greater risk for 
complications and early mortality secondary to scoring <300 meters on the six-minute walk test 
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and having an estVO2peak of <14 ml/kg/min6,7. Moreover, patients in the pre-action stages have 
significant lower daily energy expenditures. These data suggest greater clinical emphasis should 
be placed on strategies to move patients toward the preparation and action stages of readiness. 
The clinical relevance of this work is that once an individual’s stage has been assessed, 
interventionists may have a better idea of which processes to emphasize in order to facilitate 
progress to the next stage of change. Moreover, with the appropriate activities to meet the heart 
failure patient’s stage of readiness for change, healthcare providers may facilitate a patient’s 
movement along the continuum of change to alter lifestyle behaviors, such as physical activity, 
that can result in improved outcomes. In a meta-analysis of eighty studies using the 
Transtheoretical model in the physical activity domain, no study was included that examined the 
Transtheoretical model constructs among individuals with heart failure4. Interestingly the 
majority of the guidelines for management of the heart failure syndrome emphasize the need for 
using targeted behavioral strategies8-10. Considering this is the first study to have examined the 
full Transtheoretical model in patients with heart failure, this study is unique and its findings 
could greatly facilitate the further development of even more effective heart failure programs.  
For example, research has demonstrated that an integration of the stages and processes of 
change can provide a useful guide for interventions11, 12. More specifically, knowledge of an 
individual’s self efficacy, decisional balance, and stage of readiness to begin regular physical 
activity could be used to assist clinicians in developing targeted, effective physical activity 
interventions and to guide strategies that go beyond traditional educational approaches for 
individuals with chronic heart failure. Furthermore, knowledge regarding factors that prevent a 
patient from participation may ultimately contribute to a better understanding of the reasons for 
noncompliance and to the development of improved strategies for physical activity promotion in 
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patients with heart failure.  Finally, this study suggests that the stage of change algorithm aids in 
the identification of patients with heart failure at increased risk for complications and early 
mortality. Consequently, ‘moving’ patients toward the action stages may ultimately contribute to 
the well-being of the patient and perhaps have an impact on health-care costs associated with this 
disease. 
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APPENDIX A. INFORMED CONSENT 
CONSENT TO PARTICIPATE IN RESEARCH 
 
The University of Mississippi Medical Center 
 
Study Title:  
Examination of the Constructs of the Transtheoretical Model in Patients with Heart failure: A Focus on 
Physical Activity Readiness 
 
Principal Investigator:  Charles K. Moore, M.D. 
Co-investigators: Michael A. Welsch, Ph.D., Tracie Parish, M.Ed., ATC/L 
_____________________________________________________ 
 
Introduction:  Heart failure is a significant health problem in the United States. Patients with this 
condition are often hospitalized, and complain of chronic fatigue and can not perform many of the normal 
daily activities. You are being invited to be in this study, because you have been diagnosed with heart 
failure. Please ask us about anything in this document or that we tell you that you do not understand. 
 
Purpose:  The purpose of the study is to learn about reasons why some patients with heart failure do not 
participate in certain behaviors known to help in controlling the heart condition.  
 
Procedures: If you agree to participate in this study, you will be asked a series of Behavioral and 
Knowledge questions which will give us information about your current behaviors such as your daily 
physical activity. The questions will be given to you during one visit. In addition, you will be asked to 
perform a 6 minute walking test, at a pace that is comfortable to you. We expect that it will take 
approximately one hour to answer the questions and perform the walking test. 
 
Risks: The risks associated with this study are very small and mostly involve risks during the 6-minute 
walk test. The risks associated with the walking test are muscle soreness, stiffness or tightness, or in some 
rare cases more severe problems such as chest pain, shortness of breath or cardiovascular complications. 
 
Benefits:  You may or may not receive a direct benefit from being in this research study. In identifying 
your readiness to participate in heart healthy behaviors, we may be able to provide you with more 
appropriate information that will help you understand how to stay healthy given your condition. We also 
hope to learn information that may help others in the future. 
Alternatives: This is not a treatment study and the only alternative is to not participate in the study. 
 
Costs: There will be no additional costs to your participation in this study. In the case of injury or illness 
resulting from your participation in this study, medical treatment is available to you at the University of 
Mississippi Medical Center.  You will be charged the usual and customary charges for any such treatment 
you receive. 
 
Compensation: You will not be paid for participating in this study. 
 
Voluntary Participation and Withdrawal: Your participation is voluntary.  If you decide not to 
participate in this study you will not suffer a penalty or loss of benefits to which you are otherwise 
entitled.  If you decide to participate in this study you may discontinue your participation at any 
time, without penalty or loss of benefits and it will have no effect on the quality of your medical 
care, academic standing, job status, etc. (whatever phrase is appropriate).    
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Confidentiality:  Every effort will be made to keep the information we learn about you private.  
Study personnel, the Food and Drug Administration (FDA), the Office for Human Research 
Protections (OHRP) and the University of Mississippi Medical Center’s Institutional Review 
Board (IRB) and Office of Compliance may review the study records.  If study results are 
published your name will not be used.   
 
Protected Health Information:  Protected health information is any personal health information 
through which you can be identified.  The data collected in this study include your medical 
history and information from the questionnaires and walking test.  A decision to participate in this 
research means that you agree to the use of your health information for the study described in this 
form.  This information will not be released beyond the purposes of conducting this study.  The 
information collected for this study will be kept until the study is complete.  While this study is 
ongoing you may not have access to the research information, but you may request it after the 
research is completed.    
 
Number of Participants:  We expect about 200 participants to enroll in this study. 
 
Questions: If you have questions about this study you may discuss your rights as a research 
participant with the Chairman of the University of Mississippi Medical Center’s Institutional 
Review Board, 2500 North State Street, Jackson, Mississippi  39216; telephone, 601 984-2815; 
facsimile, 601 984-2961.  The Institutional Review Board is a group of people not involved with 
this study who have reviewed the study to protect your rights.  
 
Statement of Participation: Your signature indicates that you have decided to participate after 
having read the information provided above.  
 
You will be given a copy of this consent document for your records.  
 
 
SIGNATURES  
 
By signing this form I am not waiving any legal rights I may have.   
 
 
___________________________________________________________ 
Participant’s Printed Name      Date/Time 
 
 
___________________________________________________________ 
Signature of Participant       Date/Time 
 
 
___________________________________________________________ 
Printed Name of Person Obtaining Informed Consent  Date/Time 
 
 
 
___________________________________________________________ 
Signature of Person Obtaining Informed Consent  Date/Time 
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I acknowledge that the participant identified above has been entered into this study, with properly 
obtained informed consent. 
 
________________________________ 
Signature of Principal Investigator  
 
________________________________ 
Date* 
 
*Absent extenuating circumstances, the investigator’s signature should be obtained within 48 
hours of the participant’s signature.  
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INTRODUCTION 
Heart failure (HF) is defined as the pathophysiological state in which an abnormality of cardiac 
function is responsible for failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolizing tissues, or to do so only from an elevated filling pressure 
(Braunwald, 1988). Heart failure is not a homogenous disease. Rather, it is the final common 
pathway of several other disorders that impair the heart’s pumping ability (Pernenkil, Vinson, et 
al., 1997). Coronary artery disease is the cause of HF in about two thirds of patients with left 
ventricular systolic dysfunction (Gheorghiade, Bonow, 1998). Other causes of HF are associated 
with a nonischemic cardiomyopathy, which may result from long-standing hypertension, a toxin-
related illness (e.g., alcohol), a systemic illness affecting the heart (e.g., thyroid disease), 
valvular disease, myocarditis, or idiopathic causes. Finally, heart failure could be the result of 
underlying pericardial disease (Hunt, Baker, Chin, et al., 2001).  
The insult to the cardiovascular system is frequently met with a variety of compensatory 
adaptations with short- to long-time constants aimed to maintain cardiac output and arterial 
pressure to adequately perfuse the brain and the heart.  These compensatory adaptations include 
(1) an increase in ventricular end-diastolic volume and pressure (ventricular dilatation); (2) 
sympathetic nervous system activation; (3) neurohumoral vasoconstriction; (4) renal sodium and 
water retention; (5) myocardial hypertrophy; (6) impaired vasodilatory capacity; and (7) intrinsic 
changes in skeletal muscle.  Although, these compensatory adaptations may be remarkably 
effective under resting conditions, the capacity to sustain cardiac performance in the face of 
hemodynamic overload relative to myocardial contractility is finite and exacts a price (Zelis, 
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Figure 1. Hospital Discharges for Congestive Heart Failure 
Sinoway, Leuenberger, et al., 1991).  In fact, it is those compensatory mechanisms that 
ultimately contribute significantly to the clinical severity of the disease. 
   The purpose of this review is twofold: (1) to describe the compensatory adaptations to 
heart failure, with the focus on the morphological, biochemical, cellular, and neurohumoral 
changes characteristic of heart failure and how these relate to the exercise tolerance, a marker of 
the clinical severity of the disease, (2) to examine currently available strategies to manage the 
heart failure patient, with specific focus on the need for multidisciplinary programs.  
HEART FAILURE STATISTICS 
An estimated 4.9 million Americans have heart failure, a chronic condition associated 
with frequent hospitalizations, widespread functional impairment, and a high mortality rate. Each 
year, approximately 550,000 new cases are diagnosed and nearly 300,000 patients die of heart 
failure as a primary or contributory cause 
(AHA Heart & Stroke Facts, 2003). 
Elderly individuals are particularly at risk 
for developing heart failure. In fact, HF is the 
most common hospital discharge 
diagnosis for patients over 65 years. The 
syndrome is the underlying reason for 12 to 
15 million office visits and 6.5 million 
hospital days each year (O’Connell & 
Bristow, 1993). Furthermore, during the last 10 years, the annual number of hospitalizations has 
increased from approximately 550,000 to nearly 900,000 for HF as a primary diagnosis and from 
1.7 to 2.6 million for HF as a secondary diagnosis (Haldeman, Croft, et al., 1999).  In addition to 
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the substantial morbidity and mortality associated with this condition, there is a significant 
financial impact on our society. In fact, heart failure is now the single most costly cardiovascular 
illness in the United States, with total treatment costs estimated at $24.3 billion (AHA Heart & 
Stroke Facts, 2003). The cost to society is expected to increase due to an aging population and 
prolonged survival rates of individuals with cardiovascular disease, therefore imposing a large 
burden on individuals and the healthcare system (Bourassa, Gurne, & Bangdiwala, et al., 1993).  
THE HEART IN HEART FAILURE 
      Following partial destruction of the myocardium, and/or a pressure or volume overload, the 
heart uses a series of short- to long-term adaptive strategies to maintain cardiac output 
compatible with survival.  Within seconds to minutes of a reduction in stroke volume, an 
increase in venous return and inotropic state can cause ventricular dilation and increased 
myocardial contractility (Ross, 1976). 
Ventricular dilatation and myocardial contractility 
Ventricular dilatation is the result of adaptive lengthening of the non-infarcted 
sarcomeres (Pfeffer, M.A., & Braunwald, E. 1987) or may develop secondary to expansion of an 
infarcted zone  (Hutchins et al., 1978).  This adaptive strategy aims to restore cardiac output 
through the Frank-Starling mechanism despite a loss in contractile function (Starling, 1895).  If 
the preload reserve is inadequate to maintain cardiac output, activation of the sympathetic 
nervous system results in an increase in myocardial contractility.  Sympathetic activation causes 
stimulation of beta-receptors and intracellular second messenger systems.   
Unfortunately, stretching of the sarcomeres to a more optimal length is an adaptive 
strategy that is easily pushed to the maximum, increases wall stress (and therefore myocardial 
oxygen demand), and does not work well chronically (Zelis, Sinoway, Leuenberger, et al., 1991). 
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In fact, left ventricular dilation (in particular end-systolic volume) represents one of the most 
powerful prognostic indicators for cardiac failure and death (White, Norris, Brown, et al., 1987).  
Furthermore, down-regulation or decreased responsiveness of beta-receptors and gradual 
development of dysfunction of the stimulatory guanylate nucleotide binding protein, which 
couples the beta-receptor to the adenylate cyclase system, and contractile apparatus ultimately, 
renders catecholamine stimulation of the myocardium ineffective over the long-term 
(Longabaugh et al., 1988).   
Cardiac remodeling 
To cope with a chronic elevation of myocardial wall stress, the heart remodels and 
hypertrophies.  Gradually, new sarcomeres (contractile units) are laid down to share the work 
load and reduce the wall stress.  Patients with cardiomyopathies have shown that an increase in 
left ventricular end-diastolic volume and an almost doubling of left ventricular mass counter a 
reduction in ejection fraction (Holubarsch et al. 1991).  Clearly, such an adaptation has a much 
longer time constant and is slow in onset and slow to regress.  However, myocardial hypertrophy 
exacts a price.  More sarcomeres means more muscle that needs to be oxygenated which results 
in an increase in myocardial oxygen demand.  The increase in myocardial oxygen demand may 
subsequently result in myocardial ischemia due to an inability to raise coronary flow beyond the 
ceiling imposed by coronary artery atherosclerotic obstruction. Consequently the aim of 
treatment of overt heart failure is to control the vicious cycle of cardiac failure through 
restriction of physical activity, restriction of sodium intake, diuretics, vasodilators, digitalis 
glycosides, and/or other inotropes. 
Unfortunately if the underlying cause of heart failure is not corrected, patients enter the 
next phase of the disease known as chronic heart failure defined by a gradual decline in physical 
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function with occasional exacerbations of their condition. Chronic heart failure is a complex 
clinical syndrome, or constellation of signs and symptoms, that may include fatigue and 
shortness of breath on exertion (progressing to symptoms at rest), peripheral edema, orthopnea, 
paroxysmal nocturnal dyspnea, nocturia, mental status changes, anorexia, and abdominal pain. 
The symptoms appear to be the consequence of a variety of compensatory adaptations with 
short- to long-time constants aimed to maintain cardiac output and arterial pressure to adequately 
perfuse the brain and the heart.  These compensatory adaptations were described above and will 
be discussed in further detail in the next sections regarding the consequence of the heart failure 
syndrome on physical function, as defined by exercise tolerance. It is important to recognize that 
the compensatory adaptations are remarkably effective early on in the disease process and under 
resting conditions. However, the capacity to sustain cardiac performance in the face of the 
compensatory adaptations exacts a price (Zelis et al., 1991), as they ultimately contribute 
significantly to the clinical severity of the syndrome. In fact, the cardinal symptoms of HF 
include (1) dyspnea (2) significant intolerance to physical activity, and (3) chronic fatigue. 
Consequently, the long-term management of the chronic heart failure patient must focus on the 
control of the heart failure syndrome and the need to manage the compensatory changes 
associated with the disease. It is clear from the present literature that clinicians and therefore 
patients struggle tremendously with the long-term management of the syndrome, despite 
evidence of available efficacious strategies.  
THE PERIPHERY IN CHRONIC HEART FAILURE 
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Figure 2a and b. Relationship between exercise capacity and tolerance and Left Ventricular Ejection Fraction 
Intuitively, one would hypothesize that the clinical severity of heart failure is directly related to 
the degree of cardiac dysfunction.  Yet, most clinical measures of cardiac function (e.g. 
cardiothoracic ratio; left ventricular ejection fraction) correlate poorly with the clinical severity 
of heart failure, as defined by exercise capacity or tolerance (see Figures 2a and b) (Coats, 2001; 
Parish, Alomari, Wood, et al., 2002). This discordance has led to the identification of multiple 
compensatory mechanisms with short- to long-time constants, which may contribute to the 
marked exercise intolerance in heart failure.  These compensatory mechanisms include: (1) 
"hyper"-activation of neurohumoral factors, e.g. increased catecholamines and fluid-regulatory 
hormones and a decrease in endothelium-mediated dilators, (2) alterations in skeletal muscle 
blood flow, metabolism and function, and (3) structural vascular and skeletal muscle changes 
(Drexler, 1991).  
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Figure 3a and b. Acute and Long-term Compensatory Changes in heart failure, which contribute to the clinical syndrome
Although, the purpose of the compensatory adaptations in heart failure is thought to be an 
attempt to maintain a cardiac output and arterial pressure that adequately perfuse the brain and 
the heart, it is the magnitude of these compensatory adaptations that eventually sows the seed for 
a series of maladaptive processes which lead to a decompensated state or even end-stage heart 
failure (Zelis, Sinoway, Leuenberger, et al., 1991).  Yet, to date, it is not clear to what degree the 
compensatory adaptations in heart failure are inherent to the disease or to other contributing 
factors such as physical deconditioning and/or malnutrition. The peripheral alterations in heart 
failure are thought to be, in part, protective as they prevent blood pressure from decreasing when 
the failing heart cannot adequately increase cardiac output (Zelis, Sinoway, Leuenberger, et al., 
1991). Others suggest that the peripheral alterations in heart failure in part mimic the 
deconditioning process seen with prolonged physical inactivity (Adamopoulos & Coats, 1991; 
Stratton, Dunn, Adamopoulos, et al., 1994). Thus, it is presently not clear to what degree the 
exercise intolerance in heart failure is inherent to the disease itself, level of inactivity, or one or 
more unidentified contributing factors.   
Circulatory Compensatory Adaptations  
In patients with low cardiac output, arterial pressure is supported by a rise in systemic 
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vascular resistance.  Therefore, in addition to the cardiac compensatory mechanisms discussed 
above, heart failure is characterized by a complex series of circulatory adaptations which aim to 
maintain arterial blood pressure.  These circulatory adaptations include (1) neural 
vasoconstriction, (2) humoral vasoconstriction, and (3) local impairment of vasodilatory 
capacity.  The compensatory mechanisms often act in concert to maintain arterial pressure, but 
each has its own time-constant and ultimately contributes to the development of the "Heart 
Failure Syndrome".   
Alterations in cardiovascular reflexes 
In the acute phase of low-output heart failure, arterial and cardiopulmonary baroreflexes 
are activated to help maintain blood pressure.  However, sensitivity of both receptors diminishes 
contributing to blunted reflexes (Dibner-Dunlap & Thames, 1992; Eckberg, Drabinsky, & 
Braunwald, 1971; Ellenbogen, Mohanty, Szentpetery, et al., 1989). It is thought that the marked 
desensitization of the reflexes contributes to abnormal neurohumoral stimulation.  Although the 
precise mechanisms involved are not entirely understood, it is proposed that in patients with 
heart failure the abnormalities in the cardiovascular reflexes could lead to a reduced restraining 
influence on the sympathetic nervous system, thereby removing the restraining or "braking" 
influence on the heart and circulation.  In time, this would favor the development of a 
neurohumoral excitatory state with tachycardia and sympathetically mediated vasoconstriction. 
Alterations in the autonomic nervous system  
 
A rise in systemic vascular resistance is accomplished initially, by activation of the 
sympathetic nervous system.  The effect of systemic activation on the heart was described above.  
Activation of the sympathetic nervous system is very effective over the short term to maintain 
blood pressure (Zelis & Flaim, 1982). Plasma norepinephrine concentrations, an index of the 
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Figure 4a and b. Heart Rate Variability in a Healthy Woman (a) and Heart Failure Patient 
activity of this system, are generally two or three times higher in patients with heart failure in 
comparison to healthy controls (Cohn, Levine, Olivari, et al., 1984). The magnitude of elevation 
of plasma norepinephrine is related to the degree of left ventricular dysfunction and carries an 
ominous prognosis (Cohn, Levine, Olivari, et al., 1984). The purpose of the increase in 
sympathetic activation is to maintain cardiac output and arterial pressure through stimulation of 
myocardial contractility and α1-adrenoreceptors in the vascular wall.  Stimulation of the α1-
adrenoreceptors causes an increase in vasomotor tone and systemic vascular resistance.  
However, any supportive effect of the increased sympathetic nervous system activity on arterial 
blood pressure is, in time, superseded by a number of organ-specific consequences.  The 
potential adverse effects of sympathetic activation on cardiac muscle (see figure 4a and b), the 
kidneys, and the vasculature is numerous and contributes to the clinical manifestations of heart 
failure (Hackenthal, Paul, Genten, et al, 1990).  
Humoral activation 
Humoral activation is one of the hallmarks of the heart failure syndrome (Drexler, 1991). 
The purpose of humoral activation is to maintain arterial pressure secondary to an increase in 
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blood volume. The increased volume also assists the failing heart by increasing the preload 
which subsequently stretches the sarcomeres in the myocardium to a more optimal length during 
the early phases of heart failure until myocardial hypertrophy develops.  However, as a result of 
chronic humoral activation two vicious cycles develop: (1) vasoconstriction and (2) sodium and 
water retention.  Arterial vasoconstriction causes an increase in systemic vascular resistance and 
inevitably an increase in afterload and systolic wall stress.  The sodium and water retention 
causes an increase in circulating volume, which may be beneficial at first, but ultimately results 
in an increased ventricular filling pressure and diastolic wall stress.  Together, these vicious 
cycles may eventually lead to progressive myocardial and vascular dysfunction, peripheral tissue 
abnormalities, fluid accumulation, and finally the clinical picture of heart failure (Remme, 1994).   
Activation of the renin-angiotensin-aldosterone axis is attributed to low renal perfusion 
and sympathetic stimulation. The formation of angiotensin II, which is catalyzed by angiotensin 
converting enzyme, located in the endothelium of the vascular tree, contributes to a rise in 
peripheral vascular resistance, enhances renal sodium reabsorption, facilitates catecholamine 
release from sympathetic nerve endings, and stimulates mineralcorticoid production in the 
adrenal gland (Hackenthal, Paul, Genten, et al., 1990). Angiotensin II has also been implicated as 
a growth factor or growth modulator in the cardiovascular system.  The renin-angiotensin-
aldosterone axis is markedly activated in patients with decompensated heart failure.   
With the discovery that the renin-angiotensin-aldosterone system is markedly activated in 
heart failure, it is not surprising that a significant number of investigators have focused on the 
role of angiotensin-converting-enzyme (ACE) inhibitors as a strategy to treat patients with heart 
failure.  Results from subsequent clinical trials have shown convincingly that cardiovascular 
morbidity and mortality can be reduced in patients with left ventricular dysfunction (ejection 
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fraction < 40%) secondary to ischemic heart disease following long-term use of ACE-inhibitors 
(SOLVD Investigators, 1991; SOLVD Investigators, 1992; Pfeffer, Braunwald, Moye, et al., 
1992).  Interestingly, the precise mechanism(s) of action of ACE-inhibitors are still not fully 
understood.  It is thought that the mechanism of action is in part cardioprotective and 
vasculoprotective.  A reduction in systemic vascular resistance secondary to inhibition of 
angiotensin II generation may reduce afterload and myocardial work.  Mechanisms for the 
vasculoprotective properties include a reduction in angiotensin II production, decreased 
bradykinin degradation, antagonism of macrophage function and migration as well as inhibition 
of sympathetic nervous system and thrombotic activity (Pepine, 1996). All of these could result 
in plaque stabilization, and may contribute to reversal of vascular dysfunction.   
Arginine vasopressin is also elevated in heart failure (Schrier & Abraham, 1999). The 
mechanism for the release of arginine vasopressin in heart failure is not well understood but is 
believed to be due to non-osmotic causes.  Perhaps a decreased sensitivity of atrial stretch 
receptors, which normally serve to inhibit arginine vasopressin release with atrial distention, 
contributes to the elevation of circulating arginine vasopressin.  Non-osmotic stimulation of 
arginine vasopressin has been linked to low stroke volume and cardiac output.  Improvement in 
cardiac performance by afterload reduction in patients with heart failure decreases arginine 
vasopressin levels and enhances water excretion.  A potential unfavorable consequence of 
elevated arginine vasopressin is hyponatremia.  Hyponatremia is a common manifestation of 
severe heart failure and occurs when water is retained in excess of sodium.  It has been shown to 
be a powerful independent predictor of cardiovascular mortality (Lee & Packer, 1986).
 Circulating atrial natriuretic peptide levels are reportedly increased in patients with heart 
failure.  The elevation in plasma atrial natriuretic peptide in heart failure patients is thought to be 
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due to increased cardiac volume and/or pressure overload.  Several studies have demonstrated 
that atrial natriuretic peptide correlates with the functional class of patients with heart failure, 
plasma renin activity, plasma norepinephrine concentrations, and mortality.  As a result atrial 
natriuretic peptide has emerged as an important diagnostic and prognostic marker in heart failure 
(Gottlieb, Kukin, Ahern, et al., 1989).   
   More recent evidence suggests that there is a diminished response to and a gradual 
impairment in the capacity to release atrial natriuretic peptide in heart failure (Volpe, Tritto, De 
Luca, 1991). The mechanism for the hyporesponsiveness to atrial natriuretic peptide is thought to 
be multifactorial and include (1) a reduction in renal perfusion, (2) increased renal sympathetic 
nerve activity, (3) increased circulating catecholamines, (4) atrial natriuretic peptide receptor 
downregulation, (5) enhanced atrial natriuretic peptide enzymatic degradation, and/or (6) 
increased activity of the renin-angiotensin-aldosterone system.  The impaired capacity to release 
atrial natriuretic peptide may be the result of chronic volume and pressure overload and inability 
of the atria to meet the demand of the system.  Thus, a relative deficiency may develop in 
patients with chronic heart failure with biologic consequences.  It may therefore be hypothesized 
that the diminished response to and impaired release of atrial natriuretic peptide contributes to 
the pathophysiology of sodium and water retention and systemic vasoconstriction in patients 
with heart failure (Brandt, Wright, Redfield, et al., 1993). 
Alterations in Vasoreactivity 
The above mentioned neurohumoral factors exert potent systemic and regional 
vasoconstriction in patients with heart failure.  However, it is surprising that there is a poor 
correlation between plasma neurohumoral factors and systemic vascular resistance.  This 
suggests that there are still other factors that affect vascular tone.  In fact clear evidence indicates 
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that patients with heart failure have impaired vasodilatory capacity (Drexler, Hayoz, Munzel, et 
al., 1992; Wilson & Ferraro, 1985). Moreover, ACE-inhibitors do not restore the vasodilatory 
response following acute administration, indicating that blockade of the renin-angiotensin-
aldosterone system does not result in an immediate improvement in blood flow to working 
muscle.  Thus, it appears that there are other mechanisms involved in the impaired vasodilatory 
capacity of patients with heart failure.  There currently are three potential mechanisms, which 
may explain the vasodilatory impairment seen in heart failure: (1) endothelial dysfunction, (2) 
vascular stiffness, (3) vascular deconditioning, and (4) changes in venous function. 
There is now compelling evidence that endothelium-mediated relaxation is attenuated in 
both the coronary and peripheral circulation of patients with heart failure (Drexler, Hayoz, 
Munzel, et al., 1992). The potential mechanism(s) of endothelial dysfunction are currently 
unknown, although several hypotheses have been proposed.  These hypotheses include (1) 
alterations in endothelial cell surface receptors, (2) decrease in endothelial derived relaxing 
factor synthesis, (3) rapid degradation of endothelial derived relaxing factor, and (4) increased 
production of endothelium-derived contracting factors.    
Alterations in endothelial cell surface receptors may be secondary to the atherosclerotic 
process or may be a consequence of chronic low flow resulting in lack of stimulation of the 
endothelial apparatus to produce dilating factors, such as nitric oxide and prostaglandins. It is 
unclear if the production of endothelium-derived relaxing factor is perhaps secondary to 
nutritional deficiencies in L-arginine, and/or the cofactors needed in the production process.  
Rapid degradation of endothelial derived relaxing factor has been linked to increased oxygen-
derived free radical activity.  The oxygen-derived free radical superoxide is a known inactivator 
of endothelial derived relaxing factors.  Oxygen-derived free radical production is increased in 
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Figure 5. Relationship between exercise tolerance and Reactive 
Hyperemic Blood Flow in Heart Failure Patients 
patients with heart failure (Belch, Bridges, Scott, et al., 1991). Thus, free radical-mediated 
inactivation of endothelium-derived relaxing factor in the vasculature of patients with heart 
failure could contribute to the impaired vasodilatory response.  
Vascular stiffness may in part be the result of an increase in the vascular sodium content 
subsequent to the hyperactivity of the renin-angiotensin-aldosterone system (Sinoway, Minotti, 
Musch, et al., 1987). The increase in vascular sodium and water content leaves the vessels stiff, 
less responsive to local metabolic stimuli, and may result in a change in the capillary basement 
membrane morphometry.  In fact, approximately one third of the reduced vasodilatory response 
during exercise in patients with heart failure can be attributed to increased sodium and water 
content in the vascular wall (Sinoway, Minotti, Musch, et al., 1987).  
  Impaired vascular function may also be the result of chronic vascular deconditioning 
(Drexler, 1991). Immobilization of 
the forearm reportedly reduces 
vasodilatory capacity.  Conversely, 
exercise training improves peak 
vasodilatory capacity (Hornig, 
Maier, & Drexler, 1996). Thus, 
vascular deconditioning may be 
secondary to a chronic decrease in 
blood flow (see Figure 5).  
Interestingly, recent 
investigations also report diminished venous function in patients with heart failure (Welsch, 
Alomari, Parish, et al., 2002; Ikenouchi, Iizuka, Sato, et al., 1991). Moreover, measures of 
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Figure 6a and b. Association between Venous Capacitance and Outflow and Exercise Tolerance in  Chronic 
Heart Failure 
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distance achieved on the 6-minute walking test, a measure of exercise tolerance (see Figure 6a 
and b) (Welsch, Alomari, Parish, et al., 2002). These findings suggest factors that contribute to 
exercise impairment in heart failure patients may extend to the venous system. Although the 
precise factors are not entirely understood, the important contributions of the venous system in 
terms of metabolic waste removal and end-diastolic volume, would suggest that any change in 
this system could have a profound impact on the exercise response. Finally, evidence that venous 
function influences arterial inflow through the venoarterial reflex (Tschakovsky & Hughson, 
2000) suggests the importance of addressing venous health in heart failure.  
Skeletal Muscle Compensatory Adaptations 
Considerable attention has been given to intrinsic alterations in skeletal muscle which 
may contribute to the clinical severity of patients with heart failure (Drexler, Riede, Munzel, et 
al., 1992; Drexler, Riede, Hiroi, et al., 1988; Sullivan, Green, & Cobb, 1990; Sullivan, Green, & 
Cobb, 1991). The consensus of these studies indicates significant skeletal muscle abnormalities 
including (1) structural changes, such as muscle atrophy; (2) a marked decline in mitochondrial 
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enzyme concentration and activity (Succinate dehydrogenase, Citrate synthase and cytochrome 
oxidase); and (3) a reduction in mitochondrial volume and density.   
Skeletal muscle atrophy 
Muscle atrophy is common in patients with heart failure (Drexler, Riede, Munzel, et al., 
1992; Sullivan, Green, & Cobb, 1990). The mechanism for muscle atrophy in heart failure is not 
entirely clear but has been linked to malnutrition, deconditioning, an increased catabolic state 
due to sympathetic nervous system hyperactivation, an increase in serum cortisol, corticotropin, 
and/or tumor necrosis factor.  Thus, it appears that skeletal muscle atrophy could be an important 
and potentially reversible contributor to exercise intolerance in patients with heart failure.   
Histologic and biochemical alterations in skeletal muscle  
It appears that skeletal muscle atrophy in heart failure is somewhat selective and more 
pronounced in the Type I (high-oxidative) muscle fibers, compared to other fiber types.  In 
addition, to these morphologic changes, a decrease in the number of capillaries per fibers for 
type I and type IIa fibers are also reported (Drexler, Riede, Munzel, et al., 1992; Drexler, Riede, 
Hiroi, et al., 1988; Sullivan, Green, & Cobb, 1990).    
The apparent loss in oxidative capacity in heart failure is further evident from studies 
which have performed biochemical analysis of skeletal muscle (Drexler, Riede, Munzel, et al., 
1992; Drexler, Riede, Hiroi, et al., 1988; Sullivan, Green, & Cobb, 1990). A consistent 
observation in these patients is a marked reduction in mitochondrial enzyme concentration for 
succinate dehydrogenase citrate synthetase, and 3-hydroxacyl-coenzyme A-dehydrogenase and 
enzymatic activities.  In addition, muscle glycogen levels are also reduced.  Ultrastructural 
morphometry of muscle biopsies of the vastus lateralis indicated significant abnormalities of 
skeletal muscle as compared to normals (Drexler, Riede, Munzel, et al., 1992; Drexler, Riede, 
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Hiroi, et al., 1988). The volume density of mitochondria and surface density of mitochondrial 
cristae, markers of structural correlates of oxidative capacity, were significantly reduced by 20% 
in patients with severe heart failure.  Capillary length density was reduced and fiber type 
distribution of skeletal muscle was shifted to type II fibers.  Cytochemical analysis of 
cytochrome oxidase activity also revealed significant decreases in heart failure.  Both the volume 
density of mitochondria and surface density of mitochondrial cristae were significantly related to 
VO2peak and VO2 at anaerobic threshold, but inversely related to the duration of heart failure 
(Drexler, Riede, Munzel, et al., 1992; Drexler, Riede, Hiroi, et al., 1988). From these studies, it 
appears that the literature supports the notion that a major component of heart failure is a 
reduction in oxidative capacity due to intrinsic alterations in skeletal muscle.   
Although, the mechanisms for the alterations in skeletal muscle metabolism in heart 
failure patients are unknown, several factors (neurohumoral, chronic reductions in muscle 
perfusion, and deconditioning) may be involved (Adamopoulos & Coats, 1991; Stratton, Dunn, 
Adamopoulos, et al., 1994; Drexler, Riede, Munzel, et al., 1992). Chronic deconditioning may be 
a key factor in the alterations in skeletal muscle metabolism, since recent studies have shown that 
physical training can improve exercise capacity in patients with heart failure by delaying the 
onset of anaerobic metabolism.  However, chronic muscle underperfusion (at rest or during 
exercise) and/or increased sympathetic stimulation could also cause many of the above-
mentioned abnormalities in skeletal muscle metabolism. Finally, “mal”-nutrition in these patients 
may also contribute to the observed changes. 
GOALS OF TREATMENT 
Because of the multi-factorial, and often patient-specific, nature of the illness, treatment 
of heart failure is extremely challenging and patients require close monitoring (Caldwell MA & 
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Dracup K, 2001). The primary goals of heart failure management are to reduce the frequency of 
heart failure exacerbations, extend survival, and improve quality of life. Additional goals include 
maximizing independence, improving exercise capacity, enhancing emotional well-being, and 
reducing resource use and cost of care (Rich, 1999). To achieve these goals, the ACC/AHA 
Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult (2001) 
have recently decided to take a new approach to the classification of HF that emphasizes both the 
evolution and progression of the disease (Hunt, Baker, Chin, et al., 2001). In doing so, 4 stages 
of HF are identified as shown in Figure 7 and Table I.  Stage A identifies the patient who is at 
high risk for developing HF but has no structural disorder of the heart; Stage B refers to a patient 
with a structural disorder of the heart but who has never developed symptoms of HF; Stage C 
denotes the patient with past or current symptoms of HF associated with underlying structural 
heart disease; and Stage D designates the patient with end-stage disease who requires specialized 
treatment strategies such as mechanical circulatory support, continuous inotropic infusions, 
cardiac transplantation, or hospice care. The treatment goals within each stage differ and focus 
on the control of risk and early detection of ventricular dysfunction in Stage A patients; 
prevention of cardiovascular events and early detection of HF symptoms in Stage B patients; 
pharmacologic approaches and behavior interventions in Stage C; and Stage D patients 
aggressive management of fluid status, utilization of neurohumoral inhibitors, intravenous drug 
therapy and mechanical or surgical intervention. The goals and steps for treatment are further 
depicted in the figure below as developed by the ACC/AHA guidelines (Hunt, Baker, Chin, et 
al., 2001).  
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Pharmacological Treatment  
The most common strategy used to manage patients with chronic heart failure is through 
the use of pharmacological agents. Clearly, the purposes of pharmacologic therapy are to reduce 
mortality, to alleviate the symptoms of HF, and to improve the patient’s functional capacity 
(Hunt, Baker, Chin, et al., 2001). Recent consensus guidelines (2001) recommend that most 
patients with symptomatic left ventricular dysfunction should be routinely managed with a 
combination of 4 types of drugs: an ACE inhibitor, a beta-adrenergic blocker, a diuretic, and 
(usually) digitalis (Packer, Cohn, et al., 1999; Hunt, Baker, et al., 2001). The value of these drugs 
has been established in numerous large-scale clinical trials, and the evidence supporting a central 
role for their use is compelling and persuasive. The purpose of this section of the review is to 
provide evidence for the use of the aforementioned drugs. In so doing it must be recognized that 
the review is somewhat biased toward individuals with left ventricular dysfunction, secondary to 
coronary artery disease. Heart failure patients with other underlying etiologies may require 
similar or vastly different pharmacological approaches from the consensus guidelines.  
Figure 7. Stages in the Evolution of Heart Failure and Recommended Therapy by Stage 
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Management of the heart failure patient with Diuretic Agents 
Clinical trials have clearly demonstrated the benefits of using diuretic agents for fast 
relief of sodium retention and symptoms of fluid overload (Patterson, Adams, Appelfeld, et al., 
1994; Sherman, Liuand, Baumgarden, et al., 1986). Moreover, diuretics contribute to improved 
cardiac function and exercise tolerance (Wilson, Reichem, Dunkman, et al., 1981). Recent 
guidelines suggest that diuretics should be prescribed to all patients who have evidence of, and to 
most patients with a prior history of, fluid retention (Hunt, Baker, Chin, et al., 2001). Diuretics 
should be administered promptly to patients with HF who present with symptoms of congestion 
and patients should continue using these agents after improvement of symptoms (Konstam, 
Dracup, Baker, et al., 1994; Packer & Cohn, 1999; Wilson, Reichem, Dunkman, et al., 1981). 
Diuretics eliminate excess fluid volume and relieve symptoms related to circulatory 
congestion (e.g., orthopnea and paroxysmal nocturnal dyspnea) by inhibiting the reabsorption of 
sodium or chloride at specific sites in the renal tubules.  Thiazides, metolazone, and potassium-
sparing agents (e.g., spironolactone) act in the distal portion of the renal tubule; whereas, loop 
diuretics (i.e., Bumetanide, furosemide, and torsemide) act at the loop of Henle (Brater, 1998; 
Cody, Kubo, Pickworth, 1994). These two classes of diuretics differ in their pharmacologic 
actions. The loop diuretics increase sodium excretion up to 20% to 25% of the filtered load of 
sodium, enhance free water clearance, and maintain their efficacy unless renal function is 
severely impaired (Damle & Talano, 1991; Hunt, Baker, Chin, et al., 2001). In contrast, thiazide 
diuretics increase the fractional excretion of sodium to only 5% to 10% of the filtered load, tend 
to decrease free water clearance, and lose their effectiveness in patients with moderately 
impaired renal function (creatine clearance up less than 30 mL per min) (Damle & Talano, 1991; 
Hunt, Baker, Chin, et al., 2001). Consequently, in some patients with mild heart failure, a 
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thiazide diuretic (e.g., hydrochlorothiazide) may be adequate, but most patients require a more 
potent loop diuretic because they are often needed to treat the volume overload associated with 
HF disease pathophysiology (Hunt, Baker, Chin, et al., 2001).  
The response to a diuretic is dependent on the concentration of the drug and the time 
course of its entry into the urine (Brater, 1998; Cody, Kubo, Pickworth, 1994). Patients with mild 
HF respond favorably to low doses because they absorb diuretics rapidly from the bowel and 
deliver these drugs rapidly to the renal tubules. However, as the HF condition worsens, the 
absorption of the drug may be delayed by bowel edema or intestinal hypoperfusion, and the 
delivery of the drug may be impaired by a decline in renal perfusion and function (Vasko, 
Cartwright, Knochel, et al., 1985; Brater, Chennavasin, Seiwell, et al., 1980; Vargo, Kramer, 
Black, et al., 1995). Consequently, the clinical progression of HF is characterized by the need for 
increasing doses of diuretics. 
Because diuretics intensify the activation of the renin-angiotensin-aldosterone system by 
decreasing renal perfusion, patients should be maintained on the lowest dose possible and may 
even be used p.r.n. if symptoms are mild (Connolly, 2000). Although diuretics are successful in 
controlling acute symptoms and fluid retention, diuretics alone are unable to maintain the clinical 
stability of patients with HF for long periods of time (Richardson, Bayliss, Scriven, et al., 1987). 
Therefore, diuretics should not be used as monotherapy in the treatment of HF. The risk of 
clinical decompensation can be reduced, however, when diuretics are combined with an ACE 
inhibitor, a beta-blocker, and digoxin (Captopril-Digoxin Multicenter Research Group, 1988; 
Hunt, Baker, Chin, et al., 2001). 
Appropriate use of diuretics is a key element in the success of other drugs used for the 
treatment of HF. The use of inappropriately low doses of diuretics will cause fluid retention, 
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which can diminish the response to ACE inhibitors and increase the risk of treatment with beta-
blockers (Cody, Franklin, Laragh, 1982). Conversely, the use of inappropriately high doses of 
diuretics will lead to volume contraction, which can increase the risk of hypotension with ACE 
inbihitors and vasodilators (Cody, Franklin, Laragh, 1982;Massie, Kramer, Haughom, 1981) and 
increase the risk of renal insufficiency with ACE inhibitors and angiotensin II receptor 
antagonists (Packer, Lee, Medina, 1987).   
The effectiveness of diuretic therapy is enhanced when the patient follows a reduced-
sodium diet. Sodium intake is strictly correlated with the administration of diuretics. If the 
diuretic dose is increased to compensate for a more liberal sodium intake, the renin-angiotensin 
system will be strongly activated and will promote thirst, as well as deplete potassium and 
magnesium (Haller C, Salbach P, et al., 1995). Moreover, in the absence of sodium restriction, 
diuretics become less effective (Cody RJ, Kubo SH, et al., 1994). Furthermore, patients may 
become unresponsive to high doses of diuretic drugs if they consume large amounts of dietary 
sodium, are taking agents that can block the effects of diuretics (e.g., nonsteroidal anti-
inflammatory drugs (Herchuelz, Derenne, Deger, et al., 1989; Gottlieb, Robinson, Krichten, et 
al., 1992; Brater, Harris, Redfern, et al., 2001), or have a significant impairment of renal function 
or perfusion (Risler, Schwab, Kramer, et al., 1994).  
 The principal adverse effects of diuretics include electrolyte depletion as well as 
hypotension and azotemia.  Diuretics can cause the depletion of important cations (i.e., 
potassium and magnesium), which can predispose patients to cardiac arrhythmias, particularly in 
combination with digitalis therapy (Steiness & Olesen, 1976). The loss of electrolytes is related 
to enhanced delivery of sodium to distal sites in the renal tubules and the exchange of sodium for 
other cations, a process that is potentiated by activation of the renin-angiotensin-aldosterone 
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system (Cody, Kubo, Pickworth, 1994).  Potassium deficits can be corrected by the short-term 
use of potassium supplements, or if severe, by the addition of magnesium supplements 
(Solomon, 1987). Concomitant administration of ACE inhibitors alone or in combination with 
potassium-retaining agents (such as spironolactone) can prevent electrolyte depletion in most 
patients with HF who are taking a loop diuretic. Therefore, when these drugs are prescribed, 
long-term oral potassium supplementation is frequently not needed and may be deleterious 
(Hunt, Baker, Chin, et al., 2001). 
Patients should be educated about the intended benefit of the medication, dosage, and 
optimal time of day for ingestion (i.e., in the morning) (Baker, Dracup, Dunbar, 1994; Godden, 
1994). Patients should also be informed about the rapidity of the diuretic effect and the need to 
have access to a bathroom (Godden, 1994). Possible adverse effects should be mentioned in 
advance, particularly those such as postural hypotension, which might precipitate falls in the 
elderly (Dracup, 1996). The patient should be monitored for signs of overdiuresis or 
hypokalemia, especially because symptoms such as lethargy and drowsiness are often 
overlooked (Dracup, 1996). 
 Overdiuresis should be particularly avoided in patients who are beginning therapy with 
ACE inhibitors because of the potential for hypotension or renal insufficiency. Once ACE-
inhibitor treatment has been established, the diuretic dose may be increased as needed to control 
any persisting symptoms of volume overload (Konstam, Dracup, Baker, et al., 1994; Baker, 
Konstam, Bottorff, 1994). 
In summary, the efficacy of diuretics is well established, especially in combination with 
other heart failure drugs. Diuretics are particularly useful in the day-to-day management of the 
heart failure patient. As patients exhibit a sudden increase in bodyweight (e.g. secondary to 
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dietary intake of foods high in sodium) and concomitant exacerbation of heart failure symptoms, 
an increase in the dose of diuretic will often result in rapid relief. As the symptoms subside the 
dosage may once again be decreased.  
Management of the heart failure patients with ACE-inhibitors 
The use of angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart 
failure is now considered a gold standard of care (Packer, Cohn, et al., 1999; Hunt, Baker, et al., 
2001). Published guidelines from the Agency for Healthcare Policy and Research (Konstam, 
Dracup, Baker, et al., 1994), the American College of Cardiology and the American Heart 
Association Task Force (Hunt, Baker, Chin, et al., 2001), and the European Society of 
Cardiology Task Force (1997) all recommend ACE inhibitors for first-line therapy for patients 
with heart failure. ACE-inhibitors decrease systemic vascular resistance and have been shown to 
improve survival, reduce hospitalizations, and enhance quality of life in a wide range of patients 
with left ventricular systolic dysfunction (Pfeiffer, Braunwald, Moye, et al., 1992; AIRE Study 
investigators, 1993; SOLVD Investigators, 1992; SOLVD Investigators, 1991). As established 
by the Studies of Left Ventricular Dysfunction (SOLVD) Prevention Trial, ACE-inhibitor 
therapy is indicated in all patients with asymptomatic left ventricular dysfunction (SOLVD 
Investigators, 1992). Additionally, controlled trials suggest that patients with advanced heart 
failure respond favorably to treatment with both ACE-inhibitors and beta blockers in a manner 
similar to those with mild to moderate disease (The CONSENSUS Trial study group, 1987; 
Packer, Coats, Fowler, et al., 2001).  
 ACE-inhibitors act by inhibiting the enzymatic conversion of angiotensin I to angiotensin 
II, a potent vasoconstrictor. Angiotensin II is elevated in patients with heart failure secondary to 
poor left ventricular performance and hypoperfusion of the kidneys. The response to this 
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situation is activation of the renin-angiotensin-aldosterone system in an effort to maintain 
adequate perfusion of the organs. Unfortunately, in chronic heart failure the renin-angiotensin-
aldosterone system contributes to significant cardiovascular mal-adaptations that contribute to 
the heart failure syndrome. The result of the inhibition of the converting enzyme is a decrease in 
afterload . Moreover, ACE-inhibitors also inhibit the stimulation of the adrenal cortex to release 
aldosterone. Consequently, sodium excretion is promoted and fluid retention controlled. 
Additionally, ACE inhibitors also inhibit the breakdown of bradykinin, a potent vasoactive 
peptide that stimulates the endothelium to produce nitric oxide, another potent vasodilator. The 
combined effects of ACE-inhibitors, therefore, is a significant increase in cardiac index and 
decrease in left ventricular filling pressures and systemic vascular resistance (Jessup, 1988). The 
beneficial effects of ACE inhibitors in heart failure and after a myocardial infarction include a 
marked improvement in survival and heart failure symptoms, and a reduction in the rate of 
hospitalization. In addition, ACE-inhibitors are also cardioprotective and limit the negative 
effects of  ventricular remodeling (Greisinger, Espadas, & Ashton, 1998; Pinkowish, 1997). The 
peak effect of the drug occurs somewhere between 1 hour and 90 minutes after oral 
administration (Jessup, 1988). The benefits of ACE inhibition are usually seen during the first 90 
days of therapy and extend to all patients, regardless of age, sex, etiology of CHF or NYHA class 
(Pinkowish, 1997). Therefore, recent consensus guidelines recommend ACE-inhibitor therapy 
for many patients with stage A heart failure and all patients with stage B, C, or D heart failure 
(Hunt, Baker, et al., 2001). 
Despite overwhelming evidence of the proven benefits of ACE-inhibitors, the unfortunate 
reality is that only 30-40% of patients with CHF are receiving treatment with ACE inhibitors 
(Fletcher & Thomas, 2001). Moreover, up to 50% of patients admitted to the hospital with 
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chronic heart failure are discharged without prescriptions for ACE-inhibitors (Philbin, Rocco, 
Lindenmuth, et al., 1999). These statistics highlight the need for motivating physicians to learn 
more about current developments and guidelines in heart failure management. 
It is not entirely clear what barriers underlie the underutilization of these drugs. However, 
1) the physician’s uncertainty of the optimal dosage and 2) fear of potential side effects (i.e., 
nonproductive cough and hypotension), have been suggested. Yet side effects are fairly 
predictable and reversible and can usually be successfully managed (Jessup, 2003).   
Consequently, physicians should be familiar with current guidelines and inform the patients of 
what to expect, such as providing information regarding the function, therapeutic dosing of 
ACE-inhibitors, and side effects may improve the rate of utilization and treatment with this class 
of drug. 
Furthermore, patients should be informed about the purpose and importance of ACE-
inhibitors to survival, quality of life, and long-term prognosis (Dracup, 1996). Patients should be 
monitored for adverse effects such as hypotension and renal insufficiency, which may be related 
to volume depletion, and hyperkalemia (serum potassium > 5.5 mmol/liter) (Heart Failure 
Guideline Panel, 1994; Dracup, Baker, Dunbar, et al., 1994). To avoid induction of 
hyperkalemia, patients should be warned not to use potassium-containing salt substitutes without 
first obtaining medical advice (Konstam, Dracup, Baker, et al., 1994). Patients should be 
informed of possible side effects and understand that dehydration, excessive perspiration, 
vomiting, or diarrhea may lead to volume depletion and a fall in blood pressure (Dracup, 1996).  
In summary, the evidence for the use of ACE-inhibitors is overwhelming and should 
represent one of the cornerstones in the management of the heart failure patient. Barriers against 
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the use of ACE-inhibitors should be aggressively dealt with through education and continued 
emphasis on available literature.  
Management of the heart failure patient with Beta-blockers  
The use of Beta-blockers in the management of patients with heart failure has remained 
controversial for many years. However, recent large-scale clinical trials (Abraham, 2000) have 
clearly shown their efficacy, especially in the long-term management of patients with HF. Recent 
consensus guidelines recommend the addition of beta-adrenergic blockade to therapy with 
diuretics and ACE-inhibitors for most patients with mild to moderate heart failure and left 
ventricular systolic dysfunction (1999). Furthermore, although controlled clinical trials are 
lacking, the use of beta-blockers in addition to ACE-inhibitor therapy for asymptomatic left 
ventricular dysfunction (Stage B heart failure) may provide further protection from progression 
to more severe HF. Consequently the use of these agents has recently been promoted (Hunt, 
Baker, Chin, et al., 2001; Adams, Baughman, et al., 1999; Vantrimpont, Rouleau, Wun, et al., 
1997). 
In the most recent Consensus Guidelines it is even suggested that in patients who respond 
favorably to diuretic therapy, additional treatment with an ACE inhibitor and a beta-blocker is 
warranted and should be maintained in patients who can tolerate them, because they have been 
shown to favorably influence the long-term prognosis of HF (Hunt, Baker, Chin, et al., 2001). 
Additionally, several studies have shown that beta-blockers may reduce hospitalizations and 
mortality and improve quality of life in patients with systolic heart failure (Doughty, Rodgers, 
Sharpe, et al., 1997; Packer, Bristow, Cohn, et al., 1996). Furthermore, beta-adrenergic blockade 
has been shown to improve left ventricular ejection fraction to an extent greater than any other 
form of pharmacological therapy for systolic heart failure (Abraham & Scarpinato, 2002). Recent 
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data show that when a beta-blocker is added to an ACE inhibitor and diuretic, disease 
progression is slowed and morbidity and mortality are significantly reduced (Packer, Bristow, et 
al., 1996; Cardiac Insufficiency Bisoprolol Study II, 1999; MERIT-HF, 1999). 
The evidence of improved ejection fraction with regression of left ventricular 
hypertrophy is substantial, making an important addition to the standard treatment of ACE 
inhibitors, diuretics, and digoxin (Connolly, 2000).  A comprehensive analysis of 18 double-
blind, placebo-controlled trials of beta-blocker use in patients with chronic heart failure revealed 
an improved overall ejection fraction of 29%, and reduced risk of mortality by 32%. These 
findings are attributed to the antagonizing effects of these drugs on sympathetic nervous system 
activity. Again in an effort to maintain adequate pressure in the face of poor left ventricular 
performance, HF patients have elevated catecholamine levels. Sympathetic activation can 
increase ventricular volumes and pressure by causing peripheral vasoconstriction (Smith, 
Macmillan, & McGrath, 1997) and by impairing sodium excretion by the kidneys (Elhawary & 
Pang, 1994). Norepinephrine can also stimulate cardiac hypertrophy needed to provide a greater 
contractile force to eject the volume of blood. Moreover, catecholamines can also increase heart 
rate and potentiate the activity and actions of other neurohormonal systems needed to help the 
failing heart. 
Unfortunately, the chronic elevation of these hormones and the hyperactivity of the 
autonomic nervous system ultimately contribute to the worsening heart failure syndrome. For 
example, ventricular hypertrophy necessitates a greater coronary blood supply. Thus, patients 
with advancing coronary artery disease may consequently have greater myocardial oxygen 
demands and increased myocardial ischemic episodes (Knowlton, Michel, Itani, et al., 1993). 
Activation of the sympathetic nervous system can also promote arrhythmias by increasing the 
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automaticity of cardiac cells, and due to the development of hypokalemia (Reid, Whyte, & 
Struthers, 1986; Billman, Castillo, Hensley, et al., 1997). Finally, by stimulating growth and 
oxidative stress in terminally differentiated cells, norepinephrine can trigger programmed cell 
death or apoptosis (Communal, Singh, Pimentel, et al., 1998). These deleterious effects are 
mediated through actions on alpha-1, beta-1, and beta-2 adrenergic receptors (Reid, Whyte, & 
Struthers, 1986; Smith, Macmillan, & McGrath, 1997; Elhawary & Pang, 1994; Knowlton, 
Michel, Itani, et al., 1993; Billman, Castillo, Hensley, et al., 1997; Communal, Singh, Pimentel, 
et al., 1998). 
The effects of Beta-blockers are to occupy beta-adrenergic receptor sites and to prevent 
norepinephrine and epinephrine from binding to these receptors and producing their stimulating 
effects. In addition, Beta blockers also slow the conduction time through the atrioventricular 
node, decreasing the chance of tachyarrhythmias, and they also help prevent the complications 
associated with acute ischemia (Fletcher & Thomas, 2001). Most all types of Beta-blockers that 
have been shown to be effective in the treatment of HF including those that selectively block 
beta-1 receptors (e.g., bisoprolol and metoprolol) and those that block alpha-1, beta-1, and beta-2 
adrenergic receptors (e.g., carvedilol) (Hunt, Baker, Chin, et al., 2001). 
In a recent sub-analysis of the SOLVD data, HF hospitalizations and mortality were 
found to be decreased in patients receiving a combination of ACE inhibitor and β-blocker, 
independent of etiology of left ventricular dysfunction (Exner, Dries, Waclawiw, et al., 1999). 
Analysis of the Survival and Ventricular Enlargement (SAVE) study demonstrated similar 
cardioprotective effects of β-blockers in a cohort of post MI patients with decreased ejection 
fraction. The use of β-blockers was associated with a decreased incidence of symptomatic HF as 
well as decreased cardiovascular mortality (Vantimpont P, Rouleau JL, Wun C, et al., 1997). 
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More recent trials further confirm the beneficial effects of beta-blockers involving patients with 
heart failure from various etiologies and stages of severity (Jessup, 2003; Hunt, Baker, Chin, et 
al., 2001). These effects include a reduction in mortality and morbidity, a decrease in rate of 
hospitalizations and the incidence of sudden death, improvements in ejection fraction and 
measures of quality of life, and favorable control of cardiac remodeling, (Foody, Farrell, 
Krumholz, 2002; Farrell, Foody, Krumholz, 2002). 
Interestingly, the short-term effects of beta-blockers may result in a temporary 
exacerbation of symptoms (Packer, 1998). The precise mechanism for this is not understood but 
may in part be secondary to the slight vasoconstricting effects of many of these agents. More 
recent studies, which have used both alpha and beta blocking agents, such as carvedilol, appear 
to be even more effective in the management of the patient, and do not seem to have the initial 
negative effects of the traditional beta-adrenergic blockers (Bristow, Gilbert, Abraham, et al., 
1996). Regardless, the long-term effects of beta-blocking agents are uniformly beneficial and 
improve the clinical status of patients (Packer, 1998). Placebo-controlled trials involving long-
term treatment have shown improved systolic function after three months of treatment and 
reverse remodeling after four months of treatment (Saxon, De Marco, Schafer, et al., 2002; 
Bristow, 2000; Groenning, Nilsson, Sondergaard, et al., 2000). An important consideration is 
that the beneficial effects of beta-blockers were also seen in patients already taking ACE-
inhibitors (Abraham & Scarpinato, 2002). This suggests that combined blockade of these two 
neurohormonal systems can produce additive effects.  
Given the potential complications associated with the initiation of beta-blocker therapy 
close monitoring of the patient is warranted. Patients may have increased dyspnea and edema, 
and may also experience symptomatic bradycardia with or without associated hypotension. It 
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must also be recognized that these symptoms may return during titration phases. However, the 
long-term benefits of using beta-blockers in the treatment of HF are far greater than the potential 
period of increased symptomatology during intitiation of therapy; therefore, clinicians are urged 
to add beta-blockers to treatment regimens without delay.  
Beta-blockers should be used in all patients with stable heart failure without substantial 
fluid retention and without recent exacerbations of heart failure requiring ionotropic therapy 
(Hunt, Baker, Chin, et al., 2001). Beta-blockers should not be used, or should be used with 
caution, in patients with reactive airway disease, patients with diabetes associated with frequent 
episodes of hypoglycemia, and those patients with bradyarrhythmias or heart block who do not 
have a pacemaker (Jessup, 2003). 
Once the target dose has been achieved, patients can generally be maintained on long-
term therapy with a beta-blocker with little difficulty. Patients should be advised that clinical 
responses to the drug are generally delayed and may require 2 to 3 months to become apparent 
(Massie, Kramer, & Haughom, 1981).  Even if symptoms do not improve, long-term treatment 
should be maintained to reduce the risk of major clinical events. Abrupt withdrawal of treatment 
with a beta-blocker can lead to clinical deterioration and should be avoided (Waagstein, Caidahl , 
Wallentin, et al, 1989).  
In summary, the long-term effects of beta-blockers are of significant benefit to the patient 
with chronic heart failure. Consequently, the use of these agents should be a part of the 
management of the patients. Particular care and monitoring should be provided during the initial 
period following drug administration and during periods when the dose of the drug is increased. 
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Management of the heart failure patient with Digitalis Glycosides 
Digitalis glycosides are of particular importance in providing symptomatic relief in 
patients with systolic dysfunction and in those with rapid atrial arrhythmias (Fletcher & Thomas, 
2001). Digoxin is the only digitalis glycoside evaluated in clinical trials by the USFDA for use in 
patients with HF (Gheorghiade et al., 1998). Digoxin is a positive ionotrope that acts directly on 
the myocardium by inhibiting sarcolemmal sodium-potassium adenosine triphosphatase (ATP-
ase) activity (Fletcher & Thomas, 2001; Akera, Baskin, Tobin, et al., 1973). Inhibition of this 
enzyme in cardiac cells results in an increase in the contractile state of the heart. Inhibition of 
ATP-ase within the kidney decreases renal tubular reabsorption of sodium and suppresses the 
renin-angiotensin-aldosterone system (Torretti, Hendler, Weinstein, et al., 1972; Fletcher & 
Thomas, 2001). Digitalis reduces the renal tubular reabsorption of sodium (Torretti, Hendler, 
Weinstein, et al., 1972); the resulting increase in the delivery of sodium to the distal tubules 
leads to the suppression of renin secretion from the kidneys (Covit, Schaer, Sealey, et al., 1983). 
These observations have led to the hypothesis that digitalis acts in HF primarily by attenuating 
the activation of neurohormonal systems and not as a positive inotropic drug (Gheorghiade & 
Ferguson, 1991). The inhibitory effects on the sympathetic nervous system in combination with 
reduced neurohormonal activity make digoxin an important pharmacologic weapon for 
controlling HF (Fletcher & Thomas, 2001). 
 The clinical benefits have traditionally been attributed primarily to its inotropic action 
(i.e., the ability to increase myocardial contractility). In view of current thinking that the 
progression of HF and the risk of mortality may be related to the extent of sympathetic activity, 
however, investigation has focused on the neurohormonal properties of digoxin. In a clinical 
study of 26 patients with HF, Krum et al., (1995) found that digoxin inhibits sympathetic activity 
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while increasing parasympathetic activity and that these effects persist over 4 to 8 weeks of 
therapy (Krum, Bigger, Goldsmith, et al., 1995). 
 Several placebo-controlled trials have shown that treatment with digoxin for 1 to 3 
months can improve symptoms, quality of life, and exercise tolerance in patients with mild to 
moderate HF (Captopril-Digoxin Research Group, 1988; Dobbs, Kenyon, Dobbs, 1977; Lee, 
Johnson, Bingham, et al., 1982; Guyatt, Sullivan, Fallen, et al., 1988; DiBianco, Shabetai, 
Kostuk, et al., 1989; Uretsky, Young, Shahidi, et al., 1993; Packer, Gheorghiade, Young, et al., 
1993). These benefits have been observed regardless of the underlying rhythm (normal sinus 
rhythm or atrial fibrillation), cause of HF (ischemic or nonischemic cardiomyopathy), or 
concomitant therapy (with or without ACE-inhibitors). In a long-term trial that enrolled patients 
who primarily had class II or III symptoms, treatment with digoxin for 2 to 5 years had little 
effect on mortality but modestly reduced the combined risk of death and hopitalization (DIG 
Investigators, 1997). In the recently completed DIG study (Digitalis Investigation Group), 6800 
patients with heart failure and an ejection fraction of less than 45% were randomized to digoxin 
or placebo and followed for an average of 37 months (DIG Investigators, 1997). Although 
digoxin had no effect on overall mortality, heart failure deaths and hospitalizations were 
significantly reduced (DIG Investigators, 1997). The effects of digoxin were similar across age 
groups. Consequently, digoxin remains an important agent for heart failure management because 
of its beneficial effects on hospitalizations and quality of life. 
 Physicians should consider using digoxin to improve the symptoms and clinical status of 
patients with HF, in conjunction with diuretics, and ACE-inhibitor, and a beta-blocker (Hunt, 
Baker, Chin, et al., 2001). If a patient is taking digoxin but not an ACE-inhibitor or a beta-
blocker, treatment with digoxin should not be withdrawn, but appropriate therapy with the 
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neurohormonal antagonists should be instituted (Hunt, Baker, Chin, et al., 2001). Digoxin is 
prescribed routinely in patients with HF who have chronic atrial fibrillation, but beta-blockers 
may be more effective in controlling the ventricular response, especially during exercise 
(Matsuda, Matsuda, Yamagushi, et al., 1991; David, Segni, Klein, et al., 1979; Farshi, Kistner, 
Sarma, et al., 1999). Digoxin is not recommended for use in patients with pure diastolic 
dysfunction unless it is used as adjunct therapy in the modulation of the neurohormonal system 
or for control of atrial arrhythmias Hunt, Baker, Chin, et. al., 2001). 
Dosing of digoxin is affected by the patient’s age, weight, and renal function. Low doses 
(0.125 mg daily or every other day) should be used if the patient is over 70 years old, has 
impaired renal function, or has a low lean body mass (Jelliffe & Brooker, 1974). Although 
physicians have been taught that digitalis produces frequent side effects, the drug is well 
tolerated by most patients with HF (Steiner, Robbins, Hammermeister, et al., 1994). The 
principle adverse reactions occur primarily when digoxin is administered in large doses, but large 
doses are rarely needed to produce clinical benefits Arnold, Byrd, Meister, et al., 1980; 
Gheorghiade, Hall, Jacobsen, et al., 1995, Slatton, Irani, Hall, et al., 1997). The major side 
effects include cardiac arrhythmias (e.g., ectopic and re-entrant cardiac rhythms and heart block), 
gastrointestinal symptoms (e.g., anorexia, nausea, and vomiting), and neurological complaints 
(e.g., visual disturbances, disorientation, and confusion). Digitalis toxicity is commonly 
associated with serum digoxin levels more than 2 ng per mL but may occur with lower digoxin 
levels, especially if hypokalemia, hypomagnesemia, or hypothyroidism co-exist (Ingelfinger & 
Goldman, 1976). Digoxin toxicity is potentiated by hypoxemia, electrolyte imbalances 
(hypokalemia and hypomagnesemia), renal insufficiency, dehydration, and hypothyroidism. The 
side effects associated with digoxin toxicity include cardiac block, gastrointestinal disturbances 
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(anorexia, nausea, and vomiting) and visual disturbances (Fletcher & Thomas, 2001). The 
possibility of drug interactions is a concern, as the concomitant use of quinidine, verapamil, 
spironolactone, flecainide, propafenone, or amiodarone can increase serum digoxin levels and 
may increase the likelihood of digitalis toxicity (Dracup, 1996). The dose of digoxin should be 
reduced if treatment with these drugs is initiated. In addition, a low lean body mass and impaired 
renal function can also elevate serum digoxin levels, which may explain the increase risk of 
digitalis toxicity in elderly patients (Hunt, Baker, Chin, et al., 2001).  
 Patient education should include information about dosage, particularly if drug amounts 
are changed, and counseling regarding possible signs and adverse effects of digitalis toxicity. 
Additionally, the patient should inform the prescribing health care provider of any other 
medications prescribed by other health care providers or taken over the counter (Dracup, 1996). 
In summary, the use of digitalis glycosides in the management of chronic left ventricular 
heart failure appears to be warranted despite the lack of understanding as to the mechanisms 
behind the agents. Digitalis glycosides do not appear to be effective for all heart failure patients. 
The narrow therapeutic window of these drugs warrants careful control and frequent monitoring. 
Patients should be educated about these drugs and in regards to their potential side effects.  
Management of the heart failure patient with combination drugs 
Recent consensus guidelines recommend that patients classified as Stage C Heart 
Failure: Symptomatic Left Ventricular Dysfunction should be routinely managed with a 
combination of the 4 types of drugs discussed above (a diuretic, an ACE inhibitor, a beta-
adrenergic blocker, and (usually) digitalis) (Packer, Cohn, et al., 1999; Hunt, Baker, Chin, et al., 
2001). The value of these drugs has been established in numerous large-scale clinical trials, and 
has been discussed in each section. The evidence supporting a central role for their use is 
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compelling and persuasive. Patients with evidence of fluid retention should be given a diuretic to 
reduce blood volume and edema, and diuretic therapy should be continued to prevent the 
recurrence of fluid retention. Even if the patient has responded favorably to the diuretic, 
treatment with an ACE inhibitor and a beta-blocker should be initiated and maintained in patients 
who can tolerate them, because they have been shown to favorably influence the long-term 
prognosis of HF (Hunt, Baker, et al., 2001). Recent data show that when a beta-blocker is added 
to an ACE inhibitor and diuretic, disease progression is slowed and morbidity and mortality are 
significantly reduced (Packer, Bristow, et al., 1996; Cardiac Insufficiency Bisoprolol Study II, 
1999; MERIT-HF, 1999). ACE inhibitors decrease systemic vascular resistance and have been 
shown to improve survival, reduce hospitalizations, and enhance quality of life in patients with 
left ventricular systolic dysfunction (Pfeiffer, Braunwald, Moye, et al, 1992; AIRE Study 
Investigators, 1993; SOLVD Investigators, 1992; SOLVD Investigators, 1991). Beta-blockers 
interrupt the “toxic effects” of the over-active sympathetic nervous system. Additionally, several 
studies have shown that beta-blockers may reduce hospitalizations and mortality and improve 
quality of life in patients with systolic heart failure (Doughty, Rodgers, Sharpe, et al., 1997; 
Packer, Bristow, Cohn, et al., 1996). Therapy with digoxin may be initiated at any time to 
increase the force of left ventricular contraction, reduce symptoms, and enhance exercise 
tolerance (Ware, Snow, Luchi, et al., 1984; Packer, Cohn, et al., 1999, Hunt, Baker, et al., 2001).  
Management of the heart failure patient with other drugs 
 The pharmacological management of the patient with chronic heart failure is constantly 
changing due to the advancing research and available data concerning new agents. The decision 
to add or replace conventional therapies with such agents rests with the physician in charge of 
the patient and should be based on the strength of evidence. 
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 Currently there are several agents under investigation, which may ultimately add to or 
change the current recommendations. Examples of some of these new investigational drugs 
include: vasopeptidase inhibitors, cytokine antagonists, angiotensin II antagonists, and 
endothelin antagonists. In some trials there appears to be some evidence for the use of these new 
agents, however, the strength of evidence is still limited in terms of long-term outcomes.  
 Finally, there is a distinct trend toward self-management by patients with heart failure. 
Many patients are looking toward supplements and hormonal therapies to improve their heart 
failure condition. The value of the majority of such agents remains unproven, and the long-term 
safety has not been established. Examples of such supplements include: coenzyme Q10, 
carnitine, taurine, and antioxidants. Growth hormone and thyroid hormone are also therapies 
under consideration. Again, the decision to implement these unconventional practices must be 
considered on an individual basis with careful attention to the strength of evidence provided for 
the type of patient under care.      
Pharmacological agents heart failure patient must avoid 
Three classes of drugs should be avoided in most patients with Stage C heart failure 
because they can exacerbate the HF syndrome. These drugs include: 1) antiarrhythmic agents, 2) 
Calcium channel blockers, and 3) Nonsteroidal anti-inflammatory drugs (Hunt, Baker, Chin, et 
al., 2001). Antiarrhythmic agents can exert important cardiodepressant and proarrhythmic effects 
(Packer, 1991). Of available agents, only amiodarone has been shown not to adversely affect 
survival (Hunt, Baker, Chin, et al., 2001). Calcium channel blockers can lead to worsening heart 
failure and have been associated with an increased risk of cardiovascular events (Packer, Kessler, 
Lee, 1987). Of available agents, only amlodipine has been shown not to adversely affect survival 
(Hunt, Baker, Chin, et al., 2001). Nonsteroidal anti-inflammatory drugs can cause sodium 
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retention and peripheral vasoconstriction and can attenuate the efficacy, and enhance the toxicity, 
of diuretics and ACE inhibitors (Heerdink, Leufkens, Herings, et al., 1998; Herchuelz, Derenne, 
Deger, et al., 1989; Gottlieb, Robinson, Krichten, et al., 1992; Bank, Kubo, Rector, Heifetz, et 
al., 1991). 
Problems with implementation of optimal pharmacological care 
Importantly, despite the clear efficacy of the above-described pharmacological 
approaches for treatment of heart failure, there is consistent evidence that many physicians fail to 
properly treat their patients. In the latest study concerning this issue, Dr. Gregg Fonarow of the 
University of California, Los Angeles, looked at how often patients hospitalized with heart 
failure were discharged with four standard kinds of care. He found they are often missing, 
although stated this varied widely from hospital to hospital. "There are certain hospitals in the 
United States where 100 percent of the patients get this," he said. "There are others where 
patients had a better chance of winning the lottery than getting the indicated care." Clearly these 
discrepancies point at significant barriers that exist on the providers’ side in the proper delivery 
of care. 
Non-Pharmacological Management 
It is interesting to consider that despite the available pharmacological strategies, the 
prevalence of heart failure continues to rise, as is the number of deaths from the disease. 
Furthermore, it is important to recognize that in spite of the overwhelming evidence that the 
aforementioned drugs are effective in the management of chronic heart failure the reduction in 
mortality and improvements in clinical manifestations of the disease are relatively modest. 
Finally, it must be recognized that heart failure patients in the general population, who are 
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receiving appropriate drug therapy, do not appear to fare as well as those patients participating in 
clinical trials.  
These factors clearly point at the complexity of the heart failure syndrome and the need 
for constant vigilance on part of the physician and patient. The purpose of the following section 
is to describe some available non-pharmacological strategies that with optimal pharmacotherapy 
appear to be of extreme importance in managing the heart failure syndrome. The fact, that many 
of these factors appear to have a large behavioral component, one must clearly recognize that the 
management of this disease has become quite multidisciplinary. 
A major goal in the non-pharmacologic management of the heart failure syndrome is 
aimed principally at modifying lifestyle and obtaining better compliance with the therapeutic 
regimen (Colonna, Sorino, D’Agostino, et al., 2003). Modifications of lifestyle can be helpful in 
controlling the symptoms of heart failure and maintaining clinical stability. For example, it has 
been suggested that basic habits of moderate sodium restriction, weight monitoring, exercise, and 
adherence to medication schedules may aid in avoiding fluid retention or alerting the patient to 
its presence (Jessup, 2003 NEJM).   In a review of the literature from 1966 to 1993 (Dracup, 
Baker, Dunbar, et al., 1994), counseling and health education increased life expectancy and 
quality of life, and reduced hospitalization of patients with heart disease. In 1994, the Agency for 
Healthcare Policy and Research (AHCPR) published guidelines for the management of patients 
with HF. Suggested topics for education and counseling of patients with heart failure are listed in 
Table II (AHCPR, 1994).  
Sodium Restriction 
Sodium retention is in part a consequence of neurohumoral activation, which is a 
fundamental hallmark of CHF. The value of this compensatory strategy is to retain fluid 
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necessary to raise blood volume in the face of a reduction of contractile function. The downside 
of this strategy is that patients are at significant risk for exacerbations of their condition when 
sodium intake is increased. Thus careful day-to-day management of sodium intake is a crucial 
component of heart failure care.  
 Excess dietary intake of sodium can induce sodium and water retention, especially in 
persons who are more sensitive to sodium intake, such as obese patients (Hall, 1997; Luft & 
Weinberger, 1997). Sodium and water retention plays an important role in the pathogenesis of 
hypertension and congestive heart failure (CHF) (Reisin, 1990; Andreoli, 1999). Chronically 
high dietary intake of sodium may contribute to the development of CHF by increasing blood 
pressure (pressure overload) or extracellular fluid (volume overload). 
Several cross-sectional epidemiologic studies (Liebson, Grandits, Prineas, et al., 1993; 
Messerli FH, Schmieder, Weir, 1997; Schmieder, Messerli, Garavaglia, et al., 1988; Kupari, 
Koskinen, Virolainen, 1994) have suggested a significant and independent association between 
dietary sodium intake and left ventricular hypertrophy. In the Treatment of Mild Hypertension 
Study (Liebson, Grandits, Prineas, et al., 1993), dietary sodium intake was estimated from 2 
consecutive overnight urine collections and left ventricular structure was assessed by M-mode 
echocardiography in 511 men and 33 women with mild hypertension. After adjusting for age, 
sex, race, body mass index (BMI), previous medication, alcohol consumption, cigarette smoking, 
physical activity, and systolic blood pressure, a difference of 25 mmol per 8 hours in urinary 
sodium excretion was associated with a 41% (95% confidence interval, 22%-63%) increase in 
the odds of left ventricular hypertrophy. Messerli and colleagues (Messerli FH, Schmieder, Weir, 
1997) revealed 9 cross-sectional studies in which the association between dietary sodium intake 
and left ventricular mass was assessed. The correlation coefficients for the relationship varied 
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from 0.22 to 0.61, with p<.05 in each of the studies. Animal studies (Frohlich, Chien, Sesoko, et 
al., 1993; Sugimoto, Fujimura, Takasaki, et al., 1998) also indicate that high sodium intake is an 
independent risk factor for the development of cardiac hypertrophy. However, there are sparse 
data on the relationship between dietary sodium intake and the risk of HF from prospective 
cohort studies. 
A recent study by Jiang, et al. (2002) took advantage of the large sample size and 
prolonged follow-up experience of participants in the first National Health and Nutrition 
Examination Survey (NHANES I) Epidemiologic Follow-up Study  (NHEFS) to examine the 
relationship between dietary sodium intake and incidence of CHF in a nationally representative 
sample of the US general population. Study participants consisted of 5233 nonoverweight and 
5129 overweight men and women without a history of CHF at their baseline examination. 
Overweight was defined as a body mass index (calculated as weight in kg divided by the square 
of height in meters) of 25.0 or greater for men and women. Dietary sodium and other nutrient 
intake estimates were obtained by a 24-hour dietary recall method at the baseline examination, 
conducted from 1971 to 1975. The incidence of CHF was assessed using medical records and 
death certificates obtained in 1982 to 1984, 1986, 1987, and 1992. During an average of 19 years 
of follow-up, 413 cases of CHF in nonoverweight and 679 cases of CHF in overweight 
participants were documented. The cumulative incidence of CHF was not significantly 
associated with baseline sodium intake in the nonoverweight participants. For example, the 
cumulative incidence of CHF at 90 years, adjusted for total caloric intake, was 35.6%, 42.9%, 
37.4%, and 47.4% among patients within the first, second, third, and fourth quartiles of dietary 
sodium intake, respectively (p=.48 for trend). In contrast, dietary sodium intake was significantly 
associated with risk of CHF among overweight individuals. The cumulative incidence of CHF at 
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age 90 years, adjusted for total caloric intake, was 44.0%, 43.6%, 53.6%, and 63.1% among 
patients within the first, second, third, and fourth quartiles of dietary sodium intake, respectively 
(p=.02 for trend).  Furthermore, after adjustment for known CHF risk factors, the relative risk of 
CHF among overweight participants was 1.43 (95% CI, 1.07-1.91) for those whose sodium 
intake was greater than 113.6 mmol/d compared with those whose intake was less than 50.2 
mmol/d. The relative risk of CHF for a 100 mmol/d higher intake of sodium or per 1743 kcal 
(average energy intake in the study population) were 1.26 (95% CI, 1.03-1.53) and 1.21 (95% 
CI, 1.04-1.40), respectively. Data suggest that a high dietary intake of sodium is an independent 
risk factor for congestive heart failure in overweight persons. Furthermore, the findings suggest 
that sodium reduction may play an important role in the prevention of CHF in the US general 
population.  
A reduction in dietary sodium intake can have substantial hemodynamic and clinical 
benefits in patients with advanced heart failure (Cody, Kubo, and Pickworth, 1994). 
Interestingly, the magnitude of sodium restriction is not clear. In a review article, many 
physicians, primarily cardiologists, showed a wide array of opinions on sodium restriction. Only 
25% suggested a sodium diet of <2g, whereas, 33% of the physicians suggested no added salt in 
cooking for patients with NYHA class II CHF (Hlatky, Fleg, et al., 1986). Although the efficacy 
of restricting sodium to specific levels has not been studied, in general the degree of sodium 
restriction depends on the severity of heart failure. It has been suggested that sodium should be 
limited to a maximum of 2-3 g per day for mild to moderate heart failure, and less than 2 g per 
day for severe heart failure (Weinberger & Kenny, 2000; Konstam, Dracup, Baker, et al., 1994). 
A 2 g sodium diet is frequently recommended (HF Guideline Panel, 1994; Dracup K, Baker DW, 
et al., 1994). However, no studies have been conducted to evaluate specific recommendations 
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related to sodium restriction (Konstam, et al., 1994). In general, a 2 g sodium diet is unpalatable 
for many patients, whereas a 3 g sodium diet may be a more realistic goal for patients with mild 
to moderate heart failure (Grady KL, Dracup K., et al., 2000). It can be achieved by avoiding 
salty foods (e.g, canned or frozen foods) and by not adding salt to foods after cooking.  When 
this goal is met the clinical results indicate improved hemodynamics and decreased CHF 
exacerbations. If sodium restriction strategies remain ineffective, patients may require larger 
doses of diuretic agents for adequate control.  (Tucker, Van Den Berg, & Knox, 1980). More 
importantly, moderate sodium restriction permits the use of lower doses of diuretics (Consensus 
Recommendations, 1999), which is clearly advantageous to the patients considering the 
problems associated with long-term diuretic use (such as electrolyte imbalance and worsening 
lipid profiles). The effectiveness of diuretic therapy is enhanced when the patient follows a 
reduced-sodium diet. Sodium intake is strictly correlated with the administration of diuretics. If 
the diuretic dose is increased to compensate for a more liberal sodium intake, the renin-
angiotensin-aldosterone system will be strongly activated and will promote thirst, as well as 
deplete potassium and magnesium (Haller C, Salbach P, et al., 1995). Moreover, in the absence 
of sodium restriction, diuretics become less effective (Cody RJ, Kubo SH, et al., 1994).  
Dietary sodium indiscretion is a common reason for exacerbations of heart failure, and 
inadequate patient education can contribute to failure to follow the prescribed diet. Both patients 
and their families or caregivers need thorough, constant and specific instructions about how to 
achieve the prescribed sodium restriction. Most people are knowledgeable about obvious sources 
of sodium but are unaware of the sodium content of less obvious sources. Patients should be 
advised not to add salt to food during preparation and to avoid foods containing large amounts of 
sodium, such as highly processed foods, canned foods, luncheon meats, and “fast” foods 
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(AHCPR, 1994). Patients should be taught to look for words other than “salt” on food labels, for 
example sodium or potassium hydrochloride (Fletcher & Thomas, 2001). The use of salt 
substitutes and spices, such as lemon, pepper, and garlic, may be helpful (Haller C, Salbach P, et 
al., 1995). Dietary instruction must take into account ethnic preferences and may require 
individualized counseling by a dietician (Grady, Dracup, et al., 2000). Referral to a dietician or 
advanced practice nurse with expertise in diet counseling may promote better patient and family 
understanding of the diet and of the options for making a sodium-restricted diet palatable 
(Konstam, Dracup, et al., 1994). 
 In summary, it appears that indiscretion of sodium intake contributes to heart failure 
exacerbations. The main problem patients face is that given the heightened neurohumoral milieu 
many patients are on a tightrope in terms of their fluid balance. Any fluctuation in sodium intake 
may therefore contribute to a condition of fluid overload, which causes additional stress on a 
weak cardiovascular system and lead to acute congestive heart failure. Consequently, patients 
must receive thorough, constant and specific instructions about how to control sodium intake. 
The evidence that moderate to aggressive sodium restriction is beneficial to the heart failure 
patient is strong, preventing hospitalization, lowering medical costs and reducing mortality.  
Alcohol 
Alcoholic beverages can be detrimental in patients with HF because alcohol is a 
myocardial depressant and may, even in small doses, further depress myocardial contractility 
(Regan, 1990). However, no studies of the effect of moderate ingestion of alcohol on functional 
status or death have been conducted. In general, alcohol intake should be strongly discouraged 
and patients with HF should limit consumption to one drink per day (HF Guideline panel, 1994; 
Grady, Dracup, Kennedy, et al., 2000). Alcohol avoidance is clearly imperative in patients with 
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alcohol-induced cardiomyopathy and, if necessary, these patients should be encouraged to attend 
Alcoholics Anonymous to maintain long-term sobriety (Soler-Soler & Permanyer-Miralda, 1994; 
Fletcher & Thomas, 2001). 
Daily Weights 
Periodic self-examination of certain parameters can be useful for the management of the 
disease. A daily weight check represents an index to identify any possible problems of water 
retention. In a retrospective review of 585 patients hospitalized for CHF, 59% of the 
exacerbations were traceable to excessive sodium retention, with a subsequent overloading of the 
circulation (Bennett, Huster, and Baker, et al., 1998). 
All patients should be instructed to weigh themselves each morning (after urinating and 
before eating) and record the data in a log, which should be taken to every visit with the clinician 
(Konstam, Baker, Dracup, et al., 1994). An unjustified increase in weight of 3-5 pounds in 1-3 
days should induce the patient to consult his or her physician for any eventual therapeutic 
adjustments that, if carried out in time, may help avoid hospitalization (Konstam, Baker, Dracup, 
1994; Fletcher & Thomas, 2001; Colonna, Sorino, D’Agostino, et al., 2003). It has been 
suggested that highly cooperative patients can be given a diuretic regimen that they can self-
adjust based on daily weights (Dracup, Baker, Dunbar, et al., 1994; Colonna, Sorino, 
D’Agostino, et al., 2003). It is imperative that the patient understands that weight gain may mean 
the body is retaining fluid and a phone call to the doctor or specific center may help prevent an 
exacerbation (Colonna, Sorino, D’Agostino, et al., 2003). 
 
Fluid Restriction 
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Drinking large amounts of fluids should be avoided, although fluid restriction is not 
recommended unless hyponatremia develops (HF Guideline Panel, 1994). Whereas sodium 
restriction has been a standard suggestion, the reduction of water intake in patients with HF has 
not always been recommended. The controversy arises from the suggestion to restrict water 
intake only in hyponatremic patients (Konstam, Dracup, Baker, 1994). No controlled prospective 
trials have examined this issue. However, patients with advanced HF may need to have their 
daily fluid restricted to 2 L per day (Fletcher & Thomas, 2001). This is a clinical judgment based 
on signs of congestion, fluid overload, and weight gain. Limiting fluid intake to 2 L per day 
usually helps to maintain weight and can reduce the use of large doses of diuretics. It is 
important to remind patients that certain foods, such as fruits or soups, contain a large amount of 
water (Colonna, Sorino, D’Agostino, et al., 2003). 
Smoking Cessation 
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Figure 8a -c. Cardiac Responses to Acute Exercise in Heart 
Smoking of tobacco is to be forbidden in patients with HF (Konstam, Dracup, Baker, et 
al., 1994). Besides the well-known coronary risk factors that lead to atherosclerotic disease, 
smoking has certain hemodynamic effects that aggravate the condition of the patient with HF. It 
leads to an increase in heart rate and 
systematic arterial pressure. Additionally, 
there is a slight increase in the pulmonary 
arterial pressure, the filling of the left 
ventricle, and peripheral vascular and 
pulmonary resistance, along with a 
reduction in the cardiac output, especially 
in patients with ischemic cardiomyopathy. 
Smoking may induce a slight reduction in 
the volume of left ventricular ejection. 
This is associated with the increased need 
for oxygen because of the increased 
cardiac workload caused, in turn, by the 
increase in heart rate and peripheral 
resistance, as well as by the reduction in the 
amount of oxygen because of the presence of 
carboxyhemoglobin. In patients with HF, this 
series of cardiocirculatory effects 
associated with bronchopathic breathing 
problems, typical for smokers, does 
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nothing to precipitate or aggravate CHF. 
Physical Activity 
As discussed in the section on pharmacological approaches to the treatment of heart 
failure there is clear evidence that numerous pharmacological agents are available which help 
improve central hemodynamics by reducing cardiac afterload or enhancing myocardial 
contractility.  Additional pharmacological agents are used to reduce excessive fluid retention.  
Following initiation of such therapy mortality is reduced, and many patients experience 
resolution of their symptoms at rest (Hunt, Baker, Chin, et al., 2001). However, most patients 
continue to experience activity-related symptoms, including shortness of breath, muscle fatigue, 
and weakness.  As a result patients with heart failure often complain of chronic fatigue and are 
unable to perform many of their normal activities of daily living.  Thus, despite traditional 
pharmacologic treatment, the clinical phase of heart failure includes a marked decline in 
functional state, as defined by exercise tolerance and capacity with a subsequent decrease in 
quality of life. 
Cardiac Responses to Acute Exercise in Heart Failure 
Previous studies which have examined the cardiac response to an acute bout of exercise 
in patients with heart failure demonstrated characteristic responses to dynamic exercise (see 
Figure 8a-c) (Sullivan, Knight, Higginbotham, et al., 1989). However, as functional class 
declines there is a progressive decrease in the cardiac output, stroke volume, blood pressure and 
heart rate reserve capacity (Hanson, 1994). A reduction in cardiac output during exercise and 
perhaps more importantly a loss in cardiac reserve is an important factor limiting exercise 
tolerance in patients with heart failure.   
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Figure 9. Leg Blood Flow during Acute Exercise in Heart Failure
Figure 10a and b. Lactate Responses to Acute Exercise in Heart 
Circulatory Responses to Acute Exercise in Heart Failure 
Studies which have examined circulatory responses to an acute bout of exercise in 
patients with heart failure generally 
report a reduction in nutritive flow to 
muscle (see Figure 9) (Sullivan, 
Knight, Higginbotham, et al., 1989). 
Consequently, exercise performance 
is markedly reduced in the majority 
of patients. It is, however, important 
to recognize that the reduction in 
blood flow to working muscle is not entirely due to a reduction in cardiac output or local 
vascular impairment. In fact, a major consideration is a change in the distribution of blood flow 
during exercise (Wilson & Ferraro, 1985).  
Whereas the blood flow distribution 
in a healthy individual may lead to as much 
as 75 to 80% of the cardiac output reaching 
the working muscle, this is not the case in 
the heart failure patient. Not only do 
patients with heart failure have difficulties 
opening up tissue beds, but due to the 
overall stiffness of the vasculature these 
patients also have an inability to constrict in 
non-working tissue (Wilson & Ferraro, 
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Figure 11. Oxygen Kinetics to and following Acute Exercise in 
Heart Failure
1985). Consequently, blood flow abnormalities are complex and not solely due to impaired 
vasodilatory function. Moreover, if the vascular problems indeed extend to the venous system, 
the inability to properly remove metabolic end-products from the tissue beds and the inability to 
increase pre-load with exercise may contribute to the reduced blood flow to tissue. Considering 
the cardiovascular system is a closed circuit, we speculate cardiac insufficiency, decreased 
arterial reactivity, reduced muscle blood flow, venous alterations and elevated cardiac pressures 
contribute to a reduction in the driving pressure across metabolic tissue. Consequently, decreased 
driving pressure could affect metabolic waste removal, alter cardiac filling kinetics and decrease 
exercise tolerance (Welsch, Alomari, Parish, et al., 2002).   
Skeletal Muscle Responses to Acute Exercise in Heart Failure 
Skeletal muscle abnormalities contribute to the clinical severity of the heart failure 
syndrome. It is, therefore, no surprise that patients with heart failure have higher lactate levels at 
submaximal workloads compared to controls (see figure 10a and b) (Sullivan, Knight, 
Higginbotham, et al., 1989).   
Recent reports also suggest the rate of change in oxygen kinetics is significantly altered 
in patients with heart failure (see Figure 11) (Cohen-Solal, Laperche, Morvan, et al., 1995). 
Heart failure patients have much 
slower recovery on-kinetics and 
off-kinetics as a result of a bout 
of exercise.  In particular the 
slower recovery from physical 
activity may carry some 
significant prognostic 
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information, and may in part explain why patients with heart failure often complain of symptoms 
of chronic fatigue.   
Finally, skeletal muscle atrophy contributes to a significant reduction in both muscle 
strength and endurance in patients with heart failure. Consequently many daily tasks are indeed 
more than a chore and often result in excessive fatigue and shortness of breath. Unfortunately, 
the chronic fatigue and shortness of breath contributes to the vicious cycle of deconditioning as 
the patient becomes more and more reluctant to engage in these sorts of activities. 
Evidence for the Importance of Exercise Training 
Until the late 1980s physical activity for heart failure patients was discouraged and many 
patients were told to refrain from physical exertion (Smith, Braunwald & Kelly, 1992). This 
conservative approach was due to a concern for a greater risk for cardiovascular complications 
during exercise.  Arguably, this conservative approach has contributed to the considerable 
morbidity in heart failure patients.  Reports since the 1980s clearly indicate that heart failure 
patients can safely participate and benefit from exercise training programs.  As a result exercise 
training has emerged as a beneficial adjunct to the management of patients with heart failure (see 
Table III and IV).  
The first report indicating that heart failure patients could safely participate and benefit 
from a cardiac rehabilitation program dates back to 1979 (Lee, Ice, Blessy, 1979). In this study, 
post myocardial infarction patients, with an average ejection fraction of 18% were trained at 70% 
to 85% of their maximal heart rate for 20 to 45 min, 4 days per week.  The training program 
averaged about 19 months and resulted in a significant increase in exercise tolerance (Lee, Ice, 
Blessy, 1979).  Since that study, a number of studies have been conducted, and despite 
considerable variation in the duration, intensity and length of training, a consistent finding is that 
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heart failure patients can increase exercise capacity and tolerance following a period of exercise 
training without increasing the risk for cardiovascular complications (see Table III) (Jette, Heller, 
Landry, et al., 1991; Belardinelli, Scocco, Mazzanti, et al., 1992; Coats, Adamopoulos, Radaelli, 
et al., 1992; Belardinelli, Georgiou, Cianci, 1995; Hambrecht, Niebauer, Fiehn, et al., 1995; 
Keteyian, Levine, Brawner, et al., 1996; Radaelli, Coats, Leuzzi, et al., 1996; Welsch, 1996; 
Dubach, Myers, Dziekan, et al., 1997; Willenheimer, Erhardt, Cline, et al., 1998; Callaerts-Vegh, 
Wenk, Goebbels, et al., 1998; Reinhart, Dziekan, Goebbels, et al., 1998; Belardinelli, Georgiou, 
Cianci, et al., 1999; Taylor, 1999; Sturm, Quittan, Wiesinger, et al., 1999; Keteyian, Brawner, 
Schairer, et al., 1999; Wielenga, Huisveld, Bol, et al., 1999; Kiilavuori, Naveri, Salmi, et al., 
2000;  McKelvie, Teo, Roberts, et al., 2002; Erbs, Linke, Gielen, et al., 2003; Giannuzzi, 
Temporelli, Corra, et al., 2003).  The average increase in exercise capacity defined as VO2peak is 
approximately 25%, with the majority of the improvement occurring by the third week, although 
improvements continue slowly up to 6 months. In addition to the consistent improvements in 
maximal exercise performance, indices of submaximal exercise such as measured by the 6-
minute walk also improve (Parish, Alomari, Wood, et al., 2002). 
The mechanism(s) involved in the improvements observed with exercise training suggest 
that the changes in exercise capacity and tolerance are more related to reversing the peripheral 
compensatory abnormalities, rather than improvements in cardiac function (see Table IV). 
Cardiac output shows either no change (Sullivan, Higginbotham, & Cobb, 1988), or a small 
increase following a period of chronic exercise training (Coats, Adamopoulos, Radaelli, et al., 
1992). However, it is important to note that exercise training does not appear to worsen the 
process of left ventricular remodeling. In fact, randomized trials do not report any adverse effects 
  
 
 
166
of exercise training on regional wall motion, left ventricular systolic function and dimensions 
(Erbs, Linke, Gielen, et al., 2003; Giannuzzi, Temporelli, Corra, et al., 2003). 
 Exercise training improves respiratory muscle function and markers of work of breathing 
(Coats, Adamopoulos, Radaelli, et al., 1992; Mancini, Henson, La Manca, et al., 1995).  In 
particular, a selective respiratory muscle training program contributed to both physiological and 
clinical improvements in patients with chronic heart failure. The improvements were evident in 
terms of greater ventilatory muscle endurance, and increases in strength of both the inspiratory 
and expiratory muscles (Mancini, Henson, La Manca, et al., 1995). Moreover, training resulted 
in an increase in the maximum walking distance on the 6-minute walk test. Perhaps, most 
importantly, the majority of the patients engaged in this type of training reported a subjective 
decrease in dyspnea during activities of daily living (Mancini, Henson, La Manca, et al., 1995). 
A consistent response of exercise training in patients with heart failure is improved 
autonomic balance (Coats, Adamopoulos, Radaelli, et al., 1992; Radaelli, Coats, Leuzzi, et al., 
1996; Kiilavuori, Toivonen, Naveri, et al., 1995; Roveda, Middlekauff, Rondon, et al., 2003).  
This is reflected through an apparent shift away from the hyperadrenergic state typically 
observed in these patients. Markers of the autonomic system including resting heart rate, heart 
rate variability, sympathetic nerve activity and plasma catecholamine concentrations are all 
favorably altered following exercise training (Coats, Adamopoulos, Radaelli, et al., 1992; 
Radaelli, Coats, Leuzzi, et al., 1996; Kiilavuori, Toivonen, Naveri, et al., 1995; Roveda, 
Middlekauff, Rondon, et al., 2003).  In addition, the concentration of the fluid regulatory 
hormones angiotensin II, aldosterone, vasopressin and arginine vasopressin under resting 
conditions are significantly reduced perhaps reflecting the improved autonomic balance (Braith, 
Welsch, Feigenbaum, et al., 1999). 
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Recent evidence also indicates the benefits of exercise training on reversing the stiffness 
and lack reactivity of peripheral arteries (Hornig, Maier, & Drexler, 1996; Hambrecht, Fiehn, 
Weigl, et al., 1998; Kobayashi, Tsuruya, Iwasawa, et al., 2003). Presumably, vessels that are less 
stiff and better able to dilate or constrict contribute to improved distribution of the available 
cardiac output to working skeletal muscles. Interestingly, the improved vasodilatory capacity 
appears to be specific to the area trained as 4 weeks of handgrip exercise only showed restored 
flow-dependent dilation in the trained arm. Moreover, the beneficial effect of training was also 
lost after 6 weeks of cessation of training (Hornig, Maier, & Drexler, 1996). This suggests the 
importance of a well-rounded training stimulus, but also emphasizes the benefits of local training 
on vascular beds, something that may be particularly useful in patients with severe heart failure. 
In fact, it is interesting to consider that a whole-body training program increases coronary flow 
reserve as evidenced by increased vasoreactivity of epicardial vessels (Hambrecht, Wolf, Gielen, 
et al., 2000). Combined these findings indicate the enormous potential of exercise training in 
reversing the maladaptive vascular changes evident in these patients. 
Exercise training significantly improves skeletal muscle function, blood flow and 
metabolic capacity in patients with heart failure (Coats, Adamopoulos, Radaelli, et al., 1992; 
Sullivan, Higginbotham, & Cobb, 1988; Stratton, Dunn, Adamopoulos, et al., 1994; Hambrecht, 
Fiehn, Yu, et al., 1997; Pu, Johnson, Forman, et al., 2001).  The magnitude of leg muscle blood 
flow increases reportedly are similar in heart failure patients compared to healthy normal 
controls, indicating the adaptive response is preserved (Sullivan, Higginbotham, & Cobb, 1988).  
Following a local forearm training protocol, muscle bioenergetics, as assessed by 31P-NMR 
spectroscopy, improved only in the trained forearm. Skeletal muscle responses to exercise after 
the one month program indicated less phosphocreatine utilization, higher muscle pH at 
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submaximal workloads, and improvement in phosphocreatine recovery kinetics. In part, these 
changes are indicative of an improved mitochondrial ATP synthesis rate.  Finally, patients with 
heart failure who engage in regular physical exercise show enhanced oxidative enzyme activity 
in the working skeletal muscle and a concomitant re-shift to type I fibers. The improvements are 
at least in part secondary to a significant increase of the surface density of cytochrome c oxidase-
positive mitochondria and the surface density of mitochondrial cristae (Hambrecht, Fiehn, Yu, et 
al., 1997). 
Moreover, recent evidence supports the safety and efficacy of resistive training in 
patients with heart failure (Pu, Johnson, Forman, et al., 2001; Hare, Ryan, Selig, et al., 1999).  
Recognizing the overwhelming evidence that resistive training can have a significant impact on 
functional ability, implementation of a tailored resistive program may be an important 
component in the management of these patients.  Evidence that heart failure patients can adapt to 
resistance training was recently shown. Training resulted in significant increases in strength and 
endurance associated with a lower O2 consumption at submaximal workloads (Pu, Johnson, 
Forman, et al., 2001).  No complications with the training program were observed. Thus, it 
would appear a program of combined aerobic and resistance training could be quite beneficial. 
However, given the lack of large clinical trials the safety of resistance training in patients with 
HF needs to be further established.  Combined, these findings suggest that skeletal muscle 
abnormalities in heart failure are, in part, due to a deconditioning process, and can be partially 
reversed through exercise training.   
Thus, there is growing evidence that exercise training may reverse many of the peripheral 
abnormalities present in the heart failure patient.  Exercise training may improve autonomic 
function, skeletal muscle blood flow and localized oxidative capacity (see Table IV).  Together, 
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Figure 12a and b. Effects of Exercise Training on Survival 
time and Hospital Admissions in Heart Failure Patients
these changes may translate in an increased exercise tolerance, reduction in activity-related 
symptoms, and improved quality of life.  These findings assume added importance in light of 
previous reports that exercise capacity is one of the most powerful predictor of survival of heart 
failure patients (Bittner, Weiner, Yusuf, et al., 1993). Perhaps most importantly, a recent meta-
analysis of randomized controlled exercise training trials reports a significant improvement in 
survival time in patients with 
chronic heart failure (see Figure 
12a) (Piepoli, Davos, Francis, et 
al., 2004). Time to death or 
admission to hospital was also 
significantly extended (see 
Figure 12b) (Piepoli, Davos, 
Francis, et al., 2004). 
Guidelines, Risk 
Stratification, and Exercise 
Prescription  
The Committee on 
Exercise, Rehabilitation, and 
Prevention of the American Heart 
Association Council on Clinical Cardiology American Heart Association, recently, published a 
scientific statement on the role of exercise in heart failure (Pina, Apstein, Balady, et al., 2003).  
The Committee concludes that exercise training in patients with heart failure seems to be safe 
and beneficial in improving exercise capacity, exercise duration, and parameters of submaximal 
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exercise performance. In addition, quality of life improves in parallel to the improvements in 
exercise capacity. Furthermore, benefits have been reported in muscle structure and 
physiological responses to exercise, such as improvements in endothelial function, 
catecholamine spillover, and oxygen extraction in the periphery, among others. The committee 
encourages the stratification of individuals in risk categories prior to engaging in a physical 
activity program.  These risk categories should be based on the individuals’ clinical 
characteristics and likelihood of untoward events.  Patients classified as Stage A, should be 
encouraged to participate in exercise training programs to prevent the further development of the 
disease. Stage B and C patients are also encouraged to participate in activity programs, but these 
patients may require more specific attention in terms of monitoring and exercise prescriptions. 
Patients in Stage D have symptoms at rest or on minimal exertion (including profound fatigue), 
and generally cannot perform most activities of daily living. Consequently, physical activity 
should be limited until these patients have improved hemodynamic function secondary to 
specialized treatments. 
 Importantly, it must be recognized that agreement on a universal exercise prescription for 
heart failure patients does not exist. Consequently, an individualized approach is recommended, 
using standards provided in the American Heart Association Standards (Fletcher, Balady, 
Amsterdam, et al., 2001).  Prior to starting the program a clear understanding of the patient's 
medical history, present medical and physiological status, and personal need is necessary to 
maximize safety and efficacy.  Once the heart failure patient is deemed medically stable, and 
fluid status is adequately controlled, the patient should be introduced to an exercise training 
program.  The exercise prescription should have specific guidelines concerning the frequency, 
intensity, duration, mode, and progression of the exercise program.  Initially, because of the 
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marked exercise intolerance, it may be necessary to use an interval training approach, with 2-6 
min low level activity interspersed with appropriate periods of rest.  Frequency of training may 
be as much as 2 to 3 times a day during the early stages of the program.  Warm-up and cool-
down periods should be longer to allow adequate time for the body to prepare and recover from 
the activity.  Depending on the patient's medical status, reported symptoms during training, and 
tolerance of the exercise session, intensity, duration and frequency may be altered.  
Determination of an appropriate exercise intensity for the heart failure patient on the 
basis of maximal exercise capacity is often difficult. If a symptom-limited graded exercise test is 
used the exercise prescription should be based on VO2reserve, rather than heart rate reserve, 
secondary to frequent impaired chronotropic responses. The use of the VO2reserve method has 
been recommended by the American College of Sports Medicine especially for low-fit clients 
(ACSM Position Stand, 1998). The starting intensity for patients with heart failure is generally 
quite low and should be as tolerated. As the patient responds favorably a more defined program 
may be developed starting at 40-50% of VO2reserve, or slightly below any significant symptoms, 
such as angina, exertional hypotension, dysrhythmias, and shortness of breath. More constant 
supervision may be needed during the early stages of the exercise program for all heart failure 
patients, with the use of more intensive monitoring of blood pressure responses and 
electrocardiograms. In addition, the rating of perceived exertion scales should be used, guiding 
patients to a rating of 11-14 (on the 15-grade category Borg scale), whereas symptoms of angina 
and dyspnea should not exceed 2+ on a "0-4" scale ("Moderate, Bothersome" on the Angina 
scale and "Mild, Some Difficulty" on the Dyspnea scale).  The duration of exercise should be 
gradually increased again depending on patient's tolerance.  The choice of exercise for heart 
failure patients has traditionally focused predominantly on cardiovascular activities, such as 
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walking and cycling. Clearly these activities are necessary to remain independent and it is 
therefore important to gradually progress the patients to higher intensities and longer durations if 
additional work is tolerated. However, decisions on progression should not solely be based on 
the observed responses during exercise, but the clinician should also determine to what extent the 
exercise impacts the patient’s remainder of the day.     
Current guidelines by the American Heart Association and other organizations do not 
include guidelines for a resistance training component for heart failure patients.  However, the 
Committee recognizes that resistive exercises can offer the opportunity to strengthen individual 
muscle groups. However, since the safety of resistance training in patients with heart failure 
needs to be further established in larger trials, it would seem a conservative approach may be to 
use light to moderate resistance training as part of a well-rounded program for select patients.  
 Thus, the principles of exercise prescription for heart failure patients are similar to those 
for healthy people.  The major differences relate to the application of these principles to the 
patient.  The goal of an exercise program for the heart failure patient is to reduce morbidity 
associated with the disease and maintain functional capacity for independent living.  Generally, 
heart failure patients should start out slowly, and initially aim to increase duration of exercise.  
How well the heart failure patient adapts to the training program should dictate the frequency 
and magnitude of progression. Finally, patients should be made familiar with the use of a 
physical activity pyramid to recognize that a gradual increase in overall activities interspersed 
with proper rest periods throughout the day is pertinent in the management of their condition (see 
Figure 13). 
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Figure 
13. Physical Activity Pyramid for Chronic Heart Failure Patients. 
In summary, patients with medically stable heart failure should be considered for 
participation in an exercise training program.  Guidelines for and components of an exercise 
program for the heart failure patient are similar to other clinical populations and healthy 
individuals.  However, the exercise prescription should be designed to meet the unique goals and 
demands of the patient. 
 
Compliance  
Up to 65% of hospital admissions are due to noncompliance with both pharmacologic 
and nonpharmocologic treatment regimes (Dahl & Penque, 2000). There are many reasons that 
patients may not comply with a therapeutic regimen. Lack of knowledge, poor motivation, 
decreased understanding, lower perceived self-efficacy, forgetfulness, and decreased support 
from family and other caregivers have been identified as factors that contribute to 
noncompliance (Bennett, Huster, Baker, et al., 1998; Conn, Taylor, & Kelley, 1991; Happ, 
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Naylor, Roe-Prior, 1997; Ni, Nauman, Burgess, et al., 1999; Jaarsma, Halfens, Huijer-Abu Saad, 
1999; Dracup, Baker, Dunbar, et al., 1994). Additionally, a patient may not comply with a 
prescribed regimen because he or she is unconvinced of the benefits of doing so or because he or 
she perceives that the side effects or inconveniences of following the regimen outweigh any 
benefits (Grady, Dracup, Kennedy, et al., 2000). Furthermore, it has been suggested that one 
reason for high rates of noncompliance may simply be lack of understanding of the treatment 
plan (Dracup, Baker, Dunbar, et al., 1994). 
Noncompliance with diet and medications can rapidly and profoundly affect the clinical 
status of patients, and increases in body weight and minor changes in symptoms commonly 
precede the major clinical exacerbations that require emergency care or hospitalization 
(ACC/AHA, 2001). In fact, some studies have demonstrated that it is the lack of recognition by 
the patient of the symptoms of a worsening pathology that has led to a delayed use of appropriate 
treatment (Friedman, 1997; Francis, 1998). It has been suggested that if patients know the 
symptoms and signs of worsening heart failure, they may be able to seek care early and avoid 
hospitalization (Dracup, Baker, Dunbar, et al., 1994; Konstam, Baker, Dracup, et al., 1994). For 
example, patients should be told that dyspnea and fatigue are normal responses during moderate 
exertion in patients with heart failure. This explanation will help alleviate anxiety over 
performing daily activities that might provoke shortness of breath. However, physicians and 
patients must understand that progressive dyspnea on exertion or sudden changes in orthopnea or 
paroxysmal nocturnal dyspnea are not expected. Moreover, excessive fatigue during and 
following exertion must also be considered. In general, a sudden deviation from the normal 
responses may indicate worsening heart failure and such information should be communicated to 
the health care provider immediately (Konstam, Baker, Dracup, et al., 1994).     
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 It is important to consider that healthcare providers also contribute to heart failure patient 
noncompliance and hospital readmissions. Impediments to patient compliance include advising 
changes that disregard the patient’s current lifestyle and failing to counsel or advise patients on 
how to adapt their current lifestyle to accommodate recommended changes (Dunbar, Jacobson, 
& Deaton, 1998). Healthcare providers may fail to follow appropriate treatment guidelines 
(Fonarow, Stevenson, Walden, et al., 1997; Hunt, Baker, Chin, et al., 2001), or make 
recommendations without detailing how to implement the recommendations (Grady, Dracup, 
Kennedy, et al., 2000). For example, clinicians may fail to adequately educate and counsel the 
patient or support person who may be responsible for purchasing food, cooking, and 
administering medications (Konstam, Baker, Dracup, et al., 1994). Another important factor that 
contributes to patient noncompliance and rehospitalization for worsening heart failure is 
inadequate discharge planning and follow-up after discharge (Vinson, Rich, Shah, et al., 1990). 
Therefore, it is important to consider that the barriers to successful management of patients are 
also present on the healthcare provider’s side. Physicians and other providers should be attuned 
to the problem of noncompliance and its causes, discuss the importance of compliance at follow-
up visits, and assist patients in removing barriers to compliance (eg, cost, adverse effects, or 
complexity of the therapeutic regimen) (Dracup, Baker, Dunbar, et al., 1994). For example, if 
medication cost is a factor in noncompliance, suggestions for lower-cost medications or financial 
assistance programs should be provided (Grady, Dracup, Kennedy, et al., 2000). 
Rosenstock (1975) explains that to comply with treatment, patients must understand the 
nature of their illness, why they are being treated, how long the treatment will last, and the 
results of treatment (Rosenstock, 1975). Descriptive research of 41 patients with chronic HF 
found that almost all patients could not correctly define HF, less than half could correctly 
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identify their medications, and almost three fourths of patients did not weigh themselves daily 
(Bushnell, 1992). A complete, comprehensible explanation of the illness has been shown to 
increase compliance with the treatment plan (Bushnell, 1992), improve functional capacity and 
quality of life, and reduce hospital readmission rates (Rich MW, Beckham, & Wittenburg, 1995; 
Fonarow, Stevenson, & Walden, 1997; Dahl & Penque, 2000). Therefore, the education of the 
patient and his family or caregiver represents a fundamental aspect of therapy.  
Education 
Given the complexity of the heart failure syndrome and the available treatment strategies, 
education and counseling of patients and their families are vitally important for maintenance and 
clinical stability (Grady, Dracup, Kennedy, et al., 2000). In a review of the literature from 1966 
to 1993 (Dracup, Baker, Dunbar, et al., 1994), counseling and health education increased life 
expectancy and quality of life, and reduced hospitalization of patients with heart disease. 
Moreover, multiple studies have shown that patients who are educated and knowledgeable about 
their disease process and understand how their medications work and the importance of 
compliance have fewer hospital readmissions and experience an increase in functional capacity 
and quality of life (Rich, Beckham, & Wittenburg, 1995; Fonarow, Stevenson, & Walden, 1997; 
Dahl & Penque, 2000).  Quality of life and social functioning may be more important to patients 
than physiological impairment and long-term survival (Rideout, Montemuro, 1986; Dracup, 
Walden, Stevenson, et al., 1992), and practitioners should emphasize that patients with heart 
failure can live active and enjoyable lives (Dracup, Baker, Dunbar, et al., 1994). A recent study 
of 51 patients with heart failure revealed that a majority placed greater importance on improved 
symptoms rather than longer survival as the preferred outcome (Stanek, Oates, McGhan, et al., 
2000). Therefore, the goals of education and counseling are to assist patients in compliance with 
  
 
 
177
the therapeutic regimen, to maintain clinical stability and function, and to improve quality of life 
(Grady, Dracup, Kennedy, et al., 2000). These goals are best achieved when the patient and 
family are knowledgeable about every aspect of the condition and treatment and are active 
participants in the plan of care (Konstam, Baker, Dracup, 1994).  
A complete, comprehensible explanation of the illness increases compliance with the 
treatment plan (Bushnell, 1992). Patients and their support group must understand their disease; 
a specific but simplistic discussion of the basic pathophysiology and etiology of heart failure, 
using language that the patient can thoroughly grasp, is vital (Dracup, Baker, Dunbar, et al., 
1994). The educational needs of heart failure patients have traditionally included topics such as 
anatomy and physiology, medications, sodium restrictions, dietary changes, activity levels, and 
psychological responses (Dracup, Baker, Dunbar, et al., 1994; Hagenhoff, Feutz, Conn, et al., 
1994). Hagenhoff et al. (1994) studied the perceived learning needs of 30 hospitalized heart 
failure patients and 26 nurses, who ranked these categories according to importance (Hagenhoff, 
Feutz, Conn, et al., 1994). Patients and nurses agreed that medication information was the most 
important to learn. Psychological concerns and activity received the lowest rankings, and the 
researchers suggested that, because of shorter lengths of hospital stay and decreased opportunity 
for patient education, these aspects could be taught in the outpatient setting (Hagenhoff, Feutz, 
Conn, et al., 1994).  The general trend across all patient education content areas was for patients 
to rate the information as more important to learn than the nurses rated the information. These 
findings suggest that patients value education regarding their condition during their 
hospitalization for HF and this should continue to be an important focus of care for this 
population (Hagenhoff, Feutz, Conn, et al., 1994). However, patient comprehension can be 
limited in the hospital due to the shortened length of stay, the unfamiliar environment, anxiety, 
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fatigue, and inability to concentrate owing to acute illness (Knox & Mischke, 1999). Therefore, 
due to the complex nature of the illness, patient education should extend to the outpatient setting 
(Connolly, 2000) and requires collaboration between the patient and health care providers from 
the inpatient, outpatient, and home care settings (Knox & Mischke, 1999). The Agency for 
Healthcare Policy and Research (AHCPR) guidelines for the management of heart failure 
patients suggest that education become a standard part of management plans and that both 
content and counseling be included (Konstam, Dracup, Baker, et al., 1994). 
A clear and organized plan of patient education and counseling is critical to the 
achievement of optimal outcomes. Counseling and education have been observed to improve 
patient outcomes and decrease unnecessary hospitalizations in patients with HF (Dracup, Baker, 
Dunbar, et al., 1994). Patients with HF benefit most when educated about sodium and fluid 
restrictions and other dietary issues as well as the pathophysiology of HF, medications, signs and 
symptoms of worsening heart failure, and activity or exercise (Dracup, Baker, Dunbar, et al., 
1994). In 1994, the Agency for Healthcare Policy and Research published guidelines for the 
management of patients with HF, and suggested topics for education and counseling of patients 
with heart failure are listed in Table II (Konstam, Dracup, Baker, et al., 1994). Because not all 
components of the program are appropriate for all patients, treatment must be individualized and 
adapted to accommodate the needs and circumstances of each patient. 
Aggressive management in the outpatient setting is essential to improving survival and 
reducing the risk for hospitalization (Connolly, 2000). Although it is important to discuss 
medications and dietary recommendations with patients who are being discharged from the 
hospital, a full discussion of these topics should be conducted in the outpatient setting and 
repeated as often as necessary (Connolly, 2000).  Patients do not absorb and retain all necessary 
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information in a single educational session (Mullen, Mains, & Velez, 1992). Therefore, patient 
education should occur over time and be an ongoing process (Dracup, Baker, Dunbar, et al., 
1994). Patient and family understanding needs to be continually assessed and counseling 
activities adjusted accordingly (Konstam, Baker, Dracup, et al., 1994). Providers should be 
sensitive to differences in patients’ language, culture, and educational level that may impair 
understanding and compliance (Estey, Musseau, & Keehn, 1991).  In addition, written 
educational materials and video or audio-tapes can help clarify information and enhance 
discussions but should serve as adjuncts to and not as replacements for one-on-one education 
(Grady, Dracup, Kennedy, et al., 2000). 
The telephone may be a simple, useful tool for enhancing compliance. Telephone 
technology was used in the medical field in the diagnosis of respiratory problems as early as 
1979 (Grument, 1979). Effective telephone care can yield correct and timely diagnosis and 
treatment, promote compliance with the treatment regimen, and enhance patient and health care 
provider satisfaction (Guy, 1995). 
Compliance is also enhanced when the patient participates actively in developing the plan 
of care and when families are informed and supportive partners in this plan (Hubbard, 
Muhlenkamp, & Brown, 1984; Swain & Steckel, 1981). Therefore, patients and their families 
should be encouraged to ask questions about any aspect of the management of heart failure or a 
recommended intervention (Dracup, Baker, Dunbar, et al, 1994). Education regarding proposed 
interventions should be designed to help patients and their families arrive at realistic expectations 
about risks and benefits (Konstam, Baker, Dracup, et al., 1994). Nursing interventions, family 
involvement, and support groups may all help patients cope with heart failure and make the 
many lifestyle changes required by the disease (Dracup, Baker, Dunbar, et al., 1994). 
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Of the general measures that should be pursued in patients with HF, possibly the most 
effective, yet least utilized is close attention and follow-up (Hunt, Baker, Chin, et al., 2001). 
Patient education and close supervision, which includes surveillance by the patient and his or her 
family between physician visits, can reduce the likelihood of noncompliance and can often lead 
to the detection of changes in body weight or clinical status early enough to allow the patient or a 
healthcare provider an opportunity to institute treatments that can prevent clinical deterioration 
and hospitalization (Konstam, Dracup, Baker, et al., 1994). ).  In general patient self-
management includes monitoring the level and intensity of symptoms (for example, shortness of 
breath or pain) and objective data (blood pressure and glucose levels) and adjusting the treatment 
plan accordingly (Dunbar, Jacobson, Deaton, et al., 1998). For patients with heart failure, the 
self-management plan includes monitoring changes in symptoms such as fatigue, shortness of 
breath, daily body weights, and knowing when to report the changes to the health provider 
(Konstam, Dracup, Baker, et al., 1994). Supervision between physician visits ideally may be 
performed by a nurse or physician assistant with special training in the care of patients with HF. 
Such an approach has been reported to have significant clinical benefits (Rich, Beckham, 
Wittenberg, et al., 1995; Shah, Der, Ruggerio, et al., 1998; Fonarow, Stevenson, et al, 1997; 
Philbin, 1999). A detailed analysis of hospital readmissions in heart failure patients who were 
participating in a clinical trial that provided comprehensive discharge planning and homecare 
intervention by an advanced practice nurse revealed that failure to adhere to the treatment plan 
was the predominant factor related to readmission (Happ, Naylor, Roe-Prior, 1997). Even though 
patients were provided with individualized intervention by advanced practice nurses who 
focused on preventing exacerbations of heart failure through symptom recognition, medication, 
dietary education, and modification of poor health behavior, there was a 33% readmission rate in 
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the intervention group within the first 6 months after hospital discharge. Most readmissions 
occurred after the intervention had ended (1 month), suggesting that more follow-up may be 
needed by some patients (Happ, Naylor, Roe-Prior, 1997). Social support and individual 
motivation to learn and manage health behavior were also viewed as influential in adherence to 
the prescribed treatment (Happ, Naylor, Roe-Prior, 1997). These findings illustrate the overall 
complexity in addressing the education process for heart failure patients. 
Education will only work if the patient’s willingness to learn is appreciated. Therefore, 
the provision to patients and their families/caregivers of behavioral strategies to increase 
adherence is vital. There are many strategies to assist patients to comply with their heart failure 
regimen, such as the use of a daily reminder routine, filling a pill box that contains 1 week’s 
medications, the implementation of incremental monitoring by caregivers, the use of medication 
information and reminder cards, and counseling (Stewart, Pearson, & Horowitz, 1998).  
Behavioral theories, such as the Transtheoretical model of behavior change (Prochaska, 
Norcross, & DiClemente, 1994), may be useful in designing effective approaches to patient 
education programs. Although there have been no studies in which outcomes of these methods 
with heart failure patients have been reported, these approaches could be used individually or in 
a combined framework to guide strategies that go beyond traditional patient educational 
approaches (Dunbar, Jacobson, Deaton, et al., 1998). 
 The Transtheoretical approach views the process of changing health behavior as 
occurring in several specific stages, referred to as stages of change (Prochaska, Norcross, & 
DiClemente, 1994). The transtheoretical model of behavior change (TTM) was first described in 
1982 as a proposed mechanism of smoking cessation (Prochaska & DiClemente, 1982). This 
model has been validated and applied to a variety of behaviors that include smoking cessation, 
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exercise behavior, and dietary behavior (Prochaska, Velicer, Rossi, et al., 1994; Hellman, 1997; 
Glanz, Patterson, Kristal, et al., 1994). Understanding behavior change as a process rather than a 
single event, the TTM attempts to explain how, rather than why, behavior change occurs 
(Prochaska, Norcross, & DiClemente, 1994). The TTM states that there are five distinct stages 
(see Table ?) involved in behavior change, during which 10 different processes of change (Dunn, 
Marcus, Kampert, et al., 1997) may be used (see figure 14).  The TTM suggests that for 
successful behavior change, interventions must be tailored to a person’s current stage of 
readiness and make use of the appropriate processes of change (Prochaska, Norcross, & 
DiClemente, 1994). 
One role of the physician is to assist patients in understanding their health and to help 
them make the changes necessary 
for health improvement 
(Zimmerman, Olsen, & Bosworth, 
2000). A change in patient lifestyle 
is necessary for management of 
long-term illnesses, such as heart 
failure (Konstam, Dracup, Baker, 
et al., 1994). By assessing stage of readiness regarding a particular behavior or a lifestyle pattern 
and determining whether the patient has experience with attempting the change, the clinician can 
determine which interventions might be most effective in managing the heart failure patient. The 
specific motivational interventions vary by stage of change. For example, if patients state that 
they have never tried a low sodium diet but are considering reducing sodium, they may be in the 
contemplation phase, and interventions would include raising their consciousness about the 
The Transtheoretical Model and 
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importance through calculating the sodium in food typically consumed and investigating low 
sodium alternative products at the grocery store. Emotional arousal is also important for 
successful behavior change at this stage and could include imagery to visualize fluid building up 
in an overloaded pump (heart). If the patient reports trying to reduce sodium intake in the past 
but finding the diet intolerable, the patient’s stage of change is relapse. Interventions could 
include setting up a personal reward system, seeking the help of family members, and helping 
the patients focus on the positive aspects of what they are doing for their overall health.  
MULTIDISCIPLINARY PROGRAMS 
Heart failure rarely occurs as an isolated disease process, and management is frequently 
confounded by a host of medical, behavioral, psychological, social, and economic factors. A 
considerable amount of the economic cost associated with heart failure care is attributable to 
repeated exacerbations that frequently require hospitalization, with rates ranging from 30% to 
50% within 3 to 6 months of the initial discharge (Gooding & Jette, 1985; Rich & Freedland, 
1988; Vinson, Rich, et al., 1990). Moreover, behavioral factors contributing to readmissions 
include nonadherence to diet, medication, and activity regimens, social isolation, inadequate 
symptom self-assessment and management, inadequacies in patient and care-giver education, and 
poor discharge planning and follow-up, suggesting that such readmissions could be prevented, or 
significantly delayed, with better health care and improved patient participation in his or her 
treatment. (Konstam, Dracup, et al., 1994; Rich, Vinson, et al., 1993; Vinson, Rich, et al., 1990; 
Dracup, Baker, et al., 1994; Happ, Naylor, et al., 1997; Ghali, Kadakia, et al., 1988; Kaspar, 
Gerstenblith, et al., 2002; Rich, Beckham, et al., 1995).  
It follows that management of these patients requires appropriate attention to all aspects 
of care, both pharmacologic and nonpharmacologic, and that comprehensive disease 
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management may best be accomplished through the use of a multidisciplinary team approach 
(Grady, Dracup, et al., 2000). A recent AHA Scientific statement examined the team 
management of heart failure patients (Grady, Dracup, et al., 2000) and indicated that components 
of successful healthcare delivery models for heart failure include staff skilled in the 
understanding of the pathophysiology of heart failure, patient assessment and evaluation of 
symptoms, education and counseling (focusing on symptoms and medication compliance), 
dietary consultation, and physical activity and exercise recommendations (Grady, Dracup, et al., 
2000).  Therefore, the following section discusses the various multidisciplinary trials that have 
been conducted over the past 21 years. The trials are presented chronologically, with the 
observational studies first, followed by the randomized trials. The multidisciplinary trials are 
further summarized in Tables VI - XI. 
Observational Studies 
Tables VI-VIII summarizes characteristics from 17 observational studies evaluating the 
efficacy of various multidisciplinary heart failure disease management strategies. The first 
observational study (Cintron et al. 1983) combined meticulous management in a HF clinic with 
easy accessibility to a nurse practitioner. Fifteen HF patients were seen an average of every 3 
weeks for 7 to 48 months for a mean follow-up period of 24 months. Assessments included a 
history, physical examination, and appropriate laboratory studies. Strong emphasis was placed on 
weight control, diet, home situation, and family support. Medications were reviewed and, when 
necessary, cardiology consultation was obtained before adjusting therapy or recommending 
hospitalization. The average age of the study participants was 65 years, and all but three had 
NYHA Class IV symptoms. When compared with an equivalent period of time before enrollment 
in the clinic, hospitalizations declined by 61%, and hospital days were reduced by 85%. 
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Although annual total costs for outpatient care increased by $11,000, inpatient costs decreased 
by $131,000, yielding an average cost savings of $8,000 per patient. In addition, all patients 
reported improved satisfaction with the process of care.  
 Interestingly, despite the positive findings from Cintron (1983) it was not until 12 years 
later before the next observational study appeared.  Kornowski et al. (1995) described a program 
of 42 housebound elderly patients (mean age 78±8 years) with NYHA class III or IV heart 
failure who were examined weekly at home by internists and a paramedical team. Home visits 
consisted of providing the patient a report about the medical condition, a history and physical 
exam, review of medications, laboratory studies as necessary, and discussion of a treatment plan 
for the subsequent week. Physical therapy, oxygen, IV infusions and supplemental visits were 
also available as needed. The year prior to entry into the program was compared with the first 
year of home surveillance. Participation in the program was associated with a 62% reduction in 
total hospital admissions (3.2 +1.5 to 1.2 +1.6 hospitalizations/year), a 72% decrease in 
cardiovascular admissions (2.9+1.5 to 0.8 +1.1 hospitalizations per year), and 77% fewer 
hospital days (26+14 to 6 +7 days per year, p=0.001). In addition, functional status as assessed 
by ability to perform daily activities on the patient global status index (1 to 4 scale), improved 
from 1.4 ± 0.9 to 2.3 ± 0.7 (p<.001). This study showed improved outcomes but at an uncertain 
trade-off in resource use between increased home visits and decreased hospitalizations for the 
intervention. Although the cost of the intervention was not assessed, study coordinators projected 
that the intervention resulted in increased cost savings (Kornowski, Zeeli, Averbuch,  et al., 
1995). 
In 1996, Lasater and coworkers (1996) examined a 6 month nurse-managed, home-based 
program for cardiomyopathy and heart failure patients. In addition to the nurse, access to a 
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physician, dietician, and social worker was available as needed. 80 patients discharged with a 
primary diagnosis of heart failure were automatically enrolled in the program, which focused on 
preventing heart failure exacerbations through patient education about pharmacotherapy, diet, 
and activities of daily living. Medication compliance assessments were also performed, and 
assistance with financial concerns was provided as needed. Follow-up clinic visits were 
scheduled at the nurse’s discretion and averaged 3.7 visits per patient over the 6-month period. 
Patients recorded daily weights and a weight gain of 4 pounds served as a threshold for 
increasing diuretic therapy. Compared to the 6-month period immediately before entry into the 
program, the overall hospitalization rate decreased by 14%, and the average length of stay 
declined from 7.3 to 5.7 days, a 22% change. In addition to a 32% reduction in total hospital 
days, hospital charges decreased by $500 per patient and a retrospective cost analysis concluded 
that the intervention was cost saving.  
 Three observational trials were conducted in 1997. In the first of these studies, West el al. 
(1997) used a strategy of physician-supervised but nurse-mediated, home based heart failure 
management, not involving home visits (West, Miller Parker, et al., 1997). Like Kornowski et al. 
(1995), West and colleagues (1997) studied a disease management strategy in a group of patients 
recruited from a northern California HMO. 
Patients were followed for an average of 138 ± 44 days. The mean age of the study population 
was 66 years, with 71% men, and 40% were in NYHA functional class III or IV. Nurses directed 
the implementation of consensus guidelines to maximize vasodilator doses, reduce dietary salt 
intake, monitor patients for early evidence of worsening heart failure, and provide patient 
support and education by frequent telephone contact. The intervention consisted of an initial 
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comprehensive visit followed by regularly scheduled telephone calls. The average number of 
telephone contacts per patient during follow-up was 13. 
Compared with the 6 months before enrollment, general medical and cardiology visits 
declined by 23% and 31%, respectively (p<.03). Hospitalization rates for heart failure and for all 
causes declined 87% and 74%, respectively (p=0.001), compared with the year before 
enrollment. Additionally, self-reported dietary sodium intake measured by food-frequency 
questionnaires showed a persistent and significant reduction of 38%, declining from 3.4 to 2.1 g 
per day (p<0.0001). Furthermore, patients reported substantial improvements in multiple indices 
of symptom status and quality of life, including NYHA functional class, Duke Activity Status 
Index, and both the physical and mental component scores of the Medical Outcomes Study Short 
Form 36 (SF-36) Health Survey (West, Miller Parker, et al., 1997). Although the investigators 
did not report on cost of the intervention, it is likely that the marked reduction in resource 
utilization was associated with significant cost savings.  
Also in 1997, Fonarow et al. (1997) described a program of intense inpatient 
management followed by careful post-discharge follow-up among 214 patients referred for 
treatment of advanced CHF and evaluation for heart transplant (Fonarow, Stevenson, et al., 
1997). Participants in this study were younger than those in previous studies, with an average age 
of 52 years, 81% were men, and the mean LVEF was 21%.  Forty-four percent of the patients 
were in NYHA class III, whereas 56% were in class IV. After discharge, patients received close 
follow-up with frequent telephone contact and clinic visits. Telephone calls were made 2-3 days 
after any major medication change and at routine intervals between 2 and 8 weeks, as warranted 
by clinical stability and patient need for reassurance. 
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The protocol consisted of invasive hemodynamic monitoring and intensification of the 
medical regimen, including high-dose vasodilators, diuretics, and digoxin. Patient education and 
lifestyle modification were emphasized by nurses with specialized training in heart failure and 
reinforced by printed teaching materials. Furthermore, regular, unsupervised exercise was 
recommended, although no specific detail was provided.  
Compared to the 6-month period preceding referral, there was an 85% reduction in 
hospital admissions (Fonarow, Stevenson, Walden, et al., 1997). Factoring in the initial 214 
admissions for transplant evaluation yielded a net reduction in total hospitalizations of 44%. 
Additionally, dosages of ACE-Inhibitors or isosorbide dinitrate, and diuretics markedly 
increased; whereas calcium channel blockers and type I antiarrhythmic agents were virtually 
eliminated. Furthermore, NYHA functional class improved significantly (p<0.001) with 49% of 
the patients reclassified as functional class I or II. Finally, peak oxygen consumption increased 
from a mean of 11.0 + 3.6 to 15.2 + 4.4 mL/kg/min, an increase of 38% at the 6-month follow-
up, which placed these patients outside of the cardiac transplant range (Fonarow, Stevenson, 
Walden, et al., 1997). The estimated net savings of the intervention, after subtracting the initial 
hospital costs and nursing costs during follow-up, was $9,800 per patient. The potential to reduce 
both symptoms and costs suggests that referral to a heart failure program may be appropriate not 
only for potential heart transplantation, but also for medical management of patients with 
functional class III and IV heart failure (Fonarow, Stevenson, Walden, et al., 1997). 
A similar study was conducted by Hanumanthu et al. (1997), in which 134 patients were 
referred to a heart failure and transplantation program for periods ranging from 30 days to 1 year 
(Hanumanthu, Butler, Chomsky, et al., 1997). The average age of the participants was also 
52+12 years and the mean LVEF was 29+11. In comparison to Fonarow’s study, the HF/ 
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transplant team provided comprehensive management, which included intensive medical therapy 
and patient education. Compared with the 1-year period prior to the intervention, cardiovascular 
hospitalizations declined from 210 to 104, a reduction of 53% (p<0.01), and heart failure 
admissions decreased from 97 to 30, a 69% reduction. Additionally, at 6-month follow-up, mean 
peak exercise oxygen consumption improved from 12.8+4.7 to 15.7+4.8 mL/kg/min (p<0.01) an 
increase of 23%. An added component of this study in comparison to Hanamanthu’s work was 
that Quality of life was also assessed, using the Minnesota Living with HF Questionnaire (scale: 
0 –105, higher score=more impairment). Composite scores improved significantly from 57+27 to 
35+26 (p<0.01), a difference of 34 points.  
Tilney et al. (1998) referred 1,915 medicare HMO patients with CHF in a proprietary 
disease management program (Tilney, Whiting, Horrar, et al., 1998). The average age was 74 
and 50% of participants were male. In this 12-month program nurse-managers coordinated 
patient education and clinical surveillance, in collaboration with home care specialists, 
pharmacists, and the patient’s primary physician. Using patients as their own controls and other 
historical reference groups, investigators found a 20% reduction in daily dietary salt intake. 
Additionally, hospitalization rates decreased significantly from 164 to 60, a reduction of 60%, 
resulting in a marked decrease in health care costs (55%). 
 The apparent success of the multidisciplinary programs also spurred individual 
physicians to attempt such strategies in a setting with fewer resources. Smith et al. (1997) 
followed up 21 patients in a cardiomyopathy clinic composed of a cardiologist and nurse 
practitioner. New patients referred to the clinic with LVEF < 45% were enrolled in the program. 
The average age was 61 years, 90% were white and 100% were male. The intervention included 
comprehensive patient education, optimization of medication dosages, and regular clinic visits. 
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Compared with the 6-month period preceding entry into the clinic, heart failure admissions and 
emergency visits declined by 87% (14 to 2, p= 0.017) and 100% (8 to 0, p=0.002), respectively. 
However, the frequency of clinic visits was determined by symptom severity and the need for 
medication changes and increased 5-fold, averaging approximately 10.5 per patient during a 6-
month follow-up period. Additionally, LVEF increased from 24% to 36%, NYHA class 
improved significantly from 2.6 + 0.5 to 2.2 + 0.5, as did the Minnesota Living with Heart 
Failure Scores, with an average improvement of 23 points (p=0.001). Finally, exercise time 
increased from 6.7 to 8.8 min (p=0.005), although maximum oxygen consumption remained 
unchanged (15.4 ml O2/kg/min initially and 15.3 ml O2/kg/min at the end of 6 months (Smith 
LE, Fabbri SA, Pai R, Ferry, et al., 1997).  
Similar results were obtained in patients enrolled in an outpatient interactive home 
monitoring program (Shah, Ruggerio, Heidenreich, et al., 1998). In this study, Shah and 
colleagues examined the utility of a high technology approach that used patient self-assessment 
with automated reminders (Shah, Ruggerio, Heidenreich, et al., 1998). Twenty-seven men with 
NYHA class II to IV heart failure and average age of 62 (range 42-81) participated in the 8-week 
program, which consisted of weekly mailings of heart failure educational materials and weekly 
telephone counseling sessions by a heart failure nurse. In addition, a paging system was used to 
transmit computer-generated reminders to the patient to take medications and to maintain daily 
records of weight, heart rate, and blood pressure, and these data were monitored by a study 
nurse. Physicians received monthly progress reports, as well as immediate notifications by fax 
whenever significant changes in clinical status occurred. Patients were followed up for an 
average of 8.5 months, and hospitalizations for equivalent periods before and after the 
intervention were compared. Although hospitalization rates declined by 50%, this difference was 
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not significant. However, cardiovascular admissions were reduced significantly, as were total 
hospital days and hospital days for cardiovascular causes. Patient acceptance of the program was 
high; 82% of patients rated the program useful or very useful. Enthusiasm was particularly high 
among the NYHA class III to IV patients, of whom 15 of 17 (88%) rated the program very 
useful, compared with 4 of 10 class II patients. These data suggest that close telephone 
monitoring can prevent hospitalizations for heart failure among both recently discharged patients 
and ambulatory outpatients and among both elderly and middle-aged persons (Shah, Der, 
Ruggerio, et al., 1997). 
Heidenrich and colleagues (1999) provide further evidence supporting the clinical use 
and cost-effectiveness of heart failure disease management programs (Heidenreich, Ruggerio, & 
Massie, 1999). Sixty-eight patients with NYHA class II or III heart failure and an average age of 
73 years were enrolled from multiple small practices (largely primary care) in northern 
California and followed-up for an average of 7.4 months. A nonrandomized parallel control 
group was composed of 86 patients matched to the intervention group on the basis of medical 
claims during the preceding year.  As an adjunct to physician care, the intervention consisted of a 
low-intensity, home-based, computer-assisted telemonitoring system supplemented by weekly 
educational mailings and phone calls. The mailings described 52 HF topics (1 per week for 1 
year), including diet, exercise, common therapies, and simple anatomy and physiology. A nurse 
discussed the topics during 10-minute weekly phone calls and educational points were 
reinforced. The nurse only offered education and made no changes in management. New 
symptoms, medications, and physician visits were recorded. Physicians were notified by fax 
when there was a change in the patient’s clinical condition, but such notification occurred 
infrequently (approximately once in 3 months per patient) and was nonintrusive, thereby 
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facilitating physician acceptance.  Compared with the pre-intervention period, total medical 
claims during the 1-year period after implementation of the intervention declined by $1100 per 
patient in the treatment group but increased by an average of $9600 in the comparison group. 
Hospital days were also reduced significantly in the intervention group, but there was little 
change in quality of life as measured by the SF-36. As in other studies, the beneficial effects of 
the intervention were greater in patients at higher risk for recurrent hospitalizations. The 
intervention was well accepted by study participants, and compliance rates with the 
telemonitoring program were high (Heidenreich, Ruggerio, & Massie, 1999). 
This study differs in several aspects from previous studies that have noted reduced 
resource use with multidimensional programs for patients with heart failure. Several of these 
programs were limited to patients with severe heart failure (Fonarow, Stevenson, Walden, et al., 
1997) or were limited to discharge planning (Rich, Beckham, Wittenberg, et al., 1995). 
Additionally, all medical care was provided by the patient’s physician, and the study nurses 
served only as counselors and educators. This is in contrast to the programs reported by West et 
al (1997), and Cintron (1983), which used nurse practitioners to aid in medication management 
with the supervision of physicians. Because the program is of low cost and does not require 
direct supervision by the primary physician, it may be easily adaptable to a wide range of health 
care providers and clinical practice settings. Limitations include the nonrandomized design, 
small sample size, relatively low recruitment rate (implying potential sampling bias), and 
inability to assess the effects of individual program components. Despite these limitations, this 
study is an important contribution to the growing body of literature supporting the use of novel, 
multidisciplinary programs of patient monitoring, education, and physician notification in the 
management of heart failure.  
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Knox et al. (1999) described the efforts of a physician-led multidisciplinary team to 
provide coordinated care across the continuum of health care for patients with heart failure. The 
integrated 18-month program comprised components of inpatient consultation and education, an 
outpatient CHF clinic, home care, and a telephonic system to monitor patient compliance with 
recommended therapy. The program employed daily monitoring, ongoing education, and 
consistent communication by all members of the health care team and was designed to decrease 
length of stay, reduce costs, prevent readmissions, and improve compliance with the treatment 
regimen. As a result of pathway implementation, direct costs declined 50% and length of stay 
decreased to 4.0 days compared with 6.2 days before the program’s inception. Results also 
revealed reductions in the 30-day readmission rate, from 17% to 2.3%, and hospitalization rates 
of 0.6/pt/year compared with the national benchmark of 1.7/pt/year. After 18 months, 
telemanagement patients’ compliance rates averaged 89.5%. Additional clinical outcomes 
included patient satisfaction, improvements in percentage of daily weights recorded, frequency 
of dietary consultation, documentation of LV function, prescribing appropriate medications, & 
scheduling follow-up care (Knox & Mischke, 1999).  
Results of this study (Knox & Mischke, 1999) support previous reports that 
hospitalization rates in patients with heart failure can be substantially reduced by improved 
patient education, patient self-monitoring of weight, and rapid response to early signs of clinical 
decompensation (Rich, Beckham, Wittenberg, et al., 1995; Fonarow, Stevenson, Walden, et al., 
1997; Hanumanthu, Butler, Chomsky, et al., 1997) A unique aspect of this study was that 
patients were viewed as “co-managers” of their illness and education and treatment were 
individualized to the specific learning styles and needs of each patient (Knox & Mischke, 1999). 
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In 1999, Wilson and coworkers examined whether home health care services for heart 
failure were associated with decreased hospitalization frequency and costs (Wilson, Smith, 
Dahle, et al., 1999). 35 patients, mean age 57 +11 and average LVEF of 20 +10%  were referred 
to 18 home health agencies for administration of IV diuretics (n=19), home inotropic therapy 
(n=10), and general monitoring to ensure compliance with diet and medication and to detect 
clinical deterioration (n=6). Specific instructions for patient care were provided to each home 
care agency. Patients were enrolled for a mean of 94+94 days and nursing visits averaged 2.8 
+1.7 days, and ranged from daily to weekly. The average weekly charges were $348/patient and 
costs increased to $1,382/patient with inotropic therapy.  Patients were hospitalized 47 times for 
HF during the 3-month period prior to enrollment compared to 52 times after referral (p=NS). 
Furthermore, after adjusting for deaths, patients were hospitalized at a rate of .45 per month 
before enrollment compared to .66 per month after (p<0.05).    Annualized hospitalization rates 
averaged 5.4 hospitalizations per year in this study versus 3.2 hospitalizations per year in the 
study by Kornowski et al (Kornowski, Seely, et al., 1995), and approximately 2.7 
hospitalizations per year in a randomized study by Rich et al (Rich, Beckham, et al, 1995).  
 Despite the use of relatively costly services, no significant decrease in hospitalization 
rates was seen in this population (Wilson, Smith, Dahle, et al., 1999). Several potential reasons 
exist why this study, in contrast to previous studies, failed to demonstrate reduced hospitalization 
rates after home-care referral. First, the overall quality of home health care delivered to these 
patients was less consistent than in previous studies. For example, the present study used 18 
home health agencies with different protocols and nursing staff with varying levels of expertise. 
In contrast, Kornowski (Kornowski, Seely, et al., 1995), Rich et al. (Rich, Beckham, Wittenberg, 
et al., 1995), Stewart et al. (Stewart, Pearson, Horowitz, 1998), and Knox and Mischke (1999) 
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used a single agency of home health care nurses who delivered care using standard protocols. 
However, the authors argue that the type of protocol used in the present study more likely 
reflects actual clinical practices in the United States, as most clinicians are compelled to work 
with a diverse group of home health agencies (Wilson, Smith, Dahle, et al., 1999).  
Constantini et al. (2001) assembled a disease management team to achieve goals of 
adhering to nationally published guidelines (Task Force of the Working Group on HF, 1997) for 
care of patients with HF, and of identifying opportunities to improve quality & efficiency of 
hospitalized HF patients (Constantini, Huck, Carlson, et al., 2001). Hospital length of stay, total 
costs, and use of recommended guidelines were compared between 173 patients before team 
implementation but with available guidelines, 283 care managed patients, and 126 concurrent 
non-care managed patients. The nurse provided patient education, assessed discharge needs, 
evaluated the patient’s ability to comply with a prescribed plan, and recorded daily responses to 
medical treatment. Based on individual responses, the nurse or cardiologist modified the 
treatment plan as necessary. Patients were referred as needed to ancillary services such as 
physical therapy, social services, and dietary and substance abuse counseling. Results revealed 
that care-managed patients achieved higher rates of ACE-inhibitor use than baseline or non care 
managed  patients (95%, 60%, & 75%, respectively; p<0.001), as well as increased adherence to 
guidelines for daily weight monitoring and assessment of LV function. Hospital length of stay 
was lower (median 3,4, & 5 days, respectively; p<0.001) as were costs of hospitalization 
(median, $2934, $3209, & $4830, respectively; p<0.01). These results clearly indicate the 
importance for physicians to strictly follow the available guidelines for the management of these 
patients (Constantini, Huck, Carlson, et al., 2001). 
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Hershberger et al. (2001) described a program of extensive telemanagement, preemptive 
hospitalization for decompensated patients, continuity of care from inpatient to outpatient, and 
implementation of effective therapy as defined by consensus statements (Konstam, Dracup, 
Baker, et al., 1994; Williams, Bristow, Fowler, et al., 1995; Packer, Cohn, et al., 1999). One 
hundred eight patients with HF were enrolled in the university-based outpatient HF management 
program (Hershberger, Hanyu, Nauman, et al., 2001). Average age of the participants was 52 
+12 years, 73% male, and 87% were white. Nurse coordinators contacted patients weekly or 
biweekly for 4 to 6 weeks for close symptom surveillance & adherence to medical regimens. 
Telephone follow-up was estimated at 20 to 30 minutes per patient per month for the first three 
months, 5 to 10 minutes per patient per month thereafter. The total outpatient visits were 361, 
with an average of 3.3 per patient during the 6 months of follow-up. Although patients were seen 
collaboratively, each clinic patient encounter was discussed briefly with the group of 2-4 
cardiologists, 4-5 nurses, and social worker to provide comprehensive ongoing knowledge of 
each patient’s status. Educational topics included sodium restriction, pharmacological therapy, 
warning symptoms of adverse medical interactions and HF progression, behavioral techniques 
for improving adherence to dietary and medical therapy, and guidelines of when to notify a nurse 
of a change in condition. Additionally, patients were given a brochure with information on 
sodium restriction, physical activity, smoking cessation, self-monitoring of drug related 
symptoms, and daily monitoring of symptoms and weight. Furthermore, nurses assessed 
knowledge of HF and care, QOL, confidence to control symptoms, and health habits.  
Compared with 6 months before referral, the intervention was accompanied by a 52% 
reduction in risk of hospitalization for CV causes (56.1% vs. 27.2%,p<.001) and a 72% reduction 
in ER visits for CV causes (53.6% vs. 14.5%, p<.01). Total hospital admissions decreased by 
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59% from 94 to 39; whereas, total ER visits decreased from 83 to 19, a difference of 77%. QOL 
scores improved over time with a change score of 11.2 (p<.001) at 3 months & 10.7 (p<.001) at 
6 months. Finally, the proportion of patients with NYHA class III-IV decreased from 67% at 
baseline to 49.1% at 6 months (p=0.01). 
This study was the first to examine the pre-and postprogram differences in patient 
knowledge of and adherence to self-care recommendations (Hershberger, Hanyu, Nauman, et al., 
2001). There was a significant improvement at 6 months after referral in the patients’ knowledge 
regarding daily weight monitoring, importance of restricting dietary salt intake, and contacting 
providers if experiencing a sudden weight change. The proportion of patients weighing 
themselves daily increased by 24% (p=0.02). Nevertheless, no changes were observed in self-
reported adherence to dietary salt restriction and medical dosage compliance. This finding 
suggests that an increase in knowledge is not necessarily accompanied by concomitant changes 
in self-care behaviors among patients with heart failure (Hershberger, Hanyu, Nauman, et al., 
2001). 
Holst et al. (2001) assessed the ability of a 6-month HF care management program 
including intensive education, and referral to a tailored exercise program to reduce readmissions 
and improve quality of life and functional status in 42 outpatients with class III-IV HF. Average 
age of the population was 54+12 and 75% were male. The program consisted of an initial 1-hour 
consultation with a cardiologist and a 30 min introductory session with a study nurse to establish 
communication for subsequent management coordination.   All patients later attended a 2-hour 
education session for partners and families, which was predominately a group session, but done 
on an individual basis if required. Similar to the study by Knox and Mischke (1999), patients 
were encouraged to take an active role and follow an action plan with instruction to seek medical 
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care if symptoms worsened (Holst, Kaye, Richardson, et al., 2001). Purpose of education was to 
improve patients’ understanding of HF, stressing warning signs & symptoms of deterioration. 
Additionally, Patients received advice from a dietician regarding diet, fluid, & sodium 
management, daily weights, and instructions on diuretic adjustment. Medication advice was also 
outlined, with a goal to optimize use of ACE inhibitors and beta-blockers. Moreover, Patients 
attended an exercise program 2-3x/week for 8 weeks, which was part of an existing cardiac 
rehabilitation service. Exercise components included walking, biking, rowing, stepping, weight 
resistance training, calisthenics, and work and activity conditioning. Patients completed 3 
sessions at each attendance, and exercised at an intensity of 50-60% of HR max, a max breathing 
frequency of 24/min, and a Borg rating of 9-12 for RPE. Furthermore, patients were encouraged 
to maintain a home program of daily walking for 10-30 min, with aim for total exercise per day 
of 30-60 min, 5-7 days per week.  Patients attended the clinic an average of 3.4 times over the 6 
month period, with an average of 4 phone contacts during the first month and 1 per month for the 
remainder of follow-up. 
 Compared with the 6 month period prior to enrollment, hospital admissions difference of 
87.2%. Additionally, visits to the general practitioner declined from 1.94+2.22 to 0.69+1.28 
visits per patient (p=.006). Dosages of ACE-inhibitors and beta-blockers administered increased 
by 42% (p<.0008) and 61% (p<.0001), respectively. Moreover, NYHA functional class 
improved from 3.1+.35 to 1.8+.82 (p<0.0001) and exercise capacity, as assessed by the 6MW, 
improved from 413+117m to 496+93.2m (p<0.0001). Furthermore, data revealed significant 
improvements in LVEF, cardiac depression scale, and QOL. The program resulted in an 
estimated cost savings of AUD $6198 per patient over a 6 month time frame (Holst, Kaye, 
Richardson, et al., 2001). 
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Also in 2001, Whellan and colleagues (2001) used a strategy of physician-supervised but 
nurse-mediated heart failure management, incorporating specific concepts from previously 
described disease management programs (Fonarow, Stevenson, Walden, et al., 1997; 
Hanumanthu, Butler, Chomsky, et al., 1997; West, Miller, Parker, et al., 1997; and Shah, Der, 
Ruggerio, et al., 1998). 117 patients with heart failure were followed in a tertiary setting for a 
median of 4.9 months. The median age of participants was 62 years, 55% were white and 62% 
male.  50% of the patients were in NYHA Class III or IV, with a median LVEF of 23% 
(Whellan, Gaulden, Gattis, et al., 2001). Nurses directed the implementation of consensus 
guidelines (Konstam, Dracup, Baker, et al., 1994; Williams, Bristow, Rowler, et al., 1995; Heart 
Failure Society of America, 1999) to maximize vasodilator dosage, reduce dietary salt intake, 
monitor patients for early evidence of worsening heart failure, and provide patient support and 
education by frequent telephone contact (Whellan, Gaulden, Gattis, et al., 2001). The group 
developed a patient education manual that reviewed topics such as medication purpose, 
importance of adherence, potential adverse effects and appropriate actions to take should adverse 
effects occur, diet, weight monitoring, physical activity, and resources available to HF patients. 
The manual also included a diary for diet and daily weights. Inpatients were provided with a 
consultation and a patient education manual and were contacted within 1 week after discharge. 
Frequency of follow-up was based on clinical stability and severity of illness and could be 
adjusted by the physician as needed. NYHA Class IV patients received weekly clinic visits for 
the first month and weekly telephone calls for the first 3 months; whereas, clinic visits for 
NYHA Class II-III patients were scheduled every 6 weeks with biweekly telephone calls.  
Data collection was performed at 3-month intervals and compared to equivalent periods 
preceding enrollment. Primary outcome measures were medication use and resource utilization. 
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Results revealed that use of ACE inhibitors was high and did not change; however, there was a 
50% increase in target dose (p<.01).  Beta-blocker use and dose significantly increased from 
52% to 76%, (p<.01) and from 6% to 25%, (p<.01), respectively. Additionally, hospitalization 
rate decreased from 1.5 to 0 per patient-year (p<.01), while the number of clinic visits 
significantly increased from 4.3 to 9.8 clinic visits per patient-year (p<.01). Finally, the total cost 
of care decreased by a median of $8571 per patient-year, excluding the cost of providing the 
program and any costs incurred by the patient such as transportation.   
Todero et al. (2002) examined symptom occurrence, symptom characteristics, and quality 
of life in 102 elderly patients recently hospitalized following an acute HF exacerbation. Nurses 
visited each patient in their home at baseline, approximately 1 month after hospital discharge, 
and again 2 months later to collect study data. At baseline all participants were shown a patient 
educational video and were given an educational manual for reference. The program content was 
derived from AHCPR clinical guidelines (Konstam, Dracup, Baker, et al., 1994) and included 
routine reminders to monitor symptoms, with suggestions for symptom management (Todero, 
LaFramboise, & Zimmerman, 2002). Patients received follow-up and further education 
reminding them when to take medications, weigh daily, reduce dietary sodium, get routine 
exercise, & manage worsening symptoms by 1 of 4 methods: Health Buddy, phone calls, home 
visits, or combination of home visits and health buddy. Phone and home visit educational 
counseling sessions were scheduled approximately weekly over 5-6 weeks until all topics were 
discussed. The health buddy assessed patient status and provided information in smaller 
segments daily.  A preliminary analysis revealed no differences based on method of follow-up; 
therefore, data were combined for the analyses.   Results revealed significant improvements in 
QOL as assessed by RP, BP, MH, & VT subscales of the SF-36 questionnaire, with trends 
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toward improvement in PF & GH subscales. The occurrence of all symptoms was less at 2 
months, with the exception of shortness of breath, which persisted. Although participants still 
reported shortness of breath as the most common symptom, it was less frequent, less severe, and 
caused less interference with activity and enjoyment. These data provide information on the most 
common and distressing symptoms in a community-based HF population. This information may 
be useful in guiding assessments and designing specific interventions to include in a home-based 
disease management program. Furthermore, results suggest that a home-based disease 
management program implemented in a variety of ways can improve symptom status and quality 
of life in heart failure patients after discharge from the hospital (Todero, LaFramboise, & 
Zimmerman, 2002).   
In summary, the available evidence regarding the efficacy of the multidisciplinary 
programs for patients with heart failure is extensive spanning approx 2 decades, across the globe, 
and across various stages of the disease. These observational studies suggest that a 
multidisciplinary approach to HF disease management may be associated with important clinical 
benefits, including fewer readmissions and hospital days, improved quality of life and patient 
satisfaction, increased exercise tolerance, and a reduction in cost of care. However, these data are 
limited by the facts that the studies were nonrandomized (and therefore lacked a suitable control 
group) and that the before-after comparison with respect to readmissions may have 
overestimated the magnitude of benefit, as well as the potential cost savings. Furthermore, 
because few of the studies were blinded, the data on quality of life, exercise tolerance, and 
patient satisfaction may be confounded by the patient’s desire to please the health care provider, 
by a learning effect, or other patient or observer biases. Therefore, although the observational 
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data are encouraging, they are by no means definitive, and they require confirmation by carefully 
conducted randomized trials.  
Randomized Studies  
At present, sixteen randomized trials regarding the management of heart failure have 
been conducted. Despite the fact that few trials are similar in design, duration of study, or 
consistency of the multidisciplinary team, a clear consensus emerges following the review of 
results. The randomized trials are further summarized in Tables IX-XI. 
The first randomized trial to examine the efficacy of a multidisciplinary program was 
conducted by Rich et al. (1993), and was a prospective randomized pilot study designed to 
evaluate a nurse-directed multidisciplinary management strategy in elderly patients hospitalized 
with heart failure (Rich Vinson, Sperry, et al., 1993). The average age of participants was 79+6 
years, 41% were men and 50% were nonwhite. Participants were randomized in a 2:1 ratio to 
traditional care supplemented by a nurse-directed multidisciplinary team (n=63) or traditional 
care as determined by the patient’s usual physician (n=35). The intervention included 
comprehensive patient education by a geriatric cardiovascular nurse, a review of medications 
with recommendations to reduce side effects and improve compliance, individualized dietary 
instruction by a registered dietician, social services consultation to facilitate discharge planning 
and aid in the transition to the home environment, and close follow-up after discharge by a home 
health nurse and the study team. Participants were followed for 90 days and primary endpoints 
were all-cause readmissions and the number of days hospitalized during follow-up. Readmission 
rates in the intervention group and control group were 33.3% and 45.7%, respectively, reflecting 
a difference of 27.1% in favor of the intervention. Additionally, the intervention group spent an 
average of 4.3 days in the hospital compared with 5.7 days in the control group, an absolute 
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difference of 1.4 days per patient. Although encouraging, none of these differences were 
statistically significant. The authors concluded that further investigation in a larger trial was 
warranted, and that an appropriate cost analysis should be incorporated into such a trial (Rich, 
Vinson, Sperry, et al., 1993).   
 In 1994, Kostis et al. (1994) conducted a small, randomized trial involving 20 patients 
with heart failure. All but one participant was in NYHA Functional Class II, and all were 
receiving ACE-inhibitors. Participants were randomly assigned to one of three groups: 
nonpharmacologic treatment (n=7), digoxin (n=7), or placebo (n=6). Nonpharmacologic 
treatment included exercise training, cognitive therapy, stress management, and dietary 
instruction aimed at weight control and salt reduction. After 12 weeks, patients randomized to 
nonpharmacologic therapy experienced significantly greater improvements in exercise tolerance, 
anxiety and depression scores, and weight control when compared with the digoxin and placebo 
groups. These benefits occurred despite the fact that ejection fraction increased with digoxin use 
but was unchanged in the other two groups (Kostis, Rosen, Cosgrove, et al., 1994).  
Based on findings from his previous study (Rich, Vinson, Sperry, et al., 1993), Rich and 
coworkers (1995) performed a controlled trial of a nurse-directed, care management program to 
determine readmission rates within 90 days of hospital discharge, quality of life, and costs of 
care for high-risk elderly patients hospitalized with HF (Rich, Beckham, Wittenberg, et al., 
1995). A total of 282 HF patients in an urban tertiary center who were at high risk of hospital 
readmission were randomly assigned to one of two groups: 1) conventional physician-directed 
care (n=140), or 2) conventional care supplemented by a nurse-directed multidisciplinary team 
(n=142). The study intervention was similar to their pilot study (Rich et al., 1993) and included 
intensive patient education prior to discharge, which was reinforced during frequent and regular 
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contacts by a home health representative and the study team. The intervention continued for 90 
days following discharge, and during this period all-cause readmissions were reduced 44%, heart 
failure readmissions were reduced 56%, readmissions for other reasons were reduced 29%, and 
the proportion of patients requiring multiple readmissions was 61% lower in the intervention 
group (Rich, Beckham, Wittenberg, 1995). Additionally, patients receiving the study 
intervention reported improved quality of life, enhanced compliance with medications and diet, 
and a greater knowledge of the heart failure syndrome (Rich, Beckham, Wittenberg, 1995). The 
monetary savings associated with fewer hospitalizations offset the costs of the program, resulting 
in an average reduction in medical costs of $460 per patient during the 3-month study. 
Importantly, during an additional 9-month post intervention follow-up period, heart failure 
readmissions remained 29% lower in the intervention group, suggesting a persistent beneficial 
effect of the program and implying additional cost savings.  
 Weinberger et al. (1996) described a program of intensive primary care during and 
immediately following hospital discharge among 1,396 severely ill veterans with CHF, diabetes, 
chronic obstructive pulmonary disease or more than one of the three diagnoses (Weinberger, 
Oddone, & Henderson, et al., 1996).  Six hundred ninety five patients were randomized to the 
intervention, which involved close follow-up by a nurse and a primary care physician, beginning 
prior to discharge and continuing for six months, while the remaining 701 patients received usual 
care. Primary outcome measures were readmissions and secondary outcomes included quality of 
life and patient satisfaction with care. The average age of study participants was sixty-three 
years, 99% were male, and 65% were white. Of the 504 patients with HF, 51% were in Class III 
or IV. During the 6-month follow-up period, patients in the intervention group had significantly 
higher rates of readmission per month than those in the control group, 0.19 vs 0.14, respectively. 
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Additionally, total days of re-hospitalization were significantly higher in the intervention group 
when compared with controls 10.2 vs. 8.8, respectively.  Although patients in the intervention 
group reported improved satisfaction with care, there were no differences between groups in 
quality of life scores, which remained very low. The results were similar regardless of the 
patient’s primary diagnosis. 
 These findings appear to challenge results from previous studies. There are several 
possible explanations for the inconsistencies. First, the design is different from that used in other 
studies. For example, the intervention merely provided increased access to healthcare, rather than 
represented a "disease management program". Second, in most cases, the primary care physician 
only had a single contact with the patient before hospital discharge, thereby prohibiting the 
establishment of an effective physician-patient relationship. Moreover, there was inadequate 
opportunity to perform a complete evaluation of the patient and optimize treatment during the 
initial hospitalization.  Lastly, the intervention was not disease specific and did not provide any 
kind of algorithm or systematic approach to the treatment of heart failure exacerbations. These 
results imply that providing increased access to healthcare without providing an improved 
structure or algorithm for healthcare delivery is unlikely to enhance outcomes. 
 Three additional trials (Stewart, Pearson, & Horowitz, 1998; Cline, Israelsson, 
Willenheimer, et al., 1998; Serxner, Miyaki, & Jeffords, 1998) were published in 1998 that 
contradicted the findings of the previous study (Weinberger, Oddone, & Henderson, 1998), but 
supported the findings of Rich (1995). In the first study, Stewart et al. (1998) randomly assigned 
ninety-seven elderly patients admitted for heart failure to standard care after discharge (n=48) or 
a home-based intervention (n=49) (Stewart, Pearson, Horowitz, 1998). The intervention was 
unique in that it comprised a single home visit one week after discharge by either a nurse or a 
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pharmacist. The purpose of the visit was to optimize medication management, identify early 
clinical decompensation, and intensify medical follow up and caregiver vigilance as appropriate. 
The average age of the participants was 75 years and 50% of the patients were women. All 
patients had at least one prior hospitalization for heart failure, and all but 6 patients were in 
NYHA Functional Class II (n=48) or III (n=43). The primary end point of the study was the 
frequency of unplanned readmission plus out of hospital death within 6 months of discharge. 
Results revealed that patients randomized to the home based intervention had 42.3% fewer 
unplanned readmissions (36 vs 63; p=0.03) and 45.1% fewer out-of-hospital deaths. 
Additionally, home-based intervention patients also had 43% fewer days of hospitalization (261 
vs 452; p=0.05) and fewer multiple (>3) readmissions for HF during follow-up (0 vs 5 patients; 
p=0.02).  Furthermore, hospital costs averaged $3,200 per patient in the intervention group 
compared with $5,400 in the control group, a nonsignificant reduction of 40.7%. The estimated 
cost of the study intervention was $190 Australian dollars. Outpatient medical costs did not 
differ between groups. 
 This study (Stewart, Pearson, Horowitz, 1998) should be compared with two previously 
reported, randomized controlled investigations (Weinberger, Oddone, & Henderson, 1996; Rich, 
Beckham, Wittenberg, et al., 1995). In one of these studies, broad interventions (increased access 
to outpatient primary care) yielded unfavorable results in relation to extent and duration of 
readmissions (Weinberger, Oddone, & Henderson, 1996). In the other study, however, use of a 
similar but more intensive intervention specific to management of HF was associated with a 
significant increase in the time to first readmission or out-of-hospital death at 3 months after 
discharge (Rich, Beckham, Wittenberg, et al., 1995). As with this study (Stewart, Pearson, 
Horowitz, 1998), the difference between groups was largely mediated by fewer multiple 
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readmissions among patients exposed to the nurse-directed home-based intervention (Rich, 
Beckham, Wittenberg, et al., 1995).  
In another report, Cline and coworkers (1998) add further evidence in favor of a nurse-
led multidisciplinary intervention following hospitalization due to HF (Cline, Israelsson, 
Willenheimer, et al., 1998). The unique aspect of this program was that families also received 
education about the HF syndrome. One hundred ninety patients with HF were randomized by 
computer-generated allocation to the intervention group (n=56) or usual care (n=76) to evaluate 
the efficacy of a HF management program on hospitalization and health care costs one year after 
admission for heart failure. The intervention group and their families received education about 
heart failure and self-management, with follow-up at an easy access, nurse directed outpatient 
clinic for one year after discharge. The control group was managed according to routine clinical 
practice. The education program consisted of two thirty-minute information visits by a nurse 
during hospitalization and a one-hour information visit for patients and families two weeks after 
discharge. There was only one prescheduled clinic visit at 8 months after hospital discharge. 
However, the nurse was available by telephone during clinic hours and was able to see patients at 
short notice. Adherence to prescribed medication was emphasized and patients received 
guidelines for self-management of diuretics. The control group was followed up at the outpatient 
clinic by either cardiologists in private practice or by primary care physicians. One-year 
mortality did not differ between groups. Time to first readmission over the same period however 
was 33% longer in the intervention group (106 vs 141 days; p<0.05), with 49% fewer total days 
of hospitalization (8.2 vs 4.2; p=0.07). Furthermore, there was a trend toward a mean annual 
reduction in healthcare costs per patient of US $1300 in the intervention group compared with 
costs in the controls (US$2294 vs 3594; p=0.07). It should be noted that this study recruited 
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patients with a much lower rate of readmission than those in the previous two studies (Rich, 
Beckham, Wittenberg, et al., 1995; Stewart, Pearson, Horowitz, 1998). 
In a third report, Serxner et al. (1998) reported findings of a study involving 109 patients 
randomized to an educational mailing intervention (n=55) or standard care (n=54) after 
hospitalization for heart failure. The intervention was designed to encourage self-management 
and consisted of a series of mailings at 3 to 4 week intervals that contained a personalized letter 
and a variety of educational materials (booklets, brochures, fact sheets, resource guides, and a 
video), as well as compliance aids (medication sheets and a weight chart). Interviews were 
conducted before and after the three-month intervention to assess compliance and quality of life, 
and readmissions were monitored for 6 months. The average age of the participants was 71 
years, and 52% were women. Results indicated that 27% of the patients in the intervention group 
were readmitted at least once during the 6-month follow-up period compared with 50% of the 
patients in the control group (p=0.025). Moreover, multiple readmissions were more common in 
the control group, and the study intervention resulted in 52% fewer total readmissions (43 vs. 21 
readmissions; p<0.01). Additionally, individuals receiving the study intervention reported better 
overall health status, greater confidence in self-management, and enhanced compliance with diet, 
medications, and weight monitoring as compared to control group patients. Furthermore, the 
investigators reported that although the cost of the education program was $50 per patient, the 
intervention reduced overall costs, and there was a net return on investment of $8:$1 for the 
hospital and $19:$1 for third party payers (Serxner, Miyaki, & Jeffords, 1998). 
 In 1998, Ekman and colleagues evaluated the feasibility of a nurse-monitored, outpatient 
care program for elderly patients (mean age = 80 years) previously hospitalized with moderate to 
severe HF (Ekman, Andersson, Ehnfors, et al., 1998). Upon hospital discharge, one hundred fifty 
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eight patients with NYHA class III-IV HF were randomized to the structured-care intervention 
(n=79) or standard care (n=79). The structured care program followed established guidelines for 
medical treatment and principles for care of the patients were based on previously documented 
experiences (Konstam, Dracup, Baker, et al., 1994; Dracup, Baker, Dunbar, et al., 1994; Rich, 
Vinson, Sperry, et al., 1993). The main goal of the intervention was that patients would learn to 
recognize and monitor symptoms of deterioration and be familiar with effects and side effects of 
the medication they had been prescribed (Ekman, Andersson, Ehnfors, et al., 1998). Patients 
were instructed to call the nurse if worsening symptoms occurred or if they had questions 
pertaining to their illness. The nurse was available by beeper during business hours; however, an 
attending doctor was responsible for medical decisions. Each patient was contacted a week after 
hospital discharge and offered a visit to the clinic, together with a caregiver. In addition to clinic 
visits, nurses regularly contacted patients by telephone to follow-up discussions concerning 
medication, weight, diet, or questions raised by the patient’s apprehension of the illness. During 
the six month follow-up period, the median number of telephone contacts was four calls per 
patient. Twenty-two (28%) patients and eighteen (23%) relatives or caregivers made spontaneous 
telephone contacts; whereas, seven patients (9%) made spontaneous clinic visits due to 
decompensation, leading to acute admissions. Among the seventy-nine patients randomized to 
the structured care group, 23 patients (29%) never visited the nurse and this was explained by 
death (11 patients), fatigue or unwillingness (11 patients), and institutional care (1 patient). 
Patients who never visited the nurse showed the following characteristics at entry: female sex, 
advanced age, and need of assistance at home.  
 Results of the structured-care program did not demonstrate any beneficial effect on the 
number of readmissions and hospital days. If anything, structured care tended to be associated 
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with an increase in hospital days (mean difference in hospital days was 8 days; p=0.29). 
Interestingly, these results are in agreement with a previously discussed study, which 
demonstrated that structured management, with increased access to primary care after hospital 
discharge, was associated with an increased rate of hospitalizations in severely ill patients 
(Weinberger, Oddone, & Henderson, 1996). One explanation for these results may be that 
structured care may lead to the detection of previously unrecognized medical problems, owing to 
improved communication between caregivers and patients as compared to conventional care. 
This, in combination with easier access to inpatient care, may increase readmission rates. The 
authors concluded that the outpatient, nurse-monitored symptom management program was not 
feasible for the majority of these elderly patients with moderate to severe HF, mainly because of 
the small proportion of eligible patients and the high dropout rate (Ekman, Andersson, Ehnfors, 
et al., 1998). Furthermore, management of these patients may have to be more individualized and 
adjusted to the patient’s home situation. 
Based on previous studies, it can be expected that patients who are able to care for 
themselves effectively will encounter fewer problems leading to rehospitalizations or 
unnecessary visits to the emergency department (Happ, Naylor, Roe-Prior, 1997; Rich, Gray, 
Beckham, et al., 1996; Rich, Beckham, Wittenberg, et al., 1995; Vinson, Rich, Sperry, et al., 
1990; Gooding & Jette, 1985). However, some authors argue that because of increased access to 
care and increased knowledge about the illness, it is also possible that education and support 
leads to an increase in health care resource use (Weinberger, Oddone, & Henderson, 1996; 
Ekman, Andersson, Ehnfors, et al., 1998). In various multi-faceted interventions, education is an 
important aspect of the intervention, such as the availability of a heart failure clinic or a heart 
failure team (Ekman, Andersson, Ehnfors, et al., 1998; Rich, Beckham, Wittenberg, 1995; 
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Fonarow, Stevenson, Walden, et al., 1997), The specific contribution of education and support 
alone to such programs is seldom isolated. Therefore, Jaarsma and colleagues (1999) conducted 
a trial to determine the effect of patient education and support by a nurse on self-care and 
resource utilization in patients with severe HF (Jaarsma, Halfens, Huijer, et. al., 1999). 
A total of one hundred seventy nine patients hospitalized with NYHA class III-IV HF 
were randomized to a nurse-led educational intervention (n=84) or to usual care (n=95) (Jaarsma, 
Halfens, Huijer, et. al., 1999). The average age of participants was seventy-three years and fifty-
eight percent were male. The supportive education intervention consisted of intensive, systematic 
and planned education by a study nurse about the consequences of heart failure in daily life, 
using a standard nursing care plan developed by the researchers for older patients with heart 
failure (Jaarsma, Halfens, Huijer, et. al., 1999). Education took place over a ten-day period, 
beginning in the hospital and continuing through a home visit within a week of discharge; 
however, all patients were followed for nine months.  An investigator telephoned the patients one 
month after discharge and visited the patient at three months and nine months after discharge for 
data collection. Data were collected on self-care abilities, self-care behaviors, readmissions, 
visits to the emergency heart center, and use of other health care resources.  
No statistically significant differences were found between the two groups in self-care 
abilities. The supportive educational intervention was effective, however, in enhancing self-care 
behavior after discharge. On average, patients were compliant with nine of nineteen items of 
self-care behavior at baseline. As can be expected, the effects of the intervention were most 
powerful on short-term behavior, which is reflected in significant differences in self-care 
behavior between the two groups both at one month and at three months after discharge (14 vs 
12; t=3.8, p=0.001, and 12.2 vs 10.6; t=2.9; p=0.05, respectively). Both control and intervention 
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patients decreased self-care behavior over time; however, the intervention patients still reported 
complying with more behaviors than control patients at nine months (11.2 vs. 10.3; 
t=1.6;p=0.11). Although the difference between groups at nine months was not statistically 
significant, the increase from baseline remained substantially significant in the intervention 
group, but not in the control group. No significant effects on resource utilization were found. The 
authors concluded that education and support from a nurse in a hospital setting and at home can 
significantly increase self-care behavior in patients with severe HF (Jaarsma, Halfens, Huijer, et. 
al., 1999). The decrease in self-care behaviors over time suggests that although patient self-
management should play an important role in care management strategy, the study design should 
ensure concomitant outpatient supervision and enforcement of education to achieve success. 
Additionally, it can be expected that certain aspects, for example those relating to adapting 
activities, may not be affected by education and support. The data indicated that, due to their 
poor physical behavior, most patients already rested during the day, spread activities throughout 
the day, and decreased activities when needed, (Jaarsma, Halfens, Huijer, et. al., 1999). 
Therefore, interventions that encourage regular exercise at the patient’s own pace may be 
needed, because it has been shown that exercise can improve functional capacity and attitudes 
(McKelvie, Teo, Roberts, et al., 2002). 
 Jerant and colleagues (2001) compared the effectiveness of three hospital discharge care 
models for reducing CHF-related hospital readmission costs: 1) home telecare delivered via a 2-
way video-conference device with an integrated electronic stethoscope (n=13); 2) telephone 
follow-up (n=12), and 3) usual outpatient care (n=12) (Jerant, Azari, & Nesbitt, 2001). Prior to 
hospital discharge, thirty-seven patients were randomized to one of the three care models using 
sealed envelopes containing randomly generated numbers and were followed for one year. 
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Patients assigned to telephone care received scheduled phone calls from the study nurse in the 
intervening period, whereas, those assigned to the video-based telecare group received scheduled 
home telecare visits. For urgent questions or problems, the groups in telecare and telephone 
groups had access to nurse via the medium appropriate to their group assignment. Patients in all 
groups received a home nursing visit shortly after discharge and a second home nursing visit 
approximately sixty days later, during which subjects completed the SF-36 questionnaire (Ware 
& Sherbourne, 1992) and the Minnesota Living with HF questionnaire (Rector & Cohn, 1992). 
Additionally, during all in-person, telecare, and telephone encounters, the study nurse assessed 
signs and symptoms, activities of daily living, medication use, and dietary factors, provided 
education, and developed patient-centered goals for the frequency and content of follow-up visits 
(Jerant, Azari, & Nesbitt, 2001). Furthermore, a set of algorithms were drawn from national 
consensus recommendations to help the study nurse better determine the adequacy of HF drug 
regimens (Advisory Council to Improve Outcomes Nationwide in HF, 1999). Patients 
randomized to usual care received only the care directed by their primary care physicians in the 
period between in-person nursing visits (Jerant, Azari, & Nesbitt, 2001). The primary outcome 
measure was HF-readmission charges during a 6-month period after randomization.  
Ninety-two telecare encounters (76%) were limited by at least one technical problem. 
Video problems were judged to be severe in only five encounters (4%) and heart and lung sound 
resolution was inadequate in only two encounters (2%). Mean HF-readmission charges were 
86% lower in the telecare group ($5,850+$21,094) and 84% lower in the telephone group 
$7,320+$24,440) as compared to the usual care group ($44,479+$121,214). However, the 
between-group difference was not statistically significant (P=0.262). Both the intervention 
groups had significantly fewer HF-related emergency department visits (P=0.0342) and charges 
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(P=0.0487) than the usual care group. Trends favoring both interventions were noted for all other 
utilization outcomes.  
Based on these results, video-based home telecare does not appear to offer incremental benefits 
beyond telephone follow-up in reducing frequent hospital readmissions and emergency 
department visits for patients with HF (Jerant, Azari, & Nesbitt, 2001). More importantly, these 
data imply that deployment of distance technologies, such as telephone follow-up, to provide 
post-hospitalization monitoring could yield substantial reductions in hospital readmissions, 
emergency visits, and costs of care in select patients with HF.  
 In 2002, Doughty and coworkers examined the effect of an integrated heart failure 
management program on quality of life and hospital readmissions in patients with NYHA class 
III-IV HF (Doughty, Wright, Pearl, et al., 2002). The aim of this study was close liaison between 
patient, family, general practitioner (GP), and the hospital-based heart failure clinic. One 
hundred and ninety seven patients admitted to Auckland Hospital with an exacerbation of HF 
were enrolled in the study. Participants were randomized to the intervention group (n=100 
patients, 64 GPs) or usual care (n=97 patients, 68 GPs) using the general practitioner as the unit 
of randomization. The intervention consisted of an evaluation and an individual education 
session with the nurse within two weeks of hospital discharge. Subsequently, two group 
educational sessions (each lasting 1.5 to 2 hours) were offered within six weeks of hospital 
discharge, and a third session after 6 months. These sessions were led by a cardiologist and a 
study nurse, and content was based on current HF guidelines (Konstam, Dracup, et al., 1994).  
Each patient was given a diary for recording medication information and daily weights, and a 
follow-up plan was devised for each patient aiming for 6 weekly visits alternating between the 
GP and heart failure clinic (Doughty, Wright, Pearl, et al., 2002). A letter was faxed to the GP on 
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the same day patient visited the HF clinic to document any changes in the management plan. 
Patients randomized to usual care continued under standard care of the GP with additional 
follow-up measures as recommended by the inpatient medical team. 
Patients in the intervention group attended the HF clinic an average of four times during 
the twelve-month follow-up period. Sixty percent of the intervention group attended the first 
group education session, and forty percent attended the six-month session. The main effect of the 
intervention was attributable to the prevention of multiple readmissions. Although first 
readmissions for all causes were similar in intervention and control groups (64 vs 59, 
respectively), subsequent all-cause readmissions were fewer in the intervention group compared 
with the control group (56 vs 95, respectively, 2p=0.015) with an associated reduction in bed 
days. Additionally, the Minnesota Living with Heart Failure scores showed markedly impaired 
quality of life at baseline, with mean physical functioning and emotional scores of 25.6+12 and 
10+7, respectively. The physical dimension of quality of life showed a greater improvement in 
the intervention group from baseline to twelve months compared with the control group (-11.1 vs 
–5.8, respectively; 2p=0.015); however, there was no significant change in the emotional score in 
either group (-3.3 vs –3.3, respectively; 2p=0.97).  
These results are in contrast to those previously discussed by Weinberger et al. (1996), 
who reported higher readmission rates in the intervention group as compared to controls (0.19 vs 
0.14 per month, p=0.005), implying that a disease-specific protocol of primary with specialist 
care, as in the current study (Doughty, Wright, Pearl, et al., 2001), may be important 
requirements for the success of such management programs. Additionally, Cline et al. (1998) 
reported only modest effects of a nurse-led hospital-based clinic for HF management, with an 
increase in the time to first readmission but only a trend to fewer hospital admissions in the 
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intervention. The study design by Cline et al. (1998) differed from this study (Doughty, Wright, 
Pearl, et al., 2001), as it did not involve a structured approach to integration between the patient 
and primary and secondary care. Therefore, these authors (Doughty, Wright, Pearl, et al., 2001) 
suggest that not only is it necessary to have a disease specific protocol, but also a structured, 
integrated approach between the patient and primary and secondary care.  
Previous studies have suggested that multidisciplinary disease management programs can 
substantially reduce the risk of readmission, with as much as a fifty-six percent reduction in HF 
readmissions and a forty-four percent reduction for all-cause readmission (Rich, Beckham, 
Wittenberg, et al., 1995). However, these interventions have generally included medical 
management components, and consequently, it is difficult to identify the critical factors 
responsible for success. Additionally, it has been suggested that behavioral factors such as 
noncompliance with medications and diet, and delay in seeking preventive care may contribute 
to readmissions and premature mortality (Dracup, Baker, Dunbar, et al., 1994; Happ, Naylor, 
Roe-Prior, 1997). Therefore, Krumholz and coworkers (2002) evaluated the effect of a formal 
education and support intervention on the rate of readmission or mortality, and hospital costs for 
patients with HF (Krumholz, Amatruda, Smith, et al., 2002).  
Eighty eight patients aged >50 admitted with HF to Yale-New Haven Hospital were 
enrolled in the study, and randomized to the intervention (n=44) or usual care (n=44). The 
intervention was designed to empower the patient and improve compliance, and occurred in two 
phases: 1) the initial phase, and 2) the telemonitoring phase. The initial phase consisted of an 
initial educational session with a nurse within two weeks of hospital discharge using a teaching 
booklet. Home visits were performed for forty-five percent of the patients unable to travel to the 
hospital. Baseline meetings did not include clinical assessments or modification of treatment. 
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During the telemonitoring phase, a nurse contacted the patient by phone weekly for four weeks, 
then biweekly for eight weeks, and then monthly for a total intervention period of one year. The 
purpose of telephone contact was for education, not for modification of current regimens or to 
provide recommendations for treatment. 
The median age of the participants was 74 years; 57% were men and 74% were 
Caucasian. Among the eighty-eight participants in the study, twenty-five patients (56.8%) in the 
intervention group and thirty-six patients (81.8%) in the control group had at least one 
readmission or died during the one-year follow-up. Overall, there were 49 all-cause readmissions 
in the intervention group and 80 in the control group in the year following discharge (p=0.06), 
indicating a 39% reduction in readmissions. After adjusting for clinical and demographic 
characteristics, the intervention group had a significantly lower risk of readmission compared 
with the control group. Although the average cost of the intervention was $530 per patient, 
hospital readmission costs were higher in the control group by an average of $7,515 per patient 
(p=0.02), yielding an overall cost reduction of $6,985 per patient in the intervention group. 
Krumholz et al. (2002) extends previous work on disease management for patients with 
HF (Rich, Vinson, Sperry, et al., 1993; Rich, Beckham, Wittenberg, et al., 1995; Stewart, 
Pearson, Horowitz, 1998) by specifically evaluating the impact of education and support without 
medication management as an outcome for these patients. This intervention differs from other 
programs, as it focuses on enabling patients to take an active role in managing their illness based 
on knowledge and education rather than relying on physicians or nurses actively intervening to 
adjust medical care and regimens (Krumholz, Amatruda, Smith, et al., 2002). In comparison to 
work by Jaarsma and colleagues (1999), this study demonstrated that a brief education and 
support intervention by a nurse could increase self-care behaviors among patients who had been 
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hospitalized with HF (Krumholz, Amatruda, Smith, et al., 2002). However, unlike this study, the 
nurse in the Jaarsma study made a home visit to every patient and all of the intervention occurred 
within 10 days of discharge (Jaarsma, Halfens, Huijer Abu-Saad, et al., 1999). Furthermore, in 
contrast to this study, Jaarsma et al. (1999) found no significant change in resource utilization, 
although there were trends that favored the intervention group, indicating that a longer follow-up 
may be necessary. Although it was theorized that the outcomes were achieved through promotion 
of patient compliance and empowerment, this trial did not explicitly test the mechanism of 
intervention (Krumholz, Amatruda, Smith, et al., 2002). Future studies may explore the potential 
mechanisms for maximal benefits of education and support. 
The findings of a study by Kasper and coworkers (2002) extend the work of Rich et al. 
(1995) to a longer intervention period (six months vs. three months) and to a younger population 
(median age of sixty four years vs. seventy nine years). Additionally, Kasper et al. (2002) 
emphasized the involvement of the patient’s primary physician, as well as active initiation and 
titration of medications by nurses. The purpose of the study  was to determine whether an 
outpatient program designed to implement optimal medical therapy, increase patient 
understanding and compliance and reduce financial barriers to care, coupled with frequent 
telephone monitoring and clinic follow-up, could decrease mortality and hospital readmissions, 
as well as improve compliance and quality of life, at no extra cost in patients with HF (Kasper, 
Gerstenblith, Hefter, et al., 2002). Two hundred patients hospitalized with HF at increased risk 
for readmission were randomized to a six-month multidisciplinary program (n = 102) or usual 
care (n = 98). The median age of the study patients was sixty-four years, forty percent were 
women, and ninety four percent were in NYHA functional class II or III. A cardiologist and a HF 
nurse evaluated each patient and made recommendations to the patient’s primary physician 
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before randomization. It is important to note that primary-care physicians were not excluded 
from HF disease management, but rather were integrated into the team care of their patients. The 
intervention consisted of an algorithm designed by cardiologists according to available HF 
guidelines and clinical experience (Konstam, Baker, Dracup, et al., 1994; Williams, Bristow, 
Fowler, et al., 1995). Nurses adjusted medications according to the algorithm which also 
included a 2-g sodium restricted diet, as well as a recommendation to exercise by walking for 20 
min at least four days per week (Kasper, Gerstenblith, Hefter, et al., 2002). The treatment plan 
was individualized for each patient. All patients in the intervention group were provided a pill 
sorter, list of correct medications, list of dietary and physical activity recommendations, contact 
number available 24 hours per day, and patient education material. Additionally, patients with 
limited financial resources were provided, if needed, a scale, a 3-g sodium “meals on wheels” 
diet, medications, transportation to the clinic, and a telephone.  
Contact with the patient was on a prespecified schedule, and consisted of telephone 
follow-up and clinic visits. A telephone nurse coordinator made scheduled follow-up calls to 
patients within 72 hours of hospital discharge, then weekly for one month, twice in the second 
month, and monthly thereafter, unless a problem occurred that required more frequent contact. 
The telephone nurse followed a set script and pursued problems as clinically indicated, but did 
not adjust medications over the telephone. Patients had at least monthly clinic visits with a HF 
nurse; however, some visits occurred in the home. Patients in the control group were followed as 
usual. Data were collected at six months, and patients were followed for an additional three 
months. Telephone calls averaged 9.5 per patient, with duration of 16+9 min per call; whereas 
clinic visits averaged 8.5 per patient, and the average length of a visit by a HF nurse was 57+21 
minutes (Kasper, Gerstenblith, Hefter, et al., 2002).  There were 43 HF hospital admissions and 7 
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deaths in the intervention group, as compared with 59 HF admissions and 13 deaths in the 
control group (p=0.09). Additionally, dietary compliance was described to be good or average in 
patients in the intervention group vs the control group, based on a review of dietary history (65 
of 94 patients vs 38 of 85 patients, p=0.001). There was no difference, however, in medication 
compliance. Moreover, quality of life scores, as assessed by the Minnesota Living with Heart 
Failure Questionnaire (Rector & Cohn, 1992), and percentage of patients on target vasodilator 
therapy were significantly better in the intervention group. Finally, costs per patient in 1998 US 
dollars, were similar in both groups (Kasper, Gerstenblith, Hefter, et al., 2002).  
These results may not apply to all patients with HF, because the investigators specifically 
targeted patients thought to be at high risk for readmission. It is likely that not all patients require 
such an extensive intervention (Kasper, Gerstenblith, Hefter, et al., 2002). Additionally, the 
program was multidisciplinary in nature and not designed to analyze the relative contributions of 
its various components. Moreover, it is unclear from these data whether telephonic management 
alone results in a benefit (Kasper, Gerstenblith, Hefter, et al., 2002). Therefore, further research 
is needed to identify which of these components is essential and if a briefer, less intense 
intervention will be as effective in a HF patient population. 
Although previous studies evaluating the use of multidisciplinary care management have 
included telephone follow-up as a component of the intervention (Kasper, Gerstenblith, Hefter, 
et al., 2002), with the exception of Jerant et al. (2001), no studies have examined whether 
telephonic management alone results in improved outcomes in patients with HF. However, in the 
study by Jerant and colleagues (2001), patients also received a home nursing visit shortly after 
discharge and a second home nursing visit approximately sixty days later.  Therefore, Riegel et 
al. (2002) evaluated the effectiveness of a standardized telephonic care-management intervention 
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to decrease resource use in patients with chronic heart failure. Three hundred fifty-eight patients 
were identified at hospitalization and assigned to receive six months of intervention (n=130) or 
usual care (n=228) based on randomization of their physician. Outcome data were collected at 
three and six months. 
Nurses monitored, educated, and counseled patients by telephone in a standardized 
fashion guided by a computer program designed by clinical experts to support national 
guidelines for treatment of HF (Konstam, Dracup, Baker, 1994; Packer, Cohn, Abraham, 1999). 
The intervention group was telephoned within five days of hospital discharge and thereafter at a 
frequency guided by the software and case manager judgment based on patient symptoms, 
knowledge, and needs (Riegel, Carlson, Kopp, et al., 2002). During the calls, the nurses educated 
patients regarding such topics as medication adherence, diet recommendations, and identification 
of worsening signs and symptoms, with the goal of improving intermediary factors that would 
influence important outcomes such as hospitalization. Additionally, printed education material 
was mailed to patients monthly. Moreover, physicians were sent guidelines for the treatment of 
systolic HF with their first notification of patient progress (Konstam, Dracup, Baker, et al., 
1994), and automated progress reports produced by the software on a regular basis (Riegel, 
Carlson, Kopp, et al., 2002). Furthermore, physicians were notified of discrepancies between 
patients’ reports of medications and treatments vs. actual physician orders. Care for patients in 
the usual care group was not standardized and no formal telephonic case management was in 
existence. However, these patients presumably received some education regarding HF 
management prior to hospital discharge (Riegel, Carlson, Glaser, et al., 2002). 
 The overall sample was elderly (72+12 years), almost equally divided by sex (51% 
female), and functionally compromised (ninety-seven percent were NYHA class III or IV). The 
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only significant differences between groups on demographic or clinical descriptors were a higher 
use of beta-blockers and a lower incidence of chronic lung disease in the intervention group 
(Riegel, Carlson, Kopp, et al., 2002). Patients received an average of seventeen phone calls at 
decreasing levels of intensity, length, and frequency over the six month follow-up period 
(median, 14 calls; interquartile range, 11-22 calls). The HF hospitalization rate was 45.7% lower 
in the intervention group at three months (p= 0.03) and 47.8% lower at six months (p=0.01). 
Additionally, heart failure hospital days and multiple readmissions were significantly lower (both 
p=0.03) in the intervention group at six months. Furthermore, inpatient heart failure costs were 
45.5% lower at six months (p=0.04). A cost savings was realized even after intervention costs 
were deducted, and there was no evidence of cost shifting to the outpatient setting. Lastly, 
patients in the intervention group reported significantly higher satisfaction with care than those 
receiving usual care. 
 The reduction in hospitalizations, costs, and other resource use achieved using 
standardized telephonic case management in the early months after a heart failure admission is 
greater than that usually achieved with pharmaceutical therapy and comparable with other 
disease management approaches (The Heart Outcomes Prevention Evaluation Study 
Investigators, 2000; The Digitalis Investigation Group (1997). The authors (Riegel, Carlson, 
Kopp, 2002) suggest that the effectiveness of the approach may be a function of the intensity and 
focus of the intervention, standardization, patient characteristics, or an interaction of these 
factors. Further study is needed for a clear understanding of specific factors responsible for the 
improved outcomes (Riegel, Carlson, Kopp, 2002). 
McDonald, et al., (2002) addressed the question of whether multidisciplinary care of HF 
can reduce readmissions when optimal medical care is applied in both intervention and control 
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groups. Ninety eight patients (mean age, 71+11 years) admitted to the hospital with NYHA 
functional class IV HF were assigned to multidisciplinary care (n=51) or routine care (n=47). All 
patients received the same components of optimal inpatient medical care of HF, as defined by 
specialist-led inpatient care, titration to maximum tolerated dose of ACE inhibitor before 
discharge, and attainment of predetermined discharge criteria (symptomatically improved, 
weight stable, off all intravenous therapy, and no change in oral regimen for 2 days). 
Additionally, those in the multidisciplinary care group received nurse-led education and dietitian 
consults on three or more occasions during the index admission, followed by close follow-up for 
three months. Telephone follow-up occurred three days after discharge and weekly thereafter 
until twelve weeks.  Moreover, patients and their next of kin attended the HF clinic at weeks two 
and six. Education topics included daily weight monitoring, salt restriction, and disease and 
medication understanding. The primary study endpoint was re-hospitalization or death for a HF-
related issue at three months. At three months, four people (7.8%) had events in the 
multidisciplinary care group compared with twelve people (25.5%) in the routine care group 
(P=0.04). Additionally, readmission for HF was more frequent in the routine care group at 
25.5%, compared to 3.9% in the multidisciplinary care group. Furthermore, patients in the 
multidisciplinary care group exhibited a greater understanding of HF, medications, and 
importance of sodium restriction upon hospital discharge as compared to the routine care group. 
The superior knowledge noted at discharge was sustained at 3 months. 
These data demonstrate for the first time the intrinsic benefit of multidisciplinary care in 
the setting of protocol-driven, optimal medical management of HF (McDonald, Ledwidge, 
Cahill, et al., 2002). Moreover, the event rate of 7.8% at three months as the lowest reported rate 
  
 
 
224
of such a high-risk group, underlines the value of an integrated inpatient and outpatient 
multidisciplinary approach to the management of HF. 
Both randomized and nonrandomized controlled studies have linked HF case 
management to decreased readmissions (Rich, Beckham, Wittenberg, et al., 1995; Fonarow, 
Stevenson, Walden, et al., 1997; Stewart et al., 1998), cost savings (West, Miller, Parker, et al., 
1997; Cline, Israelsson, Willenheimer, et al., 1998; Tilney, Whiting, Horrar, et al., 1998), and 
improved functional status (Fonarow, Stevenson, Walden, et al., 1997) in mostly homogeneous 
settings. Therefore, Laramee et al. (2003) conducted a study to test the effect of hospital-based 
nurse case management on ninety-day readmission rate in a heterogeneous population of HF 
patients (Laramee, Levinsky, Sargent, et al., 2003). 
A total of 287 patients admitted to a five hundred fifty bed academic medical center with 
the primary or secondary diagnosis of HF, left ventricular dysfunction of less than forty percent, 
or radiologic evidence of pulmonary edema for which they underwent diuresis were randomized 
to the intervention (n=141) or usual care (n=146). The intervention consisted of four major 
components: early discharge planning, patient and family HF education, twelve weeks of 
telephone follow-up, and promotion of optimal HF medications. Patients in the study received 
post-discharge care locally from their own cardiologists, internists, or family practitioners. The 
dispersed outpatient setting was characterized by considerable variation of follow-up care; 
therefore, the objective of the study was to evaluate the effect of hospital-based nurse case 
management on readmission rates in a heterogeneous setting (Laramee, Levinsky, Sargent, et al., 
2003). 
Patients or family members received telephone calls at one to three days following 
hospital discharge, weekly for the first month, and every other week in the second and third 
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months. The telephone calls surveyed HF symptoms, medications, self-care activities, adherence 
to the treatment plan, and provided opportunity for patients and families to ask questions. Data, 
including demographics, NYHA classification, and readmission rates, were collected at 
enrollment and twelve weeks. Additionally, adherence to the treatment plan, as measured by self-
report, and patient satisfaction were assessed at four and twelve weeks. 
The ninety-day readmission rates were equal for the care-managed and usual care groups, 
with both at 37%. Total inpatient and outpatient median costs and readmission median cost were 
reduced fourteen percent and twenty-six percent, respectively, for the intervention group. 
Patients in the care-managed group were more likely to be taking HF medication at target doses, 
but dosages did not increase significantly throughout the twelve weeks. Although both groups 
took their medications as prescribed equally well, the rest of the adherence to treatment plan was 
significantly better in the care-managed group. Subgroup analysis of patients who lived locally 
and saw a cardiologist revealed significantly fewer HF readmissions for the intervention group as 
compared to the usual care group, at 2% and 14%, respectively (P=0.03). These results suggest 
several limitations to the generalizability of the HF care managed improved outcome link in a 
heterogeneous setting.  One explanation is that the lack of coordinated system supports and 
varied accessibility to care in an extended, non-networked physician setting limits the 
effectiveness of the case management (Laramee, Levinsky, Sargent, et al., 2003). 
In summary, the randomized trials provide strong support for the observational studies 
that multidisciplinary care management programs are efficacious in select patients with HF. Both 
randomized and nonrandomized controlled studies have linked HF care management to 
decreased readmissions (Rich, Beckham, Wittenberg, et al., 1995; Fonarow, Stevenson, Walden, 
et al., 1997; Stewart et al., 1998; Knox & Mischke, 1999; Serxner et al., 1999; Doughty et al., 
  
 
 
226
2002; Krumholz et al., 2002; McDonald et al., 2002), cost savings (West, Miller, Parker, et al., 
1997; Cline, Israelsson, Willenheimer, et al., 1998; Tilney, Whiting, Horrar, et al., 1998), 
improved functional status (Fonarow, Stevenson, Walden, et al., 1997), quality of life  (refs), and 
patient satisfaction (refs). Additionally, several studies have shown enhanced patient knowledge, 
as well as compliance with medications and diet following a multidisciplinary intervention (refer 
to Tables 3-6).    
Based on available evidence, significant benefits have consistently been observed 
following implementation of multidisciplinary programs for patients with HF (refer to tables 3-
6). However, despite the consistency of these findings, several important limitations must be 
recognized and there is considerable opportunity for additional research in this area.  
First, most of the studies to date have been conducted as single-center trials at academic 
medical centers and in mostly homogeneous settings (refer to tables 1 and 3). Additionally, many 
studies recruited hospitalized patients, thus definite conclusions regarding the effect of the 
intervention on an outpatient population cannot be drawn. For these reasons, the generalizability 
of these findings to routine care of HF patients in the community remains uncertain. Therefore, 
there is a need for further studies evaluating HF disease management programs in larger and 
more diverse populations and practice settings, particularly the inner city, community hospitals 
and physician offices, and rural environments. 
Secondly, because of the complexity of the HF syndrome and large number of topics that 
are important to discuss, a team approach has proven extremely useful in providing care and 
helping patients to understand and retain information about the treatment regimen (Fonarow, 
Stevenson, Walden, et al., 1997; Rich, Beckham, Wittenberg, et al., 1995). Indeed, physicians 
and a multitude of other clinicians including: advanced practice nurses, home health nurses, 
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dietitians, physical therapists, exercise physiologists, pharmacists, other professionals, and 
support groups may all play important roles in this process as shown by numerous studies (refer 
to Tables 1 and 2). However, many nonacademic centers may lack the necessary personnel to 
assemble an effective HF care management team. Additionally, it is unlikely that a single 
“cookbook” approach will be effective in a wide range of clinical environments and diverse 
patient populations. Therefore, more research should be done to determine the feasibility of 
translating disease management teams into clinical practice in various settings. Furthermore, a 
variety of HF care management models should be considered, and modified as needed to 
accommodate a given clinical environment.  
A third limitation relates to the diversity of the components of the care-managed 
programs used in clinical trials. Interventions have included simple telephone follow-up, video 
monitoring, home visits, clinic visits and preemptive hospitalization. Programs have ranged from 
simple telephone follow-up by a nurse coordinator to extensive interventions with multiple 
components and comprehensive management teams. The efficacy of each strategy is largely 
unknown, and published studies have not been of sufficient size to determine the contribution of 
specific components. Additionally, despite the demonstrated benefits of exercise in patients with 
heart failure, the value of exercise in the context of a comprehensive heart failure management 
program has not been adequately studied. 
Another limitation relates to individualization of the treatment plan to fit the needs of 
each patient. Table 7 displays the key components of a comprehensive nonpharmacologic heart 
failure program as recommended by the AHCPR guideline panel (Konstam, Dracup, Baker, et 
al., 1994). Because not all components of the program are appropriate for all patients, treatment 
must be individualized and adapted to accommodate the needs and circumstances of each patient. 
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Several studies indicate that factors related to patient behavior (such as knowledge of the HF 
syndrome, worsening symptoms, and compliance with treatment) account for the large numbers 
of hospital admissions (Konstam, Dracup, et al., 1994; Rich, Vinson, et al., 1993; Dracup, Baker, 
et al., 1994; Happ, Naylor, et al., 1997; Kasper, Gerstenblith, et al., 2002; Rich, Beckham, et al., 
1995). Other barriers to effective care include the cost of medications and special diets (Kasper, 
et al., 2002). Due to the high rate of noncompliance with treatment, future studies should 
examine patient knowledge of HF, and interventions based on patient readiness to change (or 
adopt) specific lifestyle behaviors.  
Lastly, although several studies indicate that factors related to patient behavior account 
for the large numbers of hospital admissions (Konstam, Dracup, et al., 1994; Rich, Vinson, et al., 
1993; Dracup, Baker, et al., 1994; Happ, Naylor, et al., 1997; Kasper, Gerstenblith, et al., 2002; 
Rich, Beckham, et al., 1995), it has also been suggested that one reason for unsuccessful 
treatment may be the patient’s lack of understanding of the treatment plan, owing to the differing 
perspectives of the health-care professionals and the patient (Dracup, Baker, Dunbar, et al., 
1994). Moreover, other barriers to effective care include a lack of coordination among various 
providers (Kasper, et al., 2002). Therefore, it has been suggested that not only is it necessary to 
have a disease specific protocol, but also a structured, integrated approach between the patient 
and primary and secondary care (Doughty, Wright, Pearl, et al., 2001). 
Furthermore, despite the availability of published HF treatment guidelines, physician 
implementation of established guidelines remains suboptimal. Therefore, future studies should 
examine the reasons for the lack of guideline implementation and determine ways to promote 
greater adherence to established treatment guidelines. 
SUMMARY 
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Heart failure develops as a response to an insult to the cardiovascular system.  This insult 
results in a series of cardiac, circulatory, and muscular alterations with short- and long-time 
constants.  These compensatory adaptations may initially be remarkably effective in normalizing 
cardiocirculatory function.  Yet, the compensatory changes which are thought to be beneficial at 
rest appear to become restrictive during an acute bout of exercise.  Furthermore, most 
compensatory changes exact a price and eventually give rise to many of the clinical syndrome of 
heart failure, including marked exercise intolerance and chronic fatigue.   
The management of patients with heart failure is frequently confounded by a host of 
medical, behavioral, psychological, social, and economic factors. A considerable amount of the 
cost associated with heart failure care is attributable to repeated exacerbations that frequently 
require hospitalization. These exacerbations are often secondary to nonadherence to diet, 
medication, and activity regimens, inadequate symptom self-assessment and management, 
inadequacies in patient and care-giver education, and poor discharge planning and follow-up. 
Consequently, the use of a multidisciplinary team approach appears warranted for adequate 
management of these patients. In fact, a recent AHA Scientific statement examined the team 
management of heart failure patients (Grady, Dracup, et al., 2000) and indicated that components 
of successful healthcare delivery models for heart failure include staff skilled in the 
understanding of the pathophysiology of heart failure, patient assessment and evaluation of 
symptoms, education and counseling (focusing on symptoms and medication compliance), 
dietary consultation, and physical activity and exercise recommendations (see Table XII and 
XIII).   
Multidisciplinary heart failure disease management programs recognize the complexity 
of medical, psychosocial, behavioral, and financial issues that are faced by many patients with 
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heart failure and their caregivers, and attempt to provide a relatively structured mechanism for 
overcoming many of the barriers to effective care. Although the optimal approach to heart failure 
disease management remains to be defined and may vary depending on the practice environment 
and patient characteristics, it is clear that such programs substantially improve the overall quality 
of care for heart failure patients and that they are likely to reduce costs. Although the trials differ 
in terms of design, duration, clinical personnel, patient characteristics, settings and outcome 
measures, the value of multidisciplinary programs has been consistently shown. Research has 
shown consistently that systematic follow-up and early treatment of symptoms can avert 
problems before they occur and reduce complications, readmissions, and costs. 
Of particular relevance to the management of heart failure is the implementation of an 
adequate and tailored physical activity program. Evidence clearly indicates that patients with 
stable heart failure should participate in exercise training. The guidelines for and components of 
exercise training are similar to other clinical populations.  However, the exercise prescription 
should be tailored to each patient’s unique demands and goals. As a result of training many of 
the peripheral abnormalities improve.  These improvements translate to increased exercise 
tolerance, reduced activity-related symptoms, and improved quality of life.  Finally, exercise 
training increases survival time and decreases health care costs in these patients. 
Finally, it is clear from the literature that despite the overwhelming evidence of the 
efficacy of multidisciplinary programs and the position stand of the American Heart Association, 
there continues to be a lack of guideline implementation. Thus future studies need to continue to 
develop ways to promote the use of these strategies and to determine ways to enhance greater 
adherence in both clinicians and patients to established treatment guidelines. 
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